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For over 2500 years physicians and other healthcare professionals take the 
Hippocratic oath swearing to use treatment for the good of their patients according 
to their ability and judgment and to avoid harming anyone.1 Despite this oath, 
there is overwhelming evidence that significant numbers of patients are harmed 
by healthcare. The reports ‘To err is human: building a safer health system’ 2 and 
‘An organization with a Memory’3 recognized that errors routinely occur during 
the delivery of health care. Although patients are more likely to suffer less serious 
adverse events (AEs), such as transient drowsiness or headache, harm may also 
be serious, such as permanent injury leading to disability, and sometimes even 
death. Many studies have focused on AEs associated with hospital care, because of 
the high-risk procedures (e.g. surgery) and high risk environment (e.g. hospital-
acquired infections). An estimated one out of ten hospitalized patients experience 
an AE from error.4-11 Deaths due to medical errors in hospitals are in the top five 
leading causes of death, while approximately 25–50% of the adverse events are 
considered potentially preventable.4,7-9,11,12
B ox 1 Clarifications of terminology chosen in this thesis
An adverse event  is any abnormal sign, symptom, laboratory test, syndromic combination of 
such abnormalities, untoward or unplanned occurrence (e.g. an accident or unplanned pregnancy), 
or any unexpected deterioration in a concurrent illness.15
An adverse drug event  is an adverse event that occurs while a patient is taking a drug or at 
some time afterwards but that may or may not be attributable to it. [amended from reference 15]
An adverse drug reac t ion  is an appreciable harmful or unpleasant reaction, resulting from an 
intervention related to the use of a medicinal product.15 An adverse drug reaction is characterised 
by the fact that there is at least a reasonable possibility of a causal relationship between a medicinal 
product and an adverse event.16,17
A medication error  is a failure in the (drug) treatment process, whether through omission or 
commission, that leads to, or has the potential to lead to, harm to the patient.18,19
A drug therapy problem  (or ‘drug-related problem’ or ‘drug-therapy related problem’ or 
‘medication-related problem’) is any undesirable event or risk thereof, experienced by a patient that 
involves, or is suspected to involve drug therapy, and that actually or potentially interferes with the 
achievement of an optimal outcome.20-22
Most patients are treated in primary care settings, however. Errors in primary care 
can also have various consequences either leading to temporary discomfort or to 
hospital admissions and even death.13 Potentially preventable AEs in primary care 
occur in less than one out of 100 contacts with the general practitioners practice.13,14 
In one out of thousand contacts the potentially preventable AEs are associated 
with unplanned hospital admissions. When extrapolated to the Dutch population, 
11
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preventable AEs in primary care may be leading to an estimated 60,000 hospital 
admissions per year in the Netherlands. Approximately one fifth of these hospital 
admissions are caused by potentially preventable AEs related to medicines.13
So, an important category of AEs is associated with the use of medicines. Because the 
literature is not consistent in its terminology we provide the definitions for ‘adverse 
event’ (AE), ‘adverse drug event’ (ADE), ‘adverse drug reaction’ (ADR), ‘medication 
error’(ME), and ‘drug-therapy problem’(DTP) in Box 1 using definitions selected 
from the literature. The relations between these definitions we show subsequently 
in Figure 1.
Figure 1 A Venn diagram showing the relation between drug therapy problems 
(DTPs), adverse events (AEs), adverse drug events (ADEs), adverse drug 
reactions (ADRs) and medication errors (MEs)15,18,20,21,23
1.  Drug therapy problems
2 + 3 + 4 + 5 = all AEs in patients taking medicines
2.  Adverse events that are not reactions to medicines
3.  ADRs not from errors
4.  ADRs from
medication
errors
5.  Medication errors
that cause harms
that are not ADRs
6.  Medication errors
that do not cause
adverse events
3 + 4 + 5 = all ADEs
3 + 4 = all ADRs
4 + 5 + 6 = all MEs
Two Dutch observational studies (HARM [Hospital Admissions Related to 
Medication]20 and IPCI [Integrated Primary Care Information])24 showed that 
ADRs in primary and outpatient care were an important cause (approximately 5%) 
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of unplanned hospital admissions, of which 30–46% were potentially avoidable. 
Extrapolation to the Dutch population provides an estimated number of 10,500 
till 16,000 potentially preventable drug related hospital admissions per year in the 
Netherlands.20,24,25 The fact that approximately one out of 20 hospital admissions are 
drug-related and that almost half of them are preventable is confirmed in several 
other international studies.26-30 In inpatients, nearly one out of 10 patients had an 
ADR, and almost half of the events were potentially preventable.4 In the ambulatory 
care setting, ADEs have been reported to occur in approximately one out of eight 
patients, and about one-sixth of these ADEs were due to error.31 The studies 
undoubtedly show that ADEs are one of the leading causes of morbidity.4,23,31-33 As 
a substantial part of ADEs are caused by medication errors, and thus are potentially 
preventable, understanding the nature of medication errors, and the underlying 
causes leading to error are needed to design effective interventions aimed at 
improving medication safety.31
C ONCEPT OF CLINICAL RISK MANAGEMENT (CRM )
The concept of clinical risk management (CRM) has been proposed to systematically 
identify, analyse and prioritize actual and potential clinical risks of medication 
errors and to prepare, implement and evaluate risk management strategies to avoid 
Figure 2 The Swiss Cheese model
No patient  harm
Risks
Caused patient  harm
System
defenses
Some holes
due to active
failures
Other holes
due to latent
conditions
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patient harm.34-36 Since the turn of the century CRM receives more attention, 
mainly because of the aforementioned reports ‘To err is human: building a 
safer health system’ 2 and ‘An organization with a Memory’ 3. These reports have 
promoted the application of the ‘Swiss cheese model’ of James Reason 37 to the 
field of healthcare.38,39 The Swiss cheese model assists in the understanding of how 
harmful events occur and how they can be prevented. The holes in the slices of the 
Swiss cheese represent the causes of error and the slices indicate the levels at which 
failures occur. The presence of holes in any one slice does not normally cause harm 
to the patient, when the system defences are effective. However, when the holes in 
all slices line up an error remains uncorrected and can result in harm to the patient 
(see Figure 2).40
Figure 3 The clinical risk management process
1A. Risk
identification
1B. Risk
assessment
3. Evaluation
of risk reduction
strategies
2A. Development
of  risk reduction
strategies
2B. Execution
of risk reduction
strategies
Concentrating on the underlying systems (i.e. the latent errors) is likely to be more 
productive and beneficial than just looking at an actual error (i.e. active failure) 
made by an individual. This promotes changes in systems to reduce the likelihood 
of future error.35 CRM offers a systematic approach to manage the risks after 
identification of the (causes of) errors. The CRM process consists of three key 
elements: (1) risk identification and assessment; (2) development and execution of 
risk reduction strategies; (3) evaluation of risk reduction strategies, see Figure 3.35,41
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CLINICAL RISK MANAGEMENT IN DRUG THER APY
In the realm of drug therapy, the systematic approach of CRM needs to be integrated 
into all steps of the drug therapy process, including development, regulation 
(including registration), marketing, distribution, prescription, dispensing, and use 
of the drug.
Clinica l  r isk  management  –  marketing authorisat ion holders
CRM has often been directed at the post-licensing phase of newly licensed 
medicines.42 Main reason for the increased regulatory use of risk management 
in recent years is that at market entry, the safety profile of a new drug is not fully 
known because of inherent shortcomings of preregistration clinical trials, such as 
small sample sizes, focus on efficacy, and inclusion of relatively healthy patients 
with limited multimorbidity.43-45 Ongoing post registration benefit–risk evaluation 
and, when indicated, safety-related regulatory precautions are required to safeguard 
a positive balance of benefits over risks of drugs in individual patients. Therefore, 
applicant/marketing authorisation holders must accompany their application for 
marketing authorisation of a medicinal product with a risk-management plan 
(RMP) in which they evaluate the possible future risks of their product and describe 
how to control these risks during its entire lifecycle.46 The basic limitations are that 
such RMPs are primarily targeted at detecting ADRs of new chemical entities at 
the population level. This can either lead to more insight in the actual prevalence 
of already known serious ADRs or to the detection of rare not previously identified 
ADRs.43 Individual patients with co-morbidities, co-medications and several other 
patient-related factors (e.g. age, sex) may have an increased risk of an ADR or may 
experience hitherto unknown ADRs.15 Therefore, CRM should also be directed 
to increase the safety of drug therapy for individual patients. In addition, CRM 
should also address the risks of older licensed medicines and unlicensed natural 
products, that are not subject to RMPs.41 A substantial part of these ADRs are 
predictable and potentially preventable, e.g. by adequate monitoring or other risk 
reduction strategies such as the addition of a prophylactic drug. Examples include 
gastrointestinal bleedings with platelet aggregation inhibitors, hyperglycaemia 
with corticosteroids, and electrolyte disturbances with diuretics. The finding that 
more than half of the potentially preventable drug-related hospital admissions are 
associated with well-known adverse effects of well-known (older) drugs stresses the 
importance of risk reduction strategies for all drugs.47
15
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Clinica l  r isk  management  -  regulator y  authorit ies  and marketing 
authorisat ion holders
Drug regulatory authorities have implemented CRM by systematic monitoring of 
the efficacy and risks of medicinal products. The authorities and the marketing 
authorisation holders are responsible to collect and collate all reports of ADEs 
concerning registered drugs. They depend on the spontaneous reports of ADEs 
from healthcare professionals and patients, on reports of suspected adverse 
reactions from the scientific and medical literature and from other sources such 
as the internet or media. In addition, they should obtain solicited reports of ADEs 
derived from, for example, clinical and pharmacoepidemiological studies.16
Therefore, they collaborate with several other organisations, such as 
pharmacovigilance centres, poison control centres, medication error institutes and 
universities. Once the safety profile of the medicinal product is characterised the 
regulatory authorities determine for which indications and under which conditions 
a product may be prescribed and define comprehensive product information 
for healthcare professionals (summary of product characteristics [SmPC]), risk 
warnings (Direct Healthcare Professional Communication [DHPC]) and the 
patient information leaflet.48
The risk reduction strategies from the regulatory authorities are only effective when 
healthcare providers adhere to guidance. Furthermore healthcare providers should 
provide feedback on potential safety issues either identified in clinical practice or in 
scientific research. This includes notifying regulatory authorities when a medicinal 
product is used improper by individual patients.
Clinica l  r isk  management  -  healthcare  professionals  and their 
associat ions
Individual healthcare professionals and their professional associations have 
increasingly come aware of the necessity for CRM. In the Netherlands, pharmacists 
initiated practical management guidelines for dosing and drug interactions in the 
1980’s. These guidelines were subsequently integrated in electronic patient records 
(EPRs) aiming to automatically detect potential drug-related problems (DRPs) 
such as incorrect dosing, drug– drug interactions, drug– disease interactions, 
drug intolerabilities, and duplicate medications.49 The pharmacotherapy and 
drug information working groups of the Royal Dutch Pharmacists Association 
(KNMP) and the Health Base Foundation developed knowledge databases for 
this purpose.50,51 More recently guidelines for pharmaceutical care for patients 
with specific diseases (i.e. diabetes, chronic obstructive pulmonary disease) were 
published.52 Within individual pharmacies the professional guidelines and the 
16
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automated tool for detecting potential DRPs stressed the necessity to manage the 
DRPs in daily pharmacy practice and thus performing clinical risk management.
Although these kind of risk reduction strategies most often are not systematically 
evaluated by the developers of the strategies, the feedback from practising 
pharmacists on the many and often less relevant signals from the automatic detection 
tool stimulated further development of decision support systems. A systematic 
CRM approach, however, is required to evaluate the effectiveness of all professional 
guidelines and tools in order to further improve the safety of drug therapy. One of 
the aims of pharmacy practice research is to evaluate these risk reduction strategies. 
An illustrative recent example concerns the Pregnancy Prevention Programme 
(PPP). A study showed that among women of reproductive age who were exposed 
to medicinal products with teratogenic potential, only 42% concomitantly used 
contraceptives.53 The same compliance was measured for the Dutch isotretinoin 
PPP of 2003.54,55 Apparently, the programmes were not successfully implemented in 
clinical practice in the Netherlands. These findings are important for reinforcement 
of the current isotretinoin PPP and for the development and implementation of 
future PPPs.
Another example are the studies by Buurma et al in which risk reduction strategies 
for drug-drug interactions, drug-disease interactions and drug intolerabilities were 
evaluated. One of these studies showed that adherence to drug-drug interaction 
management guidelines by pharmacies varied considerably, suggesting that further 
research was needed to assess the underlying reasons for the nonadherence to 
some of these guidelines.56 Another study concluded that the quality of disease and 
intolerability documentation in the EPR in community pharmacies needed further 
improvement.49 This study called for further research into the completeness and 
quality of the EPRs.
OBJECTIVE AND OU TLINE OF THE THESIS
This thesis aims to illuminate the importance of a systematic approach towards the 
clinical risk management of drug interactions. In this thesis a drug interaction is 
defined as a situation in which the pharmacological effect of a drug is reduced or 
increased because the effect of that drug is affected by another drug a person is 
taking (drug-drug interaction or duplicate medication); by food or natural products 
the person is consuming (drug-food interaction, drug-natural product interaction); 
by a disease a person has (drug-disease interaction); by an allergy the person has 
17
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(drug intolerability); by a specific condition the person has (e.g. drug-pregnancy 
interaction); or by a personal habit the person has (e.g. drug-smoking interaction).
Drug interactions in patients first need to be identified. Therefore, complete EPRs 
plus a computerised system for the detection and alerting of drug interactions are a 
prerequisite. Secondly, drug interactions have to be assessed and properly managed. 
Hence, clear and understandable guidelines have to be available for this purpose. 
Finally, it is needed to evaluate if guideline adherence is feasible in practice and 
how certain drug interactions are actually managed in daily practice.
This thesis consists of three parts. In the first part we were interested in an essential 
prerequisite to effective risk management in community pharmacies, i.e. complete 
and up-to-date medical and pharmaceutical information in the EPR. Chapter 2.1 
describes the level of completeness of documentation in the EPR after a patient’s 
first visit to a Dutch community pharmacy. Chapter 2.2 presents whether a medical 
and pharmaceutical information gap persists for patients enlisted for at least three 
months in a community pharmacy, and which drug therapy alerts failed to appear 
as a result of the information that was missing in the EPR.
The second part focuses on clinical risk management plans for drug interactions. 
Such management guidelines are developed as outcomes of the process of 
identification, assessment and prioritization of risks concerning the prescribing and 
utilization of drugs. The systematic approach of clinical risk management should 
also be applied to the development and presentation of management guidelines. 
In Chapter 3.1 we define the relevant items of a checklist for those involved in the 
development of drug-drug interaction (DDI) management guidelines based on 
broad consensus among internationally recognised experts. We tested this checklist 
for feasibility using a specific DDI example and prepared a final checklist for the 
development and presentation of DDI management guidelines. The specific DDI 
example has been added in Chapter 3.2. We present the checklist together with 
extensive guidance on how to interpret and apply the elements of the checklist when 
developing specific DDI monographs in Chapter 3.3. In Chapter 3.4 we discuss key 
areas in the clinical risk management of interactions between natural products and 
conventional drugs (NPDIs) to explore how their impact on public health can be 
minimized.
In the third part, we address the evaluation of risk reduction strategies in 
drug therapy, i.e. do these strategies actually work effectively and efficiently. 
Chapter 4.1 presents the assessment of the clarity and applicability of guidelines for 
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the management of potentially harmful DDIs. We also evaluated the management 
guidelines for drug–drug interactions between non-steroidal anti-inflammatory 
drugs (NSAIDs) and antihypertensives that recommend blood pressure monitoring 
in hypertensive patients in daily clinical practice. In Chapter 4.2 the results of the 
short-term effect of initiating NSAIDs on systolic blood pressure (SBP) in users of 
antihypertensives are reported and outpatients at risk for an increase in SBP in daily 
clinical practice are described.
Finally, the results of these studies are summarized and put into a broader 
perspective in Chapter 5.
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ABSTRACT
Background
When patients visit a community pharmacy for the first time, the creation of an 
electronic patient record (EPR) with relevant and up-to-date patient data is a 
prerequisite for adequate medication surveillance and patient counselling.
Object ive
To investigate the level of completeness of documentation in the EPR after a 
patient’s first visit to a Dutch community pharmacy.
Methods
In each participating pharmacy, newly enlisted (< 3 months) patients to whom at 
least one medication had been dispensed were enrolled in this survey. For each 
patient who could be interviewed, pharmacy master students used a structured 
questionnaire to gather relevant, mandatory patient data (i.e. basic characteristics, 
current drugs used, diseases, intolerabilities, specific conditions) and nonmandatory 
patient data (e.g. diagnostic and monitoring data, personal experiences and habits, 
drug use problems) from the patient’s EPR and from a structured telephone 
interview with the patient. Data retrieved from the patient’s EPR were compared 
with data provided by the patient during the telephone interview.
Results
Of 403 selected patients, 154 (38.2%) could be interviewed by telephone. Poor 
documentation of telephone numbers in the EPR was the main reason for 
nonresponse (134/249). Interviewers found that 67.7% of prescription drugs, 0% 
of over-the-counter drugs, 19.6% of diseases, 3.7% of intolerabilities, and none 
of the specific conditions reported by patients had been documented in the EPR. 
Nonmandatory data (personal experiences and habits, drug use problems) reported 
during the patient interview had not been documented in the EPR.
Conclusions
The EPR after a patient’s first visit to the community pharmacy is often incomplete. 
For new patients, the pharmacist should more proactively and systematically gather 
patient information, and all relevant information should be recorded, preferably in 
coded form, in the pharmacy information system to allow more adequate clinical 
risk management.
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INTRODUCTION
Community pharmacists apply the principles of clinical risk management in 
their systematic efforts to detect, prevent and manage drug-related problems 
(DRPs).1 Automated pharmacy information systems offer surveillance tools for the 
detection of DRPs such as over- and undertreatment, incorrect dosing, drug-drug 
interactions, drug-disease interactions, drug allergies, intolerance, and duplicate 
medications.1-4 However, the actual performance of these systems depends directly 
on the level of completeness and quality of patient data recorded in or linked to the 
pharmacy information system (see Table 1).5-9
For adequate medication surveillance and patient counselling, Dutch pharmacists 
must not only record which drugs have been prescribed by which prescriber and 
dispensed to which patients, but also other types of relevant patient information. 
They must also keep patients records up-to-date.2,10-12 All information systems for 
Dutch community pharmacies support the creation of electronic patient records 
(EPRs) for this purpose.13 A patient’s first visit to the pharmacy is an important 
opportunity to collect such data. Failure to do so systematically could easily result 
in the absence of computer-generated alerts concerning potentially serious DRPs.
There appears to be no published research on the quality of relevant patient 
documentation in community pharmacies for newly enlisted patients. Thus, we 
performed a study to investigate the completeness of EPRs after the first visit of 
patients to Dutch community pharmacies.
METHODS
Sett ing
Fifty-two Dutch community pharmacies belonging to the Utrecht University 
Pharmacy Practice Research Network (UPPER), which comprises about 50% of all 
Dutch pharmacies (n=1,893), were invited to participate in this survey during the 
first half of 2007. Pharmacy master students from the Utrecht University selected 
the patients during their practical training in these pharmacies and collected patient 
data according to a protocol that required the use of a structured questionnaire. The 
students received two verbal instructions from the researcher, and a help desk for 
the students was available throughout the research period. The work was conducted 
in compliance with the requirements of the UPPER institutional review board.
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Table 1 Patient data for risk management of pharmacotherapy when a drug is 
dispensed
Drug-Related Problem 9 Relevant Patient Data 5 Example
Dosing problem age a digoxin: child or geriatric dosage
weight and/or height a amoxicillin: child dosage
renal function a metformin
smoking status b theophylline
diagnostic data b digoxin: creatinine
monitoring data b insulin: blood glucose
Drug-drug interaction prescription drug a statins–macrolides
OTC drug a NSAIDs–coumarins
Duplicate medication prescription drug a oxazepam–temazepam
OTC drug a ibuprofen–naproxen
Drug-disease interaction disease a NSAIDs–heart failure
Drug intolerability intolerability a penicillin: allergy
naproxen: gastrointestinal adverse 
effects
Drug-specific condition 
interaction
desire for motherhood a, 
pregnancy a 
isotretinoin: birth defect
lactation a atenolol: toxicity in breast-fed 
infants
upcoming surgery b acetylsalicylic acid: bleeding
Drug-personal experience/ 
habit interaction
profession b benzodiazepines: driving or 
manipulating dangerous machines
smoking b hormonal contraceptives: 
cardiovascular adverse effects
sport a β2-blocking agents: decreased 
performance for professional and 
recreational sportsmen
restricted drugs: professional 
sportsmen
Drug use problem difficulty taking medication b eye drops, opening boxes, 
inhalation devices
use of dose-dispensing system b polypharmacy: dementia
religious belief b Ramadan fasting
blood products: Jehovah’s Witness
drugs of porcine origin: Judaism 
or Islam
NSAIDs = nonsteroidal antiiflammatory drugs; OTC = over-the-counter
a) Currently mandatory type of patient data.
b) Currently nonmandatory type of patient data.
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Study populat ion
At least ten patients were enrolled in each participating pharmacy shortly after 
their first pharmacy visit. Patients could be selected only if they had been newly 
enlisted (< 3 months) in the participating pharmacy and at least one medication 
had been dispensed to them in this pharmacy. If more than one patient from the 
same family, living at the same address, was selected, only the most recently enlisted 
patient was enrolled. The students were required to interview selected patients 
by telephone within three weeks after selection, using a structured questionnaire 
(requiring 10–15 minutes/patient). Only patients who were actually interviewed 
were included in the analysis (see Figure 1). For patients younger than 18 years, the 
parents or legal guardians were interviewed instead.
Data col lect ion
For each of the included patients, the students used a structured questionnaire 
form, developed and pretested by the researchers, to gather relevant patient data 
from the patient’s EPR shortly after the patient’s first pharmacy visit and from a 
telephone interview with the patient. In the interview, the patients were asked 
for relevant data by means of 18 questions. Data were considered relevant if they 
had been mentioned in the literature as potentially important for the prevention 
of DRPs and could be recorded in the EPR in specific data fields or in free text 
fields.5-7,9,14
A systematic distinction between two types of assessment was made (Table 1):
1. The summative type, which evaluated the mandatory recording of data in 
accordance with the professional Dutch Pharmacy Standard (NAN 2006) and 
its underlying guidelines: full patient name, address, date of birth, sex, telephone 
number, current drug use (prescription and over-the-counter [OTC]), specific 
conditions (disease, pregnancy, lactation, desire for motherhood), intolerabilities 
(intolerance/allergy), renal function and participation in sport.15
All automated pharmacy information systems in the Netherlands offer 
opportunities to record these data in specific data fields. To process the 
dispensing of a prescription to a new patient, the systems require at least full 
patient name, date of birth, sex, and address to create a new patient record.
2. The formative type, which evaluated the nonmandatory recording of data and 
which can be equally important for the provision of adequate pharmaceutical 
care. The systematic recording of the following is not yet required by the 
professional Dutch Pharmacy Standard: diagnostic and monitoring data (e.g. 
blood glucose, blood pressure), upcoming surgery, personal experiences and 
habits (e.g. profession, smoking), and drug use problems such as difficulties 
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taking medication, use of a dose-dispensing system, and religious belief (e.g. 
Ramadan fasting, Jehovah’s Witness).
Current community pharmacy systems offer general opportunities to store 
these data as free text, but specific fields for their recording are not yet generally 
available.
In addition, basic characteristics of the participating pharmacies were collected by 
completion of a separate form.
Data analysis
Data were entered into a Microsoft Access (Microsoft Corp., Redmond, WA) 
database. Logistic Regression Analysis (SPSS version 14.0, SPSS Inc., Chicago, IL) 
was used to compare basic characteristics of the participating pharmacies with 
national data available on Dutch pharmacies. The same statistical analysis was used 
to compare the interviewed and noninterviewed patient groups for sampling biases. 
Descriptive analysis was used to compare the data from the patients’ EPRs with 
data from the telephone interviews.
Figure 1 Response flow chart
Newly enlisted in
39 community pharmacies:
403 patients
Not interviewed: 249 (61.8%)
female:         146 (58.6%)
mean age:   32.3 y (range 0–89)
age < 39 y:   181 (72.7%)
passerby
customers:   51 (20.5%)
Interviewed: 154 (38.2%)
female:          97 (63.0%)
mean age:    34.6 y (range 0–94)
age < 39 y:    98 (63.6%)
passerby
customers:   18 (11.7%)
182 (73.1%)
35 (14.1%)
18 (   7.2%)
14 (   5.6%)
- could not be reached
- pharmacist did not
   approve interview
- not willing/able
- no reason recorded
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RESULTS
Thirty-nine pharmacies participated in the study (75% of the 52 invited UPPER 
community pharmacies and 2% of all 1,893 Dutch pharmacies). Compared with 
the average Dutch pharmacy, the pharmacies participating in our study were 
more often equipped with a certified Quality System (58% vs. 36%) (OR 2.44; 
95%CI 1.27–4.69) and had more pharmacists (1.79 vs. 1.55 full-time equivalent; 
p < 0.05).16,17 Dutch community pharmacies can be certified under the auspices of 
the Foundation for Harmonisation of Quality Review in Health Care and Welfare 
(HKZ). The certificate issued by the HKZ is compatible with ISO 9001.17 The 
majority (84.6%; n=33) of the participating pharmacies reported the availability of 
a procedure for a pharmaceutical interview for new patients and/or a form for the 
registration of new patients.
Of the 403 patients selected, 154 patients (38.2%) could be interviewed (Figure 1). 
Difficulty reaching patients by telephone, mainly because phone numbers had not 
been listed in the EPR (134/182) and could not be traced through the Internet or 
a national cell phone number service, was the main reason for nonparticipation in 
the interview. Three pharmacists did not permit that the pharmacy master students 
to call the selected patients (35 total) for a structured interview. Basic characteristics 
of the 154 interviewed patients did not differ substantially from those of the patients 
who were not interviewed. Patients who had been registered as passerby customers, 
(i.e. nonregular or once-only visitor), had a lower probability of being interviewed 
(OR 0.5; 95%CI 0.3–0.8), as did younger patients (aged < 39 years) (OR 0.7; 95%CI 
0.4–1.0).
More than half (54.5%) of the interviewed patients reported that the pharmacy 
team had asked for relevant patient data at their first pharmacy visit.
As shown in Table 2, 60.4% of the interviewed patients self-reported current use 
of one or more prescription drugs. The number of patients with information 
in their EPRs about the use of OTC drugs was low (0.6%) compared with the 
number of patients who reported during the telephone interview the use of one or 
more OTC drugs (57.1%). In the EPRs, one or more diseases had been recorded 
as contraindication for 10.4% of the patients. Of the interviewed patients, 19.5% 
reported that they had at least one disease that should have been documented 
in their EPR as a potential contraindication. For specific conditions, no data 
were recorded in the EPRs. This was in contrast to information self-reported by 
the patients; 16 women of childbearing age self-reported being pregnant, breast-
feeding or having a desire for motherhood. In the EPRs, an intolerability had only 
been recorded for one patient, whereas 21 patients (13.6%) reported at least one 
intolerability during the interview.
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No data were recorded in the EPRs for personal experiences and habits or for 
drug use problems, except for the use of a dose-dispensing system by one patient 
(Table 2). In addition, small percentages of patients reported practicing sports 
(1.9%), having a profession that involved driving a vehicle or operating dangerous 
machinery (1.3%), or having certain drug use problems (e.g. difficulties taking 
medication; 7.1%).
Information missing in  the  EPR
Of all prescription drugs that were reported during the patient interview, 32.3% 
had not been recorded in the EPRs (Table 3). Prescription drugs that were most 
frequently unrecorded in the EPRs were oral contraceptives (n=10); blood glucose-
lowering drugs, including insulins (n=6); and angiotensin II antagonists (n=6). 
Also unrecorded in the EPRs were antidepressants (n=5), drugs for chronic 
obstructive airway diseases (n=5), β-blocking agents (n=3), lipid-modifying agents 
Table 2 Information in the EPR and self-reported during patient interview
Parameter EPR (n=154) Patient Interview (n=154)
n (%) n (%)
Drug use
≥ 1 prescription drug 152 (98.7)a 93 (60.4)a
≥ 1 OTC drug 1 ( 0.6) 88 (57.1)
Specific conditions and intolerabilities
≥ 1 disease 16 (10.4) 30 (19.5)
≥ 1 intolerability (intolerances/ allergies) 1 ( 0.6) 21 (13.6)
pregnancy, lactation, desire for motherhood 
(female aged 16‐42 y) 
0 ( 0.0) 16 (10.4)
upcoming surgery 0 ( 0.0) 13 ( 8.4)
Personal experiences and habits
profession that warrants caution with drug use 0 ( 0.0) 2 ( 1.3)
smoking (age >12 y) 0 ( 0.0) 34 (22.1)
sport that warrants caution with drug use 0 ( 0.0) 3 ( 1.9)
Drug use problems
difficulty taking medication 0 ( 0.0) 11 ( 7.1)
use of dose-dispensing system 1 ( 0.6) 5 ( 3.2)
religious belief 0 ( 0.0) 11 ( 7.1)
EPR = electronic patient record; OTC = over-the-counter
a) Information gathered within three weeks after inclusion.
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Table 3 Completeness of information in the EPR compared with patient interview a 
Parameter Reported by patient Missing in EPR
 n n (%)
Number of
prescription drugs 195 63 ( 32.3)
OTC drugs 131 131 (100.0)
diseases  46 37 ( 80.4)
intolerabilities (intolerances/allergies)  27 26 ( 96.3)
EPR = electronic patient record; OTC = over-the-counter
a) n=154 patients
(n=2), antithrombotic agents (n=2), high-ceiling diuretics (n=2) and nonsteroidal 
antiinflammatory drugs (NSAIDs; n=2).
None of the OTC drugs that were self-reported had been recorded in the EPRs. 
OTC drugs most frequently reported by patients were acetaminophen (51.1%) and 
NSAIDs (21.4 %).
A high percentage of diseases were self-reported by the patients without having 
been recorded in the EPRs (80.4 %). Hypertension (n=11), cardiovascular disease 
(n=7), and chronic obstructive pulmonary disease (COPD; n=6) were the diseases 
most frequently unrecorded in the EPRs. Benign prostatic hyperplasia (n=1) and 
thyroid disease (n=1) were unrecorded as well. Of the 27 intolerances/ allergies 
self-reported by patients, 26 (96.3%) were not recorded in the EPRs. Antibiotics 
(n=11) and acetylsalicylic acid/ NSAIDS (n=5) were the most frequently missed 
intolerable drugs.
Information not  sel f-repor ted during the  patient  inter v ie w
More than half (54.2%) of all prescription drugs recorded in the EPRs were not self-
reported during patient interviews. The drugs most frequently unreported were 
antiinfectives (17.9%), NSAIDs (7.7%), and hypnotics/anxiolytics (5.1%). Eleven 
of the 20 diseases (55.0%) recorded in the EPR were not self-reported by patients 
during the interviews. They included COPD, depression, and glaucoma.
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DISCUSSION
This study reveals that telephone numbers were not always recorded and suggests 
that other mandatory patient data (e.g. OTC drugs, diseases, intolerabilities, specific 
conditions) and nonmandatory patient data (e.g. personal experiences and habits, 
drug use problems) are often not fully registered at the patient’s first pharmacy visit. 
Incomplete documentation in EPRs may pose an immediate risk to patients, and it 
is unknown to what extent documentation improves during subsequent pharmacy 
visits.
Prescription dr ugs
The completeness (67.7%) of prescription drug documentation was at the lower 
end of the range (50-93%) compared with previous Dutch studies.18,19 The 63 
prescription drugs that had not been recorded in the EPRs included several with 
a high potential for drug-drug and drug-disease interactions (e.g. cardiovascular 
drugs, antithrombotics, central nervous system drugs, NSAIDs, blood glucose-
lowering drugs).20 The most probable explanation for such discrepancies is that the 
patients in our study had a supply of these drugs at home when they visited the 
participating pharmacy for the first time and were not asked in-depth questions 
about their current drug use. On the other hand, a relatively high proportion of 
patients did not self-report the use of prescription drugs that had been registered 
in the EPRs.19 Given that these drugs were frequently antiinfectives, analgesics, and 
hypnotics/anxiolytics, a substantial part of them may have been intended for short 
or intermittent use.
OTC dr ugs
None of the OTC drugs reported by patients were documented in the EPR. This 
finding is comparable with previous research in the UK and the Netherlands.21,22 
In the Netherlands, OTC drugs are mostly purchased in drugstores (78.5%), not 
pharmacies.23 It is of concern that 21.4% of the OTC drugs in our study were 
NSAIDs, because these drugs entail a substantial risk of drug-drug interactions, 
drug-disease interactions, and duplicate medications. At a patient’s first visit, 
pharmacists should inquire more systematically about OTC drug use and storage 
at home, particularly because the patient’s awareness of potential risks with self-
medication may be poor. Moreover, we recommend that all OTC drugs with a high 
risk of DRPs (e.g. NSAIDs) should be available only in pharmacies and not through 
drug stores or general sales.24
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C ondit ions  and intolerabi l it ies
The low recording of diseases (19.6%) and intolerabilities (i.e. intolerances/
allergies; 3.7%) and no record of specific conditions in the EPRs may be due to 
the fact that information systems in physician offices and pharmacies are not 
automatically linked and that pharmacists do not systematically ask new patients 
and their physicians about diseases and intolerabilities. The completeness of the 
EPR may improve with a patient’s subsequent pharmacy visits, as pharmacists may 
be alerted when dispensing a drug that is suggestive of a particular disease (e.g. 
angiotensin-converting enzyme inhibitor for a cardiovascular disease). Buurma et 
al.1 found a high level of record completeness for diseases with an unambiguous 
relationship to currently used medication (e.g. diabetes, hypothyroidism), but 
much less completeness for heart failure, in which the relationship between disease 
and medications is more ambiguous.1
Personal  experiences  and habits  and dr ug use  problems
None of the self-reported information on nonmandatory patient data (i.e. personal 
experiences and habits and drug use problems) obtained during the patient 
interview had been documented in EPRs. Similar findings, except for smoking 
habits, have been reported in a systematic review of recording in medical practice.25 
The low level of completeness of pharmaceutical EPRs may be associated with the 
fact that most of the nonmandatory data are not yet required by the professional 
Dutch Pharmacy Standard 14 and can only be recorded in free text fields.
Possible  reasons  for  incompleteness
Although further research is needed to explore the underlying reasons for 
incompleteness of EPRs, some possible reasons were offered by participating 
pharmacists when results of this study were presented to them informally: a 
structured pharmaceutical interview may not have been administered to all patients 
visiting the pharmacy for the first time, the patient may not have been recognized 
as a first-time visitor by the pharmacy information system or the pharmacy team, 
or the dispensed medication may have been picked up by someone caring for the 
patient.
It is also possible that the pharmacy team did not have enough time, had not been 
instructed well enough to perform these pharmaceutical interviews, or that the data 
from the pharmaceutical interview were not systematically recorded in the EPR.
Other reasons might be that patients did not have time or were not willing to be 
interviewed or that they had forgotten or withheld specific information during the 
pharmaceutical interview at their first visit.
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This study has several limitations. First, it is conceivable that the pharmacists 
participating in our study had a more positive attitude toward quality of 
pharmaceutical care than do those in the average Dutch pharmacy, because all of the 
participating pharmacists were active in relaying practical experience to pharmacy 
master students, they had more full-time equivalent pharmacists, and more often 
had a certified Quality System.17 Therefore, our study may have underestimated the 
degree of incompleteness of EPRs after patients’ first visits to pharmacies.
Second, patients were only interviewed during opening hours of the pharmacy, 
which may have excluded some patients unintentionally. However, an analysis of 
noninterviewed patients did not reveal a selection bias. Third, we did not investigate 
whether paper registration forms for new patients were still filed separately for later 
recording in the EPRs. We do not believe this was a major issue in our study, as 
none of the pharmacy master students reported such behaviour. Fourth, there was 
a lag time of a maximum of three weeks between the collection of data from the 
patient’s EPR and the patient interview. However, most of the discrepancies found 
between the EPRs and the patient interviews concerned chronic diseases and 
chronically used drugs and it is unlikely that these developed in such a short time. 
Finally, the data provided by the patient during the interview cannot be considered 
the gold standard regarding current drug use, diseases, and intolerabilities. Patients 
may have forgotten to report information during the patient interview. However, 
we believe that this risk was reduced by using a structured telephone interview. 
Moreover, several studies have shown that the accuracy of self-reported information 
can be moderate to substantial.19,26
Implicat ions  for  dai ly  pharmac y pract ice
To ensure optimal medication surveillance and patient counselling the Dutch 
Pharmacy Standard concerning the content of pharmaceutical EPRs needs to be 
updated.
Pharmacists should strive to obtain more complete and accurate drug-related 
and patient-bound information, both from the patient and from the prescriber(s) 
involved.12,22,27,28 A more ideal model would be for clinical information to be 
collected and stored by physicians, and medication histories to be obtained 
and updated by pharmacists, with a structural and up-to-date data exchange 
between both information systems. Another model would entail pharmacists 
being granted access to relevant parts of prescribers’ systems or patients’ health 
records. Unfortunately, linking electronic patient information between healthcare 
professionals is still in its infancy. Although, in certain pharmaceutical care projects, 
physicians provide pharmacists with lists of their patients’ diseases, it would 
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be much better if the reason for which each drug is prescribed were structurally 
communicated to the pharmacy.
Pharmacists should be able to enter all relevant patient information into their 
pharmacy information systems in specific data fields (i.e. not as free text) to 
facilitate computerized screening and warnings for potential DRPs.29 When a 
patient visits a pharmacy for the first time, an automated signal should alert the 
pharmacy team to check whether all relevant patient data are known and recorded. 
A structured pharmaceutical interview with all new patients is recommended, and 
a concrete procedure and enough time for the interview should be available in every 
pharmacy. Last but not least, patients should be educated about the importance of 
having an adequate patient record in the pharmacy.
CONCLUSION
After a patient’s first visit to a community pharmacy, the EPR is often incomplete. 
For new patients, the pharmacist should proactively and systematically gather 
patient information, and all relevant patient information should be recorded, 
preferably in coded form, in the pharmacy information system to allow more 
adequate clinical risk management.
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ABSTRACT
Background
Complete and up-to-date medical and pharmaceutical information in the electronic 
patient record (EPR) is a prerequisite for comprehensive risk management in 
community pharmacy.
Object ives
To analyse which information is missing in the EPR and which drug therapy alerts, 
therefore, fail to appear.
Methods
Pharmacy students selected patients who were dispensed a prescription drug 
and enlisted for > 3 months in the participating pharmacies. Patients received 
a questionnaire in which they were asked to verify their medication history, and 
to provide additional patient information. For each enrolled patient, the students 
collected all relevant information from the EPR. Self-reported data from the patient 
were compared with data retrieved from the EPR. Missed information in the EPR 
was evaluated based on national professional guidelines.
Results
Questionnaires were received from 67% of the selected patients (442/660). 
Prescription drugs were missing in the EPR of 14% of the 442 patients, 
nonprescription drugs in 44%, diseases in 83% and intolerabilities in 16%. In 
38% of the patients (166/442), drug therapy alerts failed to appear because of 
missing information: drug-disease interactions in 34% of the patients, duplicate 
medications in 4%, drug-drug interactions (DDIs) in 4%, and drug intolerabilities 
in 2%. Among the (non)prescription drugs missing, NSAIDs were most frequently 
responsible for the missed alerts. Diseases most frequently associated with missed 
alerts were gastroesophageal reflux disease, renal insufficiency, asthma/chronic 
obstructive pulmonary disease, and heart failure.
Conclusions
Relevant patient information was frequently missing in the EPRs. The 
nonappearance of drug therapy alerts may have had clinical consequences for 
patients.
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INTRODUCTION
Incomplete or outdated medical and pharmaceutical information in electronic 
patient records (EPR) represents a risk of overlooking of drug-related problems 
and missing drug therapy alerts.1-3 Improving the quality of this information in the 
EPR may, therefore, contribute to more effective comprehensive risk management. 
For this reason, community pharmacists have initiated medication reconciliation, 
in which patients’ medication orders are compared with the medications they are 
actually taking. Studies have shown that medication reconciliation can identify a 
large number of potentially harmful discrepancies.4,5
Along with prescription drugs, nonprescription drugs, and complementary drugs, 
pharmacists should document other relevant patient information in the EPR for 
both therapeutic risk management and patient counselling purposes, for example, 
diseases, intolerabilities, personal experiences and habits, and practical drug use 
problems.6 A previous study showed discrepancies between the relevant patient 
information in the EPR and the information given by the patient directly after the 
patient’s first visit to a community pharmacy.5 To our knowledge, it has not been 
assessed before whether this medical and pharmaceutical information gap persists 
for patients enlisted for at least three months in a community pharmacy and 
what potential implications the missing information may have for patient harm. 
Therefore, our aim was to analyse what information was missing in the EPRs and 
what drug therapy alerts will fail to appear as a consequence.
METHODS
Sett ing
A total of 78 Dutch community pharmacies, belonging to the Utrecht University 
Pharmacy Practice Research Network (UPPER; which comprises about 50% of all 
1,948 Dutch pharmacies), were invited to participate in this survey during the first 
half of 2008. Pharmacy master’s students, who were practically training in these 
pharmacies, selected patients, distributed patient questionnaires, and collected 
pharmacy data. The students received written and verbal instructions from the 
researcher, and a help desk was available throughout the research period. The work 
was conducted in compliance with the requirements of the UPPER institutional 
review board.
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Study populat ion
We calculated that a sample size of 400 patients would be needed. On a fixed day, 
the students in each participating pharmacy selected a maximum of 12 patients 
who were dispensed a prescription drug. The selected patient had to be enlisted 
in the participating pharmacy for a period longer than three months. The students 
informed the selected patients about the purpose of the study and provided them 
with a print of their medication history from the EPR (dispensed medication data 
concerning the past 12 months as well as contraindications and intolerabilities) 
and a patient questionnaire that included written instructions (reading level: 
independent user). In this questionnaire, the patients were asked to verify their 
printed medication history and to provide additional, relevant patient information. 
They had to return the questionnaire within two weeks to their pharmacy in a 
prepaid return envelope.
The students collected all relevant patient information from the EPR of each 
selected patient (the EPR may also contain noncoded patient information in its 
free-text fields). Only patients for whom both the patient questionnaire and the 
data from the EPR were available were included in the analysis (see Figure 1). For 
patients younger than 16 years, the parents or legal guardians were contacted.
Data col lect ion
The questionnaire (see Appendix A) was adapted from our previous study 5 and 
pretested in five community pharmacies. We collected two types of relevant patient 
information 5,7:
1. The summative type, which concerns data that should be recorded according to 
the professional Dutch Pharmacy Standard (NAN 2006)8 in order to generate 
drug therapy alerts by the pharmacy information system: date of birth, sex, 
(non)prescription drugs, diseases (including renal insufficiency), pregnancy/ 
lactation/desire for motherhood, and intolerabilities (intolerance/allergy).
2. The formative type, concerning data for which information collection is 
not obligatory according to the NAN 2006 but which may nevertheless be 
important for the provision of pharmaceutical care: swallowing problems; 
walking difficulties; poor vision; poor hearing; hemoglobin A1c (HbA1c); blood 
pressure, and renal function values; smoking; periods of fasting (Ramadan); and 
difficulties opening packaging and difficulties administering medication (e.g. 
inhalers for asthma).6
In addition, basic characteristics of the participating pharmacies were collected.
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Data analysis
Data were entered into a Microsoft Access database. Univariate logistic analysis 
(SPSS version 19.0; SPSS Inc, Chicago, IL) was used to compare responding and 
nonresponding patients. Descriptive analysis was used to compare the data from 
the patient’s EPR with the self-reported data from the patient.
Two pharmacists from the research group (AFS and MH) independently evaluated 
all missing summative types of information in the EPR – that is, whether or not drug 
therapy alerts, such as a drug-drug interaction (DDI), drug-disease interaction, 
drug intolerability (allergy/intolerance) or duplicate medication (concurrent use of 
two drugs from the same therapeutic class), could have failed to appear, based on 
current national professional guidelines.9 When no consensus was reached, a third 
pharmacist from the research group (MLB or PAGMDS) was consulted.
Figure 1 Response flow chart
78  community pharmacies were
       invited to participate
60  community pharmacies
       participated (76.9%)
660  patients were selected
399  patients (90.3%)
         with an incomplete EPR
         (summative type of information)
166  patients (37.6%)
          with ≥ 1 missed drug therapy alert
Exclusion criteria patients:
tNo prescription drug dispensed
tEnlisted in pharmacy < 3 months
442  responders (67.0%) 
 female:                  60%
 mean age:            63.9 y (range 5–93)
 age ≥ 40 y:            92.5% 
 use of > 4 drugs:  58.3%
218 nonresponders (33.0%)
Data from 145 nonresponders:
female:                  66%
mean age:            53.9 y (range 1–88)
age ≥ 40 y:            76.4% 
use of > 4 drugs:  37.9%
EPR = electronic patient record
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RESULT S
In all, 60 pharmacies participated in the study (77% of the 78 invited community 
pharmacies and 3% of all 1,948 Dutch pharmacies). Compared with the average 
Dutch pharmacy, the pharmacies participating in our study had more pharmacists 
(2.23 vs. 1.49 full-time equivalents; p = 0.021) and were more often equipped 
with a certified Quality System (66% vs. 57%; p = 0.182).10,11 The most frequent 
reason for not participating was the workload in the pharmacy. Of the 660 selected 
patients, 442 (67%) returned the patient questionnaire (Figure 1). The students 
collected patient information from the EPR of 587 patients (442 responders and 
145 nonresponders). For 73 patients, no information was collected at all. Therefore, 
basic characteristics were available for 145 of the 218 nonresponders. These were 
different from the characteristics of the 442 responding patients. Older patients 
(aged ≥ 40 years) and patients with more than four medications had a significantly 
higher probability of responding (OR 3.8; 95%CI 2.3–6.5 and OR 4.3; 95%CI 
1.2–15.5, respectively).
Summative  types  of  information
Summative types of information were missing in the EPR of 399 of the 442 patients 
(90.3%). One or more prescription drugs were missing in the EPR of 13.6% 
(60/442) of patients (Table 1). In total, 82 of 2,435 prescription drugs that were self-
reported by the patients had not been recorded in the EPR. Prescription drugs that 
were most frequently missing in the EPR were analgesics (n=10), anxiolytics and 
hypnotics (n=6), dermatological corticosteroids (n=6), cardiac drugs (n=5), and 
drugs for obstructive airway diseases (n=5).
Whereas 47.5% (210/442) of patients self-reported the use of nonprescription drugs 
and herbal and dietary supplements, only 8.6% (38/442) of the patients had their 
use of nonprescription drugs and supplements registered in their EPR (in total, 25 
nonprescription drugs). Products most frequently missing were vitamins (n=146), 
acetaminophen (n=59), homeopathic and herbal medicines (n=47), glucosamine 
(n=26) and omega-3 fatty acids (n=32).
In the EPR, at least one disease had been recorded for 60.6% (268/442) of the 
patients; 91.6% (405/442) of the patients reported that they had at least one 
disease. A large number (1,111 of 1,482) of diseases self-reported by the patient 
had not been documented in the EPR, of which cardiovascular disease (n=124), 
osteoarthritis (n=98), hypertension (n=86), gastroesophageal reflux disease (n=72) 
and elevated cholesterol levels (n=58) were most frequently missing.
In the EPR of 16.3% (72/442) of the patients, a total of 97 of 144 self-reported 
intolerabilities were missing; those concerning antibiotics (n=28), acetylsalicylic 
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Table 1 Number of patients with information in the EPR, and information reported 
by the patient and information missed in the EPR (n=442 patients)
EPR Patient Missed in EPR
n (%) n (%) n (%)
Drug use
One or more prescription drugs a 438 (99.1) 435 (98.4) 60 (13.6)
One or more nonprescription drugs a 38 ( 8.6) 210 (47.5) 196 (44.3)
Diseases
One or more diseases a 268 (60.6) 405 (91.6) 365 (82.6)
I ntolerabi l i t ies
One or more intolerabilities (intolerances/ 
allergies) a
74 (16.7) 97 (21.9) 72 (16.3)
Specif ic  condit ions
Pregnancy a , lactation a (female participants 
16–42 years old) 
1 ( 3.4) 2 ( 0.5) 2 ( 0.5)
Walking difficulties b 4 ( 0.9) 101  (22.9) 97 (21.9)
Swallowing problems b 1 ( 0.2) 24 ( 5.4) 23 ( 5.2)
Poor vision b 1 ( 0.2) 65 (14.7) 64 (14.5)
Poor hearing b 1 ( 0.2) 84 (19.0) 83 (18.8)
Fasting (i.e. Ramadan) b 1 ( 0.2) 11 ( 2.5) 10 ( 2.3)
Diagnostic  and monitoring data
Blood pressure b 5 ( 1.1) 178 (40.3) 176 (39.8) c
HbA1c b 3 ( 0.7) 33 ( 7.5) 32 (7.3) d
Renal function b 8 ( 1.8) 10 ( 2.3) 8 ( 1.8) e
Personal  experiences/habits
Smoking (age > 12 years) b 3 ( 0.7) 86 (19.5) 84 (19.0)
Drug use problems
Difficulties opening medical packaging b 6 ( 1.4) 72 (16.3) 68 (15.4)
Difficulties administering medication b 3 ( 0.7) 31 ( 7.0) 31 ( 7.0)
EPR = electronic patient record; HbA1c = hemoglobin A1c
a) Summative type of patient data
b) Formative type of patient data
c) Systolic blood pressure ≥ 140 mmHg reported by 88 patients
d) HbA1c ≥ 7.0% reported by 16 patients
e) Renal function ≤ 60% of the normal renal function reported by three patients
acid/ nonsteroidal anti-inflammatory drugs (NSAIDs; n=11), statins (n=4), iodine 
(n=4) and opioids (n=4) were most frequently missing.
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Formative  types  of  information
Formative types of information were missing in the EPR of 76.2% (337/442) of the 
patients. Table 1 shows that almost no data were recorded in the EPR concerning 
specific conditions, diagnostic and monitoring data, personal experiences and 
habits, and drug use problems, whereas patients often self-reported such data 
(including HbA1c values, renal function values and blood pressure values).
Missed dr ug therapy a ler ts
The absence of medical and/or pharmaceutical data of the summative type 
contributed to the missing of 434 drug therapy alerts in 166 of 442 patients (37.6%), 
an average of 2.6 missed alerts per patient (range 1–11). Table 2 presents the 
number of patients with at least one missed alert.
Table 2 Number of patients with at least one missed drug therapy alert as a result of 
missing summative types of information in the EPR (n=442 patients)
Drug therapy alert Number of patients
n (%)
Drug-disease interaction 150 (33.9)
Duplicate medication 18 ( 4.0)
Drug-drug interaction 16 ( 3.6)
Drug intolerability 10 ( 2.2)
Drug-pregnancy interaction 1 ( 0.2)
Total 166 (37.6)
EPR = electronic patient record
For one-third of all patients (150/442), at least one drug-disease interaction alert had 
not been generated. In total, 375 drug-disease interaction alerts had been missed. 
The top 10 of these alerts are presented in Table 3. Gastroesophageal reflux disease-
NSAIDs and asthma/chronic obstructive pulmonary disease (COPD)-NSAIDs 
(excluding COX-2 [cyclooxygenase-2] inhibitors) were the most frequently missed.
The management of each of these 375 drug-disease interactions required one or 
more actions. In more than half (224/375) of these cases, the patient should have 
been consulted and instructed (e.g. contact physician when symptoms aggravate). 
In 45.1% (169/375) of the interactions, the pharmacist should have checked 
whether the dosage regimen or dosage form needed adjustment (e.g. in case of 
renal insufficiency, the dosage of triamterene should be adjusted to the estimated 
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creatinine clearance of the patient); in 35.7% (134/375), whether the drug choice 
needed adaptation (e.g. replace high-dose amitriptyline with a nontricyclic 
antidepressant drug in patients with angina pectoris); in 14.9% (56/375), whether 
the patient was adequately monitored (e.g. monitoring of blood pressure in 
hypertensive patients using prednisolone); in 6.9% (26/375), whether a prophylactic 
drug needed to be added (e.g. add proton pump inhibitor to NSAID in high-risk 
patients); and in 6.7% (25/375), whether a drug should have been withheld (e.g. 
benzodiazepines in patients with sleep apnea).
At least one DDI alert was missed in 3.6% (16/442) of the patients. In total, 27 DDI 
alerts were missed, which are presented in Table 3. Interactions with NSAIDs were 
the most frequently missed DDI alerts. According to prevailing DDI guidelines, the 
management of each of the 27 DDIs required one or more actions. The pharmacist 
should have examined in 17 of the missed DDI alerts whether the patient was 
monitored (e.g. monitoring of renal function in heart failure patients using a RAAS 
inhibitor and an NSAID, after the decision had been made that NSAID use was 
inevitable). In 14 DDIs, the pharmacist should have consulted and instructed the 
patient (e.g. take thyroid hormone at least two hours before calcium carbonate). 
In 12 DDIs, the pharmacist should have checked whether the drug needed to be 
changed (e.g. replace nonselective ß-blocker with selective ß-blocker when using 
an oral antidiabetic drug); in four DDIs, whether another drug needed to be 
added (e.g. add gastroprotection to NSAID in elderly patients using paroxetine, 
after the decision had been made that NSAID use was inevitable); in two DDIs, 
whether the drug should have been withheld (e.g. vitamin K in users of coumarin 
anticoagulants); and in one DDI, whether the dosage regimen needed adjustment 
(e.g. lower start doses of RAAS inhibitor in patients using loop diuretics).
At least one duplicate medication alert was missed in 4.0% (18/442) of the patients. 
In total, 20 duplicate medication alerts were missed (Table 3). Of these duplicate 
medications, 15 were considered nonplausible according to the guidelines (e.g. 
two topical corticosteroids); five of these duplicate medications were plausible 
(e.g. oxazepam and temazepam). Duplicate medications with NSAIDs and with 
acetaminophen were most frequently missed.
At least one drug intolerability alert was missed in 2.2% (10/442) of the patients. 
NSAIDs (n=3) were the most frequently encountered drug intolerabilities (see 
Table 3).
One pregnancy was missing in the EPRs. This pregnant patient was using ibuprofen 
according to her EPR. The pharmacist should have counselled the patient about 
the potentially negative effects during pregnancy and should have advised her to 
preferably use another analgesic.
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Table 3 Missed drug therapy alerts as a result of missing summative types of 
information in the EPR
Drug therapy alert n (%)
Drug- disease interac t ions (n=375): top 10
GERD-NSAIDs 44 (11.7)
Asthma/COPD-NSAIDs (excl. COX-2 inhibitors) 25 ( 6.7)
Heart failure-β-agonist bronchodilators 14 ( 3.7)
Asthma/COPD-Opioids 12 ( 3.2)
Hypertension-Antithrombotics 12 ( 3.2)
GERD-Nitrates 11 ( 2.9)
GERD-Calcium channel blockers 10 ( 2.7)
Sleep apnea-Benzodiazepines 10 ( 2.7)
Diabetes Mellitus-RAAS inhibitors 8 ( 2.1)
Renal insufficiency-RAAS inhibitors 8 ( 2.1)
Other 221 (58.9)
Drug- drug interac t ions (n=27)  
NSAIDs-β-blockers 5 (18.5)
NSAIDs-Diuretics 5 (18.5)
NSAIDs-RAAS inhibitors 5 (18.5)
Coumarins-Vitamin K substances 2 ( 7.4)
NSAIDs-Corticosteroids 2 ( 7.4)
NSAIDs-Serotonin reuptake inhibitors 2 ( 7.4)
Thyroid hormones-Calcium carbonate 2 ( 7.4)
Bisphosphonates-Calcium carbonate 1 ( 3.7)
β-blockers-Hypoglycemic agents 1 ( 3.7)
QT-prolonging drugs-QT-prolonging drugs 1 ( 3.7)
RAAS inhibitors-Diuretics 1 ( 3.7)
D uplicate  medicat ions (n=20)
NSAIDs 4 (20.0)
Acetaminophen 4 (20.0)
Benzodiazepines 3 (15.0)
Corticosteroids 3 (15.0)
Nitrates 2 (10.0)
Opioids 1 ( 5.0)
RAAS inhibitors 1 ( 5.0)
Insulin 1 ( 5.0)
β-agonist bronchodilators 1 ( 5.0)
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Table 4 shows the missed diseases, (non-)prescription drugs, and intolerabilities as 
a function of the drug therapy alerts that failed to appear. Among the prescription 
drugs missing in the EPR, NSAIDs (n=16), opioids (n=6), and RAAS inhibitors 
(n=6) were most frequently responsible for missed alerts. The nonprescription 
drugs most frequently responsible were NSAIDs (n=26), acetaminophen (n=6), 
benzodiazepines (apparently obtained without a doctor’s prescription; n=4), and 
calcium carbonate (n=4). The diseases most frequently associated with missed 
alerts were gastroesophageal reflux disease (n=67), renal insufficiency (n=45), 
asthma/COPD (n=39), heart failure (n=34), and hypertension (n=29). (See also 
Table 4A)
DISCUSSION
Our study shows that relevant medical and/or pharmaceutical information was 
frequently missing in the EPRs. This may lead to potentially hazardous situations in 
more than one-third of the patients because pharmacy information systems will fail 
to generate drug therapy alerts, such as DDIs, duplicate medications, drug-disease 
interactions, drug intolerabilities and drug-pregnancy/lactation interactions.
In our study, gastroesophageal reflux disease, renal insufficiency, asthma/COPD, 
heart failure, and hypertension accounted for almost 50% of all missed alerts. 
Drug intolerabi l i t ies  (n=11)
NSAIDs 3 (27.3)
Proton pump inhibitors 2 (18.2)
Acetaminophen 2 (18.2)
Atorvastatin 1 ( 9.1)
Sotalol 1 ( 9.1)
Oxazepam 1 ( 9.1)
Nifedipine 1 ( 9.1)
Drug-pregnanc y interac t ion (n=1)
NSAIDs 1 (100)
EPR = electronic patient record; GERD = gastroesophageal reflux disease; NSAIDs = non-steroidal 
anti-inflammatory drugs; COPD = chronic obstructive pulmonary disease; COX = cyclooxygenase; 
RAAS = renin–angiotensin–aldosterone system
Drug therapy alert n (%)
Table 3 continued
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Another important finding was that NSAIDs were responsible for almost 10% 
of all the missing alerts and were involved in 57% of all missed alerts involving 
nonprescription drugs. Calcium carbonate was frequently involved in missed DDI 
alerts involving nonprescription drugs. This confirms a finding by Olesen et al.12 
We also found that some drugs frequently involved in our missed alerts (NSAIDs, 
opioids, nitrates, and benzodiazepines) are described in a systematic review on 
medication history errors.2
Although we found almost three times as many patients with self-reported 
intolerabilities,13 the number of self-reported antibiotic allergies was comparable 
with that in another study.14 In our study, we did not investigate whether patients 
may erroneously have misclassified pharmacological side effects as allergies (e.g. 
diarrhea caused by antibiotics classified as penicillin allergy). For each of the missed 
drug intolerability alerts, the pharmacist should have assessed the precise nature 
of the intolerability because another study has shown that unconfirmed allergies 
occur frequently.15 Accepting these misdiagnoses as real allergies may cause harm 
to patients because they can lead to inappropriate switching to a less-effective or 
more harmful drug without a clinical need for this.
The potential clinical consequences of the 375 missed drug-disease interaction 
alerts in our study population encompassed an increased risk of disease/symptom 
aggravation (76.0%), bleeding (8.3%), cardiac arrhythmias (5.3%), hypotension 
(2.1%), myocardial infarction (1.3%), hyperkalemia (0.5%), lactic acidosis (0.5%), 
Table 4 Number of summative types of information in the EPR missing, resulting in 
missed drug therapy alerts 
Drug therapy alert Alerts (n) Information missing
Prescription 
drug
Nonpre scription 
drug
Disease Intolerability Other
Drug-disease 
interaction
375 24 18 354 – –
Drug-drug 
interaction
 27 11 16 – – –
Duplicate 
medication
 20 13 11 – – –
Drug intolerability  11  3  1 – 9 –
Drug-pregnancy 
interaction
  1 – – – – 1
Total 434 51 46 354 9 1
EPR = electronic patient record
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thrombosis (0.5%), bowel dysfunction (0.5%), hemolysis (0.3%) and several other 
side effects of the drug (8.5%). In 2.9% of the missed drug-disease interactions, 
this may have resulted in decreased effectiveness of the drug. The potential clinical 
consequences of the 27 missed DDI alerts in our study population were decreased 
effectiveness of one of the involved drugs (20 DDIs) and increased risk of side 
effects/toxicity (17 DDIs). These risks potentially encompassed nephrotoxicity 
(10 DDIs), bleeding (4 DDIs), cardiac arrhythmias (1 DDI), hypotension (1 DDI) 
and masking of hypoglycemia (1 DDI).
Our results included a limited number of missed alerts that might have had serious 
clinical consequences.16 For example, two male patients of 83 years and 76 years of 
age, were at risk for gastrointestinal bleeding because they self-reported a history 
of peptic ulcer while using low-dose acetylsalicylic acid on prescription without 
gastroprotection.17 A female patient of 64 years had both a bleeding risk and a risk 
of aggravation of heart failure because she self-reported use of ibuprofen tablet 
(600 mg) in addition to the use of ibuprofen sachet (600 mg) on prescription while 
having heart failure and diabetes mellitus.18
Relevant formative types of information (e.g. swallowing problems; walking 
difficulties; poor vision; HbA1c, blood pressure and renal function values; smoking; 
drug use problems) were missing in the majority of the EPRs of the patients in 
our study. Our results show, for example, that half of the missing diagnostic and 
monitoring information in the EPRs might be clinically relevant because patients 
reported blood pressure and HbA1c values outside the normal range. One out of 
five patients in our study population self-reported smoking, which may cause drug 
interactions, but it should have also led to counselling on smoking cessation.19 
Walking difficulties were self-reported in one-fifth of our patients. Because these 
may be associated with falls in older patients, the use of fall-risk increasing drugs 
(FRIDs) by these patients should have been reviewed.20
The patients also self-reported several practical problems related to drug taking: 
difficulties with the opening of medical packaging, difficulties administering 
medication (e.g. eye drops), swallowing problems, and poor vision. These problems 
could have been overcome by switching to an alternative medication, dosage form, 
or package or by additional counselling by the pharmacist.21
It is becoming more apparent that medication taking is prone to high error rates, 
which can decrease the effectiveness of drug therapy.22 Therefore, pharmacists 
should be aware of the practical drug use problems that patients encounter and of 
the ability of the patient to administer the medication. This suggests that formative 
types of information should also become summative, that is, it should become 
obligatory to collect and document these in the EPRs. At the same time, an overload 
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of drug therapy alerts with questionable clinical relevance should be avoided.23 
Current drug therapy alerts evolve towards clinical decision rules in which patient 
characteristics (e.g. age and disease) and relevant diagnostic and monitoring data 
are also taken into account.24 Further research is needed to fine-tune the content of 
these clinical decision rules.
Our study shows that pharmacists should ensure that EPRs are complete and 
up-to-date.24-26 This not only requires efforts from the pharmacists but also from 
patients and prescribers. It is apparent that relevant medical and pharmaceutical 
information about the patient should be collected not only at a patient’s first visit to 
the pharmacy but at consecutive contacts as well, especially in potentially hazardous 
situations (e.g. after discharge from hospital).
This study has several limitations. First, it is conceivable that the pharmacies 
participating in our study had a more positive attitude toward providing high-
quality pharmaceutical care than the average Dutch pharmacy because they had 
more full-time equivalent pharmacists and, more often, a certified quality system, 
and all of them were active in facilitating student internships. Therefore, our study 
may have underestimated the degree of incompleteness of EPRs in pharmacies 
and the number of missed drug therapy alerts. Second, our responding patients 
were older and used more drugs compared with the nonresponders. This is not 
surprising because these patients might have more time and interest in their drug 
use. Although our study population might not represent the average community 
pharmacy population, we believe the high number of incomplete EPRs and missed 
drug therapy alerts shows the importance of our research.
Finally, we considered the data provided by the patient as our point of reference, 
but patients may have forgotten to report information or may have misinterpreted 
diseases, contraindications, and intolerances. However, we believe that this risk 
was reduced by using a self-administered structured questionnaire, as a result of 
which patients were able to complete the questionnaire at a time and place that was 
convenient for them, and by providing the patients with their medication history 
and written instructions. Moreover, several studies have shown that the accuracy of 
self-reported information can be substantial.27,28
CONCLUSION
This study shows that in about one-third of patients enlisted in community 
pharmacy, drug therapy alerts failed to appear in the pharmacy information 
system because medical and/or pharmaceutical data of the summative type 
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were not complete in the EPR. The nonappearance of alerts may have had 
clinical consequences for patients. The missed diagnostic and monitoring data, 
practical drug use problems, and specific conditions in the EPR may have further 
compromised the effectiveness and safety of their drug therapies. To protect patients 
from potential risk by drug-related problems, pharmacists should make every effort 
to complete and update EPRs.
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Appendix  A Patient questionnaire
 
Patiëntenvragenlijst 
 
 
De kwaliteit van de patiëntgegevens die in de apotheekcomputer zijn vastgelegd 
 
 
 
 
 
Geachte heer/ mevrouw, 
 
Als apotheekteam willen we u graag begeleiden bij het gebruik van uw geneesmiddelen. Ook 
controleren we of al uw medicijnen bij elkaar passen en of de medicijnen die u gebruikt samen 
gaan met eventuele ziekten of overgevoeligheden die u hebt. Om deze begeleiding en bewaking 
goed te kunnen uitvoeren is het zeer belangrijk dat alle actuele gegevens over uw 
geneesmiddelengebruik en medische aandoeningen in onze apotheek bekend zijn. Alleen als wij 
de juiste en volledige gegevens van u in de computer vastleggen, kunnen wij u goede zorg 
verlenen.  
 
Waarom deze vragenlijst? 
Momenteel doen wij mee aan een onderzoek naar de kwaliteit van de patiëntengegevens die in de 
apotheekcomputer zijn vastgelegd. Voor dit onderzoek benaderen we een aantal van onze 
patiënten met het verzoek een vragenlijst in te vullen. De gegevens van elke patiënt worden 
vergeleken met de in de apotheekcomputer vastgelegde gegevens. Met dit onderzoek hopen we u 
en onze andere patiënten nu en in de toekomst nog beter te kunnen begeleiden.  
 
Wat wordt er van u verwacht? 
Wij willen u vragen om de bijgevoegde vragenlijst in te vullen. In de vragenlijst wordt gevraagd 
naar de geneesmiddelen en zelfzorgmiddelen die u gebruikt en eventuele ziekten en 
overgevoeligheden. In de vragenlijst verwijzen we af en toe naar het medicatieoverzicht dat aan 
deze vragenlijst is geniet. Het invullen van de vragenlijst duurt ongeveer tien minuten. Wilt u de 
vragenlijst zo volledig mogelijk invullen? 
 
De ingevulde vragenlijst kunt u in de bijgevoegde envelop bij de apotheek inleveren of naar de 
apotheek opsturen. Wij stellen het zeer op prijs als u de vragenlijst binnen twee weken en uiterlijk 
15 maart 2008 terugstuurt.  
 
Natuurlijk bent u helemaal vrij in de keuze of u aan dit onderzoek meedoet. Wij verzekeren u dat 
uw gegevens vertrouwelijk worden behandeld. Als blijkt dat uw gegevens anders zijn dan wij in 
onze apotheekcomputer hebben staan, dan komen wij hier graag bij u op terug. Persoonlijke 
gegevens worden niet gebruikt in verslagen of rapporten over dit onderzoek.  
 
Als u problemen heeft bij het beantwoorden van de vragen, aarzelt u dan niet contact met ons op 
te nemen.  
 
Met vriendelijke groeten, namens het hele apotheekteam,  
 
Naam apotheek:   
Naam apotheker:  
Telefoonnummer:   
 
 
 
Op de volgende bladzijde beginnen de vragen.
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Uw patiëntnummer volgens de apotheek:  
 
Naam van uw apotheek:  
 
 
Vraag 1.  Persoonlijke gegevens 
 
Op uw medicatieoverzicht, dat is bijgevoegd, staan uw persoonlijke gegevens. Wilt u voor 
onderstaande gegevens nagaan of deze kloppen. 
 
A Mijn achternaam  
 is juist 
   is onjuist  Noteer hier a.u.b. uw achternaam:   
 
B Mijn voorletters  
 zijn juist 
   zijn onjuist  Noteer hier a.u.b. uw voorletters:   
 
C Mijn adres 
 is juist 
 is onjuist Noteer hier a.u.b. uw adres:  
 
  
D Mijn geboortedatum 
Noteer hier a.u.b. uw geboortedatum:  
  
E Mijn geslacht 
Noteer hier a.u.b. of u man of vrouw bent:  
  
F Mijn huisarts 
Noteer hier a.u.b. de naam van uw huisarts:  
 
 
Op uw medicatieoverzicht staan de volgende gegevens niet vermeld. Zou u deze alsnog hieronder 
willen vermelden? 
 
G1 Mijn telefoonnummer thuis:  
 
G2 Mijn mobiele telefoonnummer:  
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Vraag 2.  Geneesmiddelgegevens 
 
Op uw medicatieoverzicht staan uw geneesmiddelgegevens. Wilt u voor onderstaande vragen 
nagaan of de gegevens op uw medicatieoverzicht kloppen. 
 
A1 De medicijnen die op mijn medicatieoverzicht staan 
 gebruik ik allemaal 
  
 gebruik ik niet allemaal Streep a.u.b. op uw medicatieoverzicht de medicijnen door 
die u op dit moment niet gebruikt 
 
A2 De volgende medicijnen ontbreken op mijn medicatieoverzicht: 
(Denk hierbij ook aan medicijnen die u krijgt via het ziekenhuis, de polikliniek, een 
verpleegkundige of internet.) 
Naam geneesmiddel: Ik gebruik dit geneesmiddel sinds 
datum (dd-mm-jjjj): 
1.  
2.   
3.  
4.  
5.  
6.  
7.  
 
B Soms haal ik medicijnen, kruiden of vitamines zonder recept bij de apotheek, de 
drogist of natuurvoedingswinkel of krijg ik ze van anderen. 
De volgende van deze medicijnen, kruiden of vitamines gebruik ik op dit moment: 
1. 
2.  
3. 
4. 
5. 
6. 
7. 
 
Vraag 3.  Medische gegevens 
 
Graag willen wij enkele medische gegevens aan u vragen. 
 
A Zijn er medicijnen waarvoor u overgevoelig (allergisch) bent?  
 Nee  
 Ja, namelijk: 1. 
2. 
3. 
4. 
5. 
 
B Hebt u momenteel een aandoening of ziekte of heeft u in het verleden een ernstig 
gezondheidsprobleem gehad?  
 Nee  
 Ja Kruis in de lijst hieronder aan welke aandoening(en) of ziekte(n) u momenteel 
hebt of in het verleden heeft gehad.  
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A.u.b. 
aankruisen 
Aandoening 
 ADHD 
 Angststoornis 
 Artrose (slijtage van de gewrichten) 
 Astma 
 Baarmoederkanker 
 Bipolaire stoornis (manische depressie) 
 Bloedstollingziekten, zoals hemofilie 
 Borderline 
 Borstkanker 
 COPD (longemfyseem en chronische bronchitis) 
 Dementie 
 Depressie 
 Diabetes type I / type II  (suikerziekte) 
 Endometriose (baarmoederslijmvlies buiten de baarmoeder in de buik) 
 Epilepsie 
 Fenomeen van Raynaud (plotselinge, kortdurende slechte doorbloeding van 
vingers en tenen) 
 Fenylketonurie (stofwisselingsziekte) 
 G6PD-deficiëntie (erfelijke bloedziekte) 
 Galstenen 
 Glaucoom (verhoogde oogboldruk) 
 Glutenovergevoeligheid (Coeliakie) 
 Hartfalen (verminderde pompwerking van het hart) 
 Hartritmestoornissen  
 Hersenbloeding  
 Herseninfarct 
 Hoge bloeddruk 
 Incontinentie voor ontlasting 
 Incontinentie voor urine 
 Jicht 
 Leverziekte (verminderde werking van de lever) 
 Maag- of darmzweer 
 Maagzuur-oprispingen (reflux oesofagitis) 
 Migraine 
 Multiple sclerose (MS) 
 Myasthenia gravis (spierziekte)  
 Nierziekte (verminderde werking van de nieren) 
 Osteoporose 
 Overgangsklachten 
 Parkinson 
 Pijn op de borst (angina pectoris) 
 Porfyrie (stofwisselingsziekte) 
 Psoriasis 
 Psychose 
 Reuma 
 Schildklier, te snel of te langzaam werkend 
 Schizofrenie 
 Slaapapneu 
 Syndroom van Sjögren (ziekte met droge ogen, mond en slijmvliezen) 
 Trombose (stolsels in de bloedvaten) 
 Vergroting van de prostaat 
 Verhoogd cholesterol 
 Ziekte van Crohn of colitis ulcerosa (chronische darmontsteking) 
 Anders, 
namelijk:  
1 
                               2 
                              3 
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Vraag 4.  Bijzondere medische gegevens en leefgewoontes 
 
Graag willen wij nog enkele bijzondere medische gegevens en leefgewoontes van u weten. 
 
A Heeft u slikproblemen?  Ja  Nee 
 B Bent u slecht ter been?  Ja  Nee 
 C Heeft u problemen met het openen van verpakkingen?  Ja  Nee 
 D Heeft u problemen met het toedienen van bepaalde 
medicijnen, zoals oogdruppels, middelen voor astma/ 
COPD?  
 Ja  Nee 
D1 Zo ja, met welke medicijnen?  
 E Bent u slechtziend?  Ja  Nee 
 F Bent u slechthorend?  Ja  Nee 
 G Rookt u?  Ja  Nee 
 H Doet u mee aan perioden van vasten?  Ja  Nee 
 I Doet u aan topsport?  Ja  Nee 
 J Bent u zwanger? (alleen te beantwoorden door vrouwen in de 
vruchtbare leeftijd) 
 Ja  Nee 
 K Geeft u borstvoeding? (alleen te beantwoorden door vrouwen 
in de vruchtbare leeftijd) 
 Ja  Nee 
 
Vraag 5.  Laboratoriumwaarden 
 
Graag willen wij drie belangrijke laboratoriumwaarden bij u navragen. 
 
A Is uw HbA1C waarde in de afgelopen 12 maanden gemeten? 
Let op de HbA1C waarde is niet dezelfde waarde als uw nuchtere glucosewaarde. 
 Nee  
 Ja, maar deze is mij onbekend  
 Ja, en deze is mij bekend, namelijk: % 
en deze is gemeten op datum:  
 B Is uw bloeddruk in de afgelopen 12 maanden gemeten? 
 Nee  
 Ja, maar deze is mij onbekend  
 Ja, en deze is mij bekend, namelijk: mm Hg 
en deze is gemeten op datum:  
 C Is uw nierfunctie in de afgelopen 12 maanden gemeten? 
  Nee  
  Ja, maar deze is mij onbekend  
 Ja, en deze is mij bekend, namelijk: ml/min 
 en deze is gemeten op datum:  
 
Einde 
Dit is het einde van de vragenlijst.  
U kunt de ingevulde vragenlijst in de retourenvelop in de apotheek inleveren of per post opsturen 
naar de apotheek. 
 
Wij danken u hartelijk voor uw medewerking! 
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ABSTRACT
Background
Inconsistencies and omissions in drug-drug interaction (DDI) management 
guidelines may lead to harm and suboptimal therapy.
Object ives
The purpose of this study was to define a checklist for DDI management guidelines 
to help developers produce high-quality guidelines that will support healthcare 
providers in clinical practice.
Methods
We carried out a two-round Delphi process with an international panel of healthcare 
providers, most of whom are pharmacists involved in providing DDI information, 
in order to select those items that should be addressed in DDI management 
guidelines (including grading systems that could be used).
Results
Twenty-three panellists reached consensus on 19 items in two main domains. These 
were consolidated into a checklist of 15 elements for standardized reporting in 
management guidelines. For each element a description is provided to specify what 
information should be documented in that specific element.
Conclusions
It was possible to reach a broad consensus on which relevant items should be 
included in a checklist for the development of DDI management guidelines.
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INTRODUCTION
The main purpose of clinical guidelines is to improve patient care, and these should 
therefore meet criteria that ensure good quality.1 Several instruments have been 
developed to assess the quality of clinical practice guidelines, including checklists 
to specify the nature of information in guidelines,2 appraisal instruments to 
evaluate the quality of guidelines,3,4 and systems for consistent rating of the quality 
of evidence and the strength of the recommendations.5
Such instruments have occasionally been used to develop or evaluate guidelines 
for the management of drug-drug interactions (DDIs).6-10 However, a well-defined 
standard for guidelines on the practical management of (potential) drug-drug 
interactions is not yet available. There is no consensus in the literature about 
how evidence relating to the harm that DDIs may cause should be graded, and 
information on susceptibility factors is not yet systematically reviewed in DDI 
management guidelines.6,10,11 Recommendations on how to manage DDIs are not 
always sufficiently detailed (e.g. 'monitor electrolytes' rather than the more precise 
'monitor potassium and sodium every 4–6 weeks')12 or supported by analyses of 
cost-effectiveness.10
These inadequacies contribute to inconsistencies between information sources with 
respect to the inclusion of DDIs, the grading of their potential seriousness and the 
grading of the quality of the underlying evidence.13-17 Consequently, management 
of DDIs will be inconsistent and may be guided by unclear or unsatisfactory 
advice, so that patients may sometimes be harmed by an avoidable DDI and may 
sometimes be denied therapeutic benefit by an overcautious approach.18
The aim of our study was to define a checklist for developers of DDI management 
guidelines. Such a checklist should assist developers in producing high-quality 
drug-drug interaction management guidelines and support healthcare providers in 
the practical application of the guidelines.
METHODS
We carried out a two-round Delphi process with a large international panel 
of healthcare providers, most of whom are pharmacists involved in providing 
DDI information, in order to select the items that should be addressed in DDI 
management guidelines, including grading systems that could be used.9,19,20
We identified and contacted potential panel members through contact information 
available in the literature and through our research network based on predetermined 
inclusion criteria: the potential panel members had published scientific papers in 
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the field of DDIs and/or were involved in writing DDI information sources and 
had either a medical or a pharmaceutical background (general practitioners, 
medical specialists, clinical pharmacologists, community pharmacists, hospital 
pharmacists). Our aim was to approach a broad range of representatives from a 
variety of countries. From the 44 invited panellists who fulfilled these criteria, 32 
agreed to participate. The main reason for non-participation was lack of time.
The panellists were asked to express their views on the relevance and 
comprehensiveness of a set of potential items for DDI management guidelines and 
their preferences on proposed grading systems. We assembled an initial set of two 
main domains with 19 potential guideline items from validated general instruments 
to assess and improve the quality of clinical practice guidelines,2-5,21-23 the systems 
for grading the levels of evidence and the strengths of recommendations 24 and the 
published instruments for developing or evaluating guidelines for the management 
of DDIs (see Appendix A: Identification of DDI management guidelines items).
The panellists received a set of potential guideline items that included a detailed 
description of each item. They also received instructions on how to indicate 
their level of (dis)agreement on the relevance of each item in the management of 
DDIs (a nine-point scale, in which point 5 was neutral, according to the RAND 
appropriateness method)25. Rating an item as 9 indicated strong agreement that it 
was relevant; rating an item as 1 indicated strong disagreement.25
We used the pretested online survey tool NetQ (http://netq.co.uk/lang/EN/) to 
present the questionnaires to the panellists. Online rating permits accurate and 
efficient data capture and analysis.26
In the first Delphi round the panellists were asked to score each item and to provide 
comments regarding their scores. They were also allowed to add, modify or reword 
items. The decision to include items in round 2 was based on an analysis of the 
scores for each of the items, the criteria for consensus on acceptance and rejection 
of items (see Analysis), the panellists’ comments or suggestions and the literature 
underpinning the initial set of items. All newly suggested items were discussed and 
classified as (1) suitable for inclusion in the proposed list of items, (2) of uncertain 
suitability for inclusion and (3) unsuitable for inclusion because, for example, an 
item was already covered by guideline items in the initial set. Suggestions classified 
as 1 and 2 were presented as new items to the panellists in the second round.
All panellists received feedback on the decisions from the first Delphi round, 
including the level of agreement for each item, the panellist’s individual score, the 
level of consensus and a summary of the free text comments of the panellists.
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In the second Delphi round all those who participated in round 1 were sent the 
second questionnaire and asked to rate the items. Again, they were asked to provide 
reasons for their scores.
The research team then decided which items were to be accepted, using the same 
criteria as in the first round. For some items minor textual changes were made for 
clarification. The results of the second round were presented to the panellists in a 
final report for information purposes only.
Finally, closely related accepted items were consolidated into a checklist of elements 
for standardized reporting.
Analysis
In both rounds, the level of agreement with each item and the level of consensus 
among the panellists were calculated using the RAND method, which is based on 
the median value and the dispersion of the rating results. A median of 7–9 indicates 
that 'the item is relevant', a median of 4–6 indicates 'uncertain whether the item is 
relevant' and a median of 1–3 indicates that 'the item is not relevant'. For evaluation 
of the variation among the ratings, we used the Disagreement Index (DI). If the DI 
was < 1.0, we concluded that there was sufficient consensus to include or exclude 
the item.27
At the end of each round, the items that achieved a positive consensus (median 7–9, 
DI < 1.0) were accepted. Any item that achieved a negative consensus (median 1–3, 
DI < 1.0) was rejected. The items for which no consensus was reached in round 1 
(median 4–6 or DI ≥ 1.0, or both) were re-rated by the panellists in round 2. At the 
end of round 2, the items for which no consensus had been reached (median 4–6 or 
DI ≥ 1.0 or both) were rejected.
RESULTS
Of the 32 panellists who agreed to take part in the checklist development, 23 
(72%) participated in the Delphi rounds. The reasons for non-response were: 
difficulties in understanding English, insufficient time and illness. Seventeen of the 
23 respondents were from Europe, five from the USA and one from Australia. The 
respondents were mostly pharmacists (83%) and physicians (17%), and they were 
actively working as healthcare service researchers (70%), educators (48%), and 
clinical pharmacologists (22%); all had experience in the writing and/or assessment 
of DDI management information. Almost 40% of the panellists indicated that they 
had experience in guideline development.
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Table 1 Outcome of the Delphi rounds: elements for standardized reporting in 
drug-drug interaction management guidelines
Guideline element Description
Main domain: 'Background'
(reason for managing a DDI)
The elements in this domain should explain why a 
healthcare provider is supposed to manage a DDI, 
and what harm can result from the DDI.
1. Quality of evidence for harm Grade the quality of evidence for harm by the 
DDI. Describe the specific grading system used 
and define or refer to a detailed explanation of 
the grading.
2. Level of evidence Express the grading of the quality of the evidence 
for harm by the DDI as levels of evidence.
3. Pharmacological plausibility of the DDI Grade the pharmacological plausibility of the DDI:
0) no known mechanism
1) plausible mechanism, but no firm evidence
2) mechanism supported by firm evidence
4. Seriousness of the potential adverse 
outcomes of the DDI
Judge the seriousness of the adverse outcomes 
of the DDI, using the code of seriousness of van 
Roon et al.6,31,32:
A. Clinically irrelevant effect
B. Temporary discomfort (< 24–28 h) without 
residual symptoms
C. Longer-lasting discomfort (48–168 h) 
without residual symptoms
D. Long-lasting discomfort (> 168 h) or 
permanent residual symptoms or handicap
E. Increased risk of failure of life-saving therapy; 
increased risk of pregnancy (without risks 
concerning mother or fetus or both)
F. Serious, irrecoverable disability or death; 
increased risk of pregnancy (with risks 
concerning mother or fetus or both)
5. Incidence of the adverse outcomes Describe the incidence of each adverse outcome 
in patients given the combination of the 
interacting drugs; if incidence is lacking for a 
specific outcome acknowledge this.
6. Clinical impact of the DDI at the population 
level
Address the clinical impact of the DDI at the 
population level and consider both the incidence 
and seriousness of the adverse outcomes.
7. Susceptibility factors List patient susceptibility factors and rate the 
quality of the evidence.
8. Clinical impact of the DDI at the patient 
level
Address the clinical impact of the DDI at the 
individual patient level, in the context of 
susceptibility factors.
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Guideline element Description
Main domain: 'Management Strategy'
(how to manage a DDI)
The elements in this domain should indicate how 
the DDI should be managed.
9. Strength of recommendations for 
interventions
Classify the strengths of recommendations for 
interventions to prevent harm from the DDI, 
based on the factors 'balance between desirable 
and undesirable effects of an intervention', 
'quality of evidence', 'patients’ values and 
preferences', and 'costs'. Describe the specific 
grading system used and define or refer to a 
detailed explanation of the grading.
10. What to manage Present the available management options for 
preventing an adverse DDI outcome, preferably in 
the form of an algorithm.
11. When to start management Specify when management of the DDI should 
start.
12. How to monitor Specify which biomarkers should be monitored, 
how frequently, which outcomes need to be 
looked for, and how to respond to the outcomes. 
Types of biomarkers are: symptoms (e.g. 
muscle pain), signs (e.g. pulse rate) or special 
investigations (e.g. drug plasma concentrations).
13. When to stop management Specify when to stop managing the DDI.
14. A set of symbols, letters, and/or numbers 
for communication
Present a set of symbols, letters, and/or numbers 
to communicate the levels of evidence and 
recommendations. Provide a clear explanation of 
the set.
15. Brief summary Provide a summary that includes essential 
information about the mechanism and 
seriousness of the DDI, the relevant susceptibility 
factors, and the management options for 
preventing an adverse outcome.
DDI = drug-drug interaction
Table 1 continued
In the first Delphi round the panellists accepted two main domains and 17 of the 19 
items. Two of the 19 items were fully returned in the second round, together with 
two newly proposed items and three items for which suggestions for modification 
and rewording were proposed.
In the second Delphi round, one of the two fully returned items, one of the two 
newly proposed items and all of the proposed modifications and rewording for the 
three other items were accepted. Appendix B presents a complete listing of all the 
items and their scores. The final outcome was that panellists identified 19 guideline 
items and two main domains to be addressed in DDI management guidelines if the 
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guidelines are to provide adequate information for good clinical management. The 
items that clearly belonged together were then combined, and a list of 15 elements 
for standardized reporting in DDI management guidelines was established. Each 
element in the list is provided with a description to indicate the nature of the 
information that should be documented for that specific element (see Table 1).
DISCUSSION
The participants in this Delphi process achieved consensus on a set of items that 
they considered to be important aspects of DDI management guidelines. We have 
grouped these in a list of elements to assist developers in producing high-quality 
DDI management guidelines and to help end users to apply guidelines more 
consistently. This checklist is designed to ensure that all important information is 
included in the guideline documentation. If adequate data on the DDI are lacking 
for a specific element (e.g. a certain patient susceptibility factor) the guideline 
should indicate this. Identification of these gaps will also be interesting for 
researchers in the field of DDIs.
We could not identify a generic comprehensive instrument to guide the 
development of DDI management guidelines, although individual organisations 
have procedures for developing DDI management guidelines and may use grading 
systems that distinguish levels of evidence for DDI-related harm.6,11 The willingness 
of our panellists from Europe and the USA to participate suggests that there is a 
widely perceived need for such a generic instrument.
The current description of the elements specifies the nature of the information 
that should be documented in the guidelines. The quality of the content of the 
information remains the responsibility of the guideline developers. It is therefore 
of real concern that several terms used in DDI management guidelines are not very 
well defined, causing difficulties in their interpretation. During the Delphi exercise 
it became clear, for example, that the term 'seriousness' is not always differentiated 
from 'intensity' or 'severity'. Guideline developers should therefore clearly define 
the terms that they use. A universally agreed set of standard operational definitions 
would be useful.
It is also left to guideline developers to decide which grading systems to use 
for the quality of evidence of harm from DDIs (see Table 1, element 1) and the 
strengths of recommendations for interventions to prevent harm by DDIs (see 
Table 1, element 9). The panellists commented that the available grading systems 
for these elements are either insufficient or unnecessarily complex. However, the 
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development of new grading systems was beyond the scope of this study. As an 
intermediate step, guideline developers should describe the specific grading system 
used and refer to a detailed explanation of the grading.
Since the success of a Delphi process largely depends on the quality of the panel,28 
we pursued a broad representation of different points of view on DDI management 
guidelines, using healthcare professionals who were involved in the field of DDIs 
from a variety of countries. A potential disadvantage of the Delphi method is that 
it tends to eliminate views that are perceived to be extreme but may nevertheless be 
relevant. We were alert to this problem and believe that it did not arise in our study 
in view of the high degree of consensus achieved in round 1 and the possibility 
for panellists to add comments. While not all those who originally volunteered 
took part in the study, we were fortunate that all respondents who completed the 
first Delphi round also completed the second round. This further increases our 
confidence in the results.
An increasingly important function of guidelines for DDI management is to act as 
a basis for meaningful clinical decision support (CDS) systems (e.g. generating DDI 
alerts) in electronic prescribing or pharmacy information systems.29 For this it is 
essential to use a systematic, transparent and comprehensive approach to assess and 
report the evidence for the potential clinical impact of a DDI in a guideline. The 
same applies for the assessment and reporting of DDI management strategies (i.e. 
interventions by the physician or pharmacist to avoid or reduce harm by a DDI). 
We believe that our list of necessary elements contributes towards achieving these 
ends.
Our Delphi rounds confirm earlier studies which found that:
t the clarity of guidelines for the management of potentially harmful drug 
interactions can be further improved by a clear differentiation between the 
strength of recommendations of the management strategies and the presentation 
of risk factors and patient modifiers;10
t the monitoring of biomarkers should be reported in more detail;12,30
t the cost-effectiveness of recommendations should preferably be addressed.10
We believe that our checklist for standardized reporting of DDI management 
guidelines can not only assist to improve these aspects but can also further the 
consistency of DDI management guidelines in other ways. This became clear when 
we tested its feasibility by applying it to a concrete example: the DDI between 
thiazides (and related diuretics) and selective-serotonin reuptake inhibitors 
(SSRIs) (or serotonin-norepinephrine reuptake inhibitors) – see Chapter 3.2. This 
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exemplary guideline differs from various current guidelines for the management of 
this DDI by providing extensive information on:
t symptoms of hyponatraemia and corresponding serum concentrations of 
sodium;
t epidemiological data on the incidence of hyponatraemia (in general and in users 
of thiazides and SSRIs);
t patient susceptibility factors for hyponatraemia (in general and in users 
of thiazides and SSRIs) including the major non-pharmacological and 
pharmacological causes of hyponatraemia;
t the different management options including details about monitoring (when to 
monitor, cost-effectiveness of monitoring) and about patient consultation and 
instruction;
t an algorithm of the different steps that can be taken when thiazides and SSRIs 
are combined for the first time;
t formalized assessments of the evidence underlying the data reviewed, 
the pharmacological plausibility of the DDI and of the strength of the 
recommendations offered;
t information about how to respond, when hyponatraemia develops during 
combined use of thiazides and SSRIs.
The test guideline also showed us that we could slightly improve the checklist that 
emerged from the Delphi rounds (e.g. by adding the obvious element that the 
drugs or drug groups involved need to be specified). We also became aware that the 
clarity and usefulness of the checklist is enhanced by explaining each of its elements 
in sufficient detail. Therefore, we prepared a well-annotated version of the final 
checklist for future consultation by DDI guideline developers and end users (see 
Chapter 3.3).
CONCLUSION
The participants in this Delphi process achieved consensus on a set of guideline 
items that resulted in a checklist for standardized reporting in DDI management 
guidelines. This checklist should allow developers to improve the quality of DDI 
guidelines that will optimally help healthcare providers to improve patient care.
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Appendix  A Identification of DDI management guidelines items
Search in Medline: “Practice Guidelines as Topic/standards"[MeSH] OR “Evidence-Based
Medicine/standards”[MeSH] AND "clinical practice guidelines" AND "quality" AND
("appraisal instrument" OR "checklist" or “assessment”) AND ("1999/01/01"[Date - Publication] :
"2011/04/01"[Date - Publication]) AND "English"[language]
Manual and online searching for additional references and papers on validated general
instruments to assess and improve the quality of clinical practice guidelines
Identification of systems for grading the level of evidence and the strength of
recommendations
59 articles retrieved on instruments for developing/evaluating guidelines for the
management of drug-drug interactions (DDIs)
Selection of articles containing information on the quality and comprehensiveness of drug
interaction information in management guidelines and other sources
36 articles selected containing information on the quality and comprehensiveness
of drug interaction information in management guidelines and other sources
Initial set of 19 potential guideline items for drug-drug interaction management guidelines
Delphi round 1
17 of 19 items and two main domains accepted. Two newly proposed items and
three items with suggestions for modification and rewording.
19 items and two main domains accepted
Final checklist of 15 elements for standardized reporting in DDI management guidelines
Delphi round 2
Search in Medline: (“drug interaction”[Title] OR “drug-drug interactions”[Title] OR “drug
interactions”[Title]) AND “Drug Interactions”[MeSH] AND (“Guidelines as Topic”[MeSH] OR
“Drug Information Services”[MeSH] OR “Drug Prescriptions/standards”[MeSH] OR “Decision
Support Systems, Clinical”[MeSH] OR "Medication Errors/prevention and control"[MeSH] OR
“Database Management Systems”[MeSH) AND (quality or assessment or “drug interaction
information” or alerts or compendia) AND ("1999/01/01"[Date - Publication] : "2011/04/01"
[Date - Publication]) AND ”English"[language]
Manual and online searching for systems grading the level of evidence and the strength of
recommendations using references from the article of Atkins et al.24
Identification of validated general instruments to assess and improve the quality of
clinical practice guidelines: Shaneyfelt’s Instrument,21 Checklist to assess the quality
of guidelines endorsed by speciality societies (Grilli et al.),22 Appraisal Instrument for
Clinical Guidelines by Cluzeau,4 Template of Guideline Attributes of the National
Guideline Clearinghouse,23 AGREE (Appraisal of Guidelines for Research and
Evaluation),3 GRADE (Grading of Recommendations Assessment, Development
and Evaluation),5 and the COGS (Conference on Guideline Standardization) checklist.2
53 articles retrieved on instruments to assess and improve the quality of clinical
practice guidelines
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3
D OMAIN BACKGROUND
(REASON FOR MANAGING THE DRUG -DRUG INTER ACTION )
1.  Interact ion dr ugs  and dr ug groups involved in  the  dr ug-dr ug 
interact ion
(only exhaustive for the Dutch drug market)
t ćJB[JEF EJVSFUJDT: bendroflumethiazide, chlorothiazide, cyclothiazide, 
hydroflumethiazide, hydrochlorothiazide, and polythiazide.
t %JVSFUJDT SFMBUFE UP UIJB[JEF EJVSFUJDT: chlortalidone, clopamide, indapamide, 
mefruside, metolazone, and xipamide.
t 4FMFDUJWF TFSPUPOJO SFVQUBLF JOIJCJUPST 	443*T
: citalopram, escitalopram, 
fluoxetine, fluvoxamine, paroxetine, and sertraline.
t 4FSPUPOJOOPSFQJOFQISJOF SFVQUBLF JOIJCJUPST 	4/3*T
: desvenlafaxine, 
duloxetine, venlafaxine. There is evidence to suggest that the noradrenaline 
reuptake inhibiting (NRI) potency of these agents is too large to enable 
substantial NRI effects at therapeutic doses, without engendering excessive 
serotonin reuptake inhibiting (SRI) effects.
t To err on the safe side of caution, clomipramine should also be included, 
because this tricyclic antidepressant has similar SRI potency as SSRIs.1
2.  Cl inica l  impact  of  dr ug-dr ug interact ion at  populat ion le vel *
4VNNBSZ
Both thiazides/related diuretics and SSRIs/SNRIs entail a risk of hyponatraemia 
(HN), when given alone. The resulting HN is most often mild (sodium ≤ 135 
mmol/l but ≥ 130 mmol/l), but both drug groups have been associated with severe 
HN in case reports [Grade C], which can potentially be fatal [Seriousness code F].
Severe HN has been observed in 0.9% of 951 thiazide users in primary care 
[Grade B] and in one of 75 (1.3%) elderly depressed patients started on paroxetine 
[Grade C]. It is generally assumed that the risk of severe HN can increase further 
by combining the thiazide with an SSRI/SNRI but the extent to which this occurs 
is unknown. A small-sized case control study has provided evidence to suggest 
* See Appendix A at the end of this monograph for details.
The quality of the body of evidence for harm caused by the DDI has been graded by using the 
rating system of the American College of Chest Physicians (ACCP), which is an adaptation of 
the grading method of the GRADE (Grading of Recommendations Assessment, Development and 
Evaluation) Working Group system.2
The seriousness of the potential adverse DDI outcome has been rated by means of the six-point 
scale developed for this purpose by the Dutch Working Group on Pharmacotherapy and Drug 
Information.3
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that such combinations may have a synergistic effect rather than an additional one 
[Grade C].
4FS JPVTOFTT PG QPUFOUJBM BEWFSTF PVUDPNFT PG  UIF ESVHESVH
JOUFSBDUJPO
The seriousness of the potential adverse outcomes of the drug-drug interaction 
(DDI) between thiazides/related diuretics and SSRI/SNRIs depends on the severity 
of the hyponatraemia (HN) that can develop. In general, HN is classified as:4,5
t mild (serum sodium < or ≤ 135 mmol/l but > or ≥ 130 mmol/l);
t moderate (serum sodium < or ≤ 130 mmol/l but > or ≥ 125 mmol/l);
t severe (serum sodium < or ≤ 125 mmol/l)
Mild to moderate cases of HN associated with a thiazide/related diuretic (HN-T) 
often remain asymptomatic, but vague symptoms such as fatigue or nausea are 
possible.6 Some patients experience gait and attention deficits which increase 
the risk of falls and fractures.7 Severe HN-T can be associated with nausea and 
vomiting, abdominal pain, muscular weakness, headache, confusion, dizziness, 
and lethargy.6,7 Severe HN-T that is rapidly evolving can lead to cerebral edema, 
seizures, coma, brain damage, respiratory arrest, brain stem herniation, and 
death.8-10 However, severe HN-T apparently has a lower risk of mortality than 
severe HN by other causes (such as heart failure or liver disease).11
*ODJEFODF PG BEWFSTF PVUDPNFT  JO QBUJFOUT VTJOH  UIF ESVHESVH
JOUFSBDUJPODPNCJOBUJPO
No concrete information has been found in the literature about the incidence of 
HN in patients given combinations of a thiazide/related diuretic and an SSRI/SNRI. 
Table 1 summarizes more general studies of the incidence of HN (in general or 
severe) in different populations as well as the risk factors observed in these studies. 
It should be noted that the latter information is determined by the selection of risk 
factors in the underlying studies.
Thiazides and related diuretics are a common cause of severe hyponatraemia 11,12 
and are thereby among the more common causes of potentially preventable drug-
related hospital admissions.13,14
In the Dutch Rotterdam Study of elderly outpatients, HN was seen in 3.9% of 
13,325 patients ≥ 45 years. The HN was severe in 48 cases (0.4%) and exposure to 
thiazide diuretics significantly increased the risk of severe HN (adjusted hazard 
ratio (HRadj) = 8.3).5,15 In a study in British primary care, HN was seen in 13.7% 
of 951 users of thiazides or related diuretics; nine (0.9 %) of the cases were severe.4
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In a prospective study, initiation of paroxetine produced HN in nine of 75 (12%) 
elderly patients with depression; the HN was moderate in six patients (8%) and 
severe in one (1.3%) patient.16
Concrete information about the incidence of individual adverse outcomes/
symptoms associated with severe HN (such as seizures) has not been retrieved 
from the literature.
3.  Patient  susceptibi l ity  factors †
4VNNBSZ
Specific studies of the risk factors which increase the susceptibility for severe HN 
in patients using a combination of a thiazide/related diuretic and an SSRI/SNRI 
have not been found in the literature. However, considerable information exists 
on the susceptibility factors which increase the risk of HN in general or the risk 
† See Appendix A at the end of this monograph for details.
The quality of the body of evidence for the identification of patient susceptibility factors has been 
graded by using the rating system of the American College of Chest Physicians (ACCP), which is 
an adaptation of the grading method of the GRADE (Grading of Recommendations Assessment, 
Development and Evaluation) Working Group system.2
Table 2 Principal risk factors to be taken into account when evaluating the potential 
risk of hyponatraemia when combining a thiazide/related diuretic with an 
SSRI/SNRI
Basic patient characteristics
Previous episode of HN-T or HN-S
Older age
Lower body mass
High fluid intake
Low sodium intake
Low serum sodium concentration
Drug use characteristics
High dose of thiazide 
Principal medical conditions 22,23,59 a
Cirrhosis. Hypothyroidism
Addison’s disease
Nephrotic syndrome
Diabetes mellitus (uncontrolled)
Pulmonary infections, COPD
Malignancies
Concurrent drug therapies
Carbamazepine or oxcarbazepine
Desmopressin or terlipressin
Certain anticancer agents b
Chlorpropamide
SSRI = selective serotonin reuptake inhibitors; SNRI = serotonin-norepinephrine reuptake inhibitors; HN-T = 
hyponatraemia associated with a thiazide/related diuretic; HN-S = hyponatraemia associated with a SNRI/SSRI; 
COPD = chronic pulmonary obstructive disease
a) See Table 3 for a more complete overview of causes. Medical conditions that are insufficiently specified or are 
reported in Table 1 as insignificant factors have been excluded.
b) Vinca alkaloids, platinum compounds, cyclophosphamide, ifosfamide (see Table 4).
92
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Table 3 Classification of hyponatraemia (after references 12 and 60)
H ypovolemia (decreased volume of extracellular fluid)
Renal loss, urine sodium > 30 mmol/l
t Diuretics
t Salt wasting nephropathy
tMineralocorticoid deficiency (Addison’s disease)
Extrarenal loss, urine sodium < 30 mmol/l
t Dermal losses, such as burns, excessive sweating
t Gastrointestinal losses, such as vomiting, diarrhoe a
t Pancreatitis
H yper volemia  b (increased volume of extracellular fluid)
Urine sodium < 30 mmol/l
t Congestive cardiac failure
t Cirrhosis with ascites
t Nephrotic syndrome
Urine sodium > 30 mmol/l
t Chronic renal failure
Euvolemia (essentially normal volume of extracellular fluid)
Urine sodium > 30 mmol/l
t Thiazide diuretics a
t Syndrome of inappropriate antidiuretic hormone secretion (SIADH) which can have various causes, 
such as:
 - Cancer
 - Central nervous system disorders
 - Drugs (e.g. desmopressin, NSAIDs, SSRIs, opioids, carbamazepine, cyclophosphamide, 
vincristine)
 - Pulmonary infections, COPD
 - Miscellaneous (postoperative state, pain, severe nausea, HIV infection)
t Hypothyroidism
t Hypopituitarism (glucocorticoid deficiency)
t Decreased intake of solutes (e.g. tea-and-toast diet)
tWater intoxication
 - Primary polydipsia
 - Excessive administration of parenteral hypotonic fluids
 - Post-transurethral prostatectomy
NSAID = nonsteroidal anti-inflammatory drug; SSRI = selective serotonin reuptake inhibitors; COPD = chronic 
pulmonary obstructive disease; HIV = human immunodeficiency virus
a) Patients with hyponatraemia induced by thiazides can present with variable hypovolemia or apparent 
euvolemia, depending on the magnitude of the sodium loss and water retention.
b) Paradoxical retention of sodium and water despite a total body excess of each.
of HN associated with a thiazide/ related diuretic or with an SSRI/SNRI. On the 
basis of this information, Table 2 summarizes the principal risk factors to be taken 
into account when evaluating the potential risk of HN when combining a thiazide/
related diuretic with an SSRI/SNRI [Grade C].
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)/JOHFOFSBM
Table 3 lists various causes of HN in general. Table 4 reviews which drugs and drug 
groups have been associated with HN. These general causes of HN must be taken 
into consideration in addition to the specific risk factors discussed below.
The risk that sodium and water homeostasis is affected by intercurrent infections, 
vomiting, diarrhea, fever, great physical strain, or a heat wave should also be 
considered.13,17,18
Pre-existing asymptomatic HN is associated with a high risk for the development of 
severe symptomatic HN.19
)/BTTPDJBUFEXJUI B  UIJB[JEFSFMBUFEEJVSFUJD  	)/5

Epidemiological studies and case reports imply that a rechallenge after HN-T, older 
age, lower body mass, lower serum potassium, and concurrent use of certain other 
drugs are among the major risk factors for HN-T. The risk can also be increased by a 
high dose of thiazide, high fluid intake (polydipsia), low sodium intake, and perhaps 
by a prior serum sodium concentration in the low–normal range. Female gender 
and impaired renal function have also been implicated but these have not emerged 
as independent risk factors in epidemiological studies (see Table 1).6,7,10,20-26
)/BTTPDJBUFEXJUI BO443* 4/3*	)/4

Epidemiological studies and case reports imply that the risk of HN-S is increased by 
a rechallenge after HN-S, older age, lower body mass, high serum potassium (> 5.0 
mmol/l), low sodium intake, and concurrent use of diuretics (see Table 1).27-29
In a prospective study, initiation of paroxetine produced moderate to severe HN in 
seven (9%) of 75 elderly patients with depression, all of whom had a pre-existing 
sodium level of 135-139 mmol/l.16
)/BTTPDJBUFEXJUI B  UIJB[JEFSFMBUFEEJVSFUJD QMVT BO443*4/3*
It is generally assumed that combinations of a thiazide/related diuretic with an 
SSRI/SNRI entail a higher risk of HN than each drug alone.17,22,24,30,31 In a small 
case control analysis of antidepressant users ≥ 65 years with sodium ≤ 130 mmol/l 
versus users with sodium > 135 mmol/l, SSRIs alone and diuretics alone yielded an 
ORadj (adjusted odds ratio) of 6.2 and 1.0, respectively, while their combination gave 
an ORadj of 148.32
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4.  Quality  of  e v idence for  harm by the  dr ug-dr ug interact ion ‡
-FWFM PG FW JEFODF  GPS IBSN<(SBEF$>
Published clinical evidence suggesting that the combined use of a thiazide/related 
diuretic and an SSRI/SNRI increases the risk of severe symptomatic HN consists of 
case reports 24,33 and a small-sized case control study.32
1IBSNBDPMPH JDBM QMBVTJCJ M JUZ PG  UIF ESVHESVH JOUFSBDUJPO
<1MBVTJCJ M JUZ DPEF >
There is evidence from epidemiological studies and case reports that thiazides/
related diuretics and SSRIs/SNRIs can both produce severe HN, when given alone. 
Positive rechallenges have been reported for the thiazide diuretics 10,20,34,35 and more 
rarely for the SSRIs/SNRIs.22,27,28,36-38
The likelihood of a pharmacodynamic DDI between these drug groups is supported 
by case reports 24,33 and a small case-control study.32 Another argument is that these 
drug groups probably induce severe HN through different mechanisms:
t ćJB[JEFTSFMBUFEEJVSFUJDT
The mechanisms underlying HN-T are not yet fully understood. The fact that 
only some individuals develop a severe, dose-independent HN suggests an 
idiosyncratic effect, which perhaps comes from a genetic predisposition.7 
Among the mechanisms suggested so far are:35,39,40
 - excess renal loss of sodium and potassium (resulting from diuretic-induced 
electrolyte losses and antidiuretic hormone (ADH)-induced water retention);
 - diuretic-induced volume depletion (which stimulates ADH secretion);
 - coexisting hypokalemia leading to an exchange in which potassium leaves the 
cells to replenish extracellular stores, whereas sodium moves into the cells;
 - direct inhibition of urinary dilution by diminishing sodium chloride 
reabsorption in the renal tubules;
 - stimulation of thirst;
 - excessive ADH secretion.
t 443*T4/3*T
HN associated with the use of SSRIs/SNRIs is generally attributed to a central 
increase of ADH secretion.33,39
‡ See Appendix A at the end of this monograph for details. The quality of the body of evidence for 
harm caused by the drug-drug interaction (DDI) has been graded by using the rating system of the 
American College of Chest Physicians (ACCP), which is an adaptation of the grading method of 
the GRADE (Grading of Recommendations Assessment, Development and Evaluation) Working 
Group system.2 The pharmacological plausibility of the DDI has been rated by means of a three-
point scale developed for this purpose by the authors of the article to which this appendix belongs.
99
Exemplar y  DDI  management  guidel ine |  Chapter  3 .2
D OMAIN MANAGEMENT
(HOW TO MANAGE A DRUG -DRUG INTER ACTION )
5.  Potentia l  management  strategies  for  pre venting adverse  dr ug-
dr ug interact ion outcome §
Strateg y I .  Do not  star t  dr ug [Grade C]
If one of the two interacting drugs has not yet been started, one may substitute the 
drug to be started with a non-interacting alternative drug, if additional risk factors 
are present (Table 2):
t a UIJB[JEF PS SFMBUFE EJVSFUJD may be replaced with another type of 
antihypertensive;
t a 443*PS4/3* may be replaced with an another type of antidepressant such as 
mirtazapine or a tricyclic antidepressant other than clomipramine (see Table 4). 
Although such alternatives have been associated less frequently with HN, it 
should be noted that they may not always be risk free in patients susceptible to 
SSRI/SNRI-associated HN.41
Substitution is especially the most appropriate course of action, if the drug to be 
started has already produced HN in the patient in the past. It has been reported that 
rechallenge of susceptible patients with a single dose of a thiazide can be enough for 
an acute drop of serum sodium concentration.20
Strateg y II .  Monitoring of  the  patient  [Grade C]
There is no consensus in the literature how useful determination of the serum 
sodium concentration is in asymptomatic patients.30 A common recommendation 
is to determine serum sodium at 5–14 days after the start of the combination 
only in users with one or more additional risk factors (Table 2).6,7,14,17,31 A repeat 
measurement is appropriate, when the risk is further increased by an additional 
risk factor (e.g. intercurrent illness) or by an increase in the dose of the thiazide/
related diuretic or SSRI/SNRI.14
§ See Appendix A at the end of this monograph for details.
The quality of the body of evidence for the presented DDI management options has been graded 
by using the rating system of the American College of Chest Physicians (ACCP), which is an 
adaptation of the grading method of the GRADE (Grading of Recommendations Assessment, 
Development and Evaluation) Working Group system.2
The strength of each recommendation for intervention has also been graded by means of this 
system.
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8IFOUP NPOJUPS
Before treatment, it should be established if the patient has additional risk factors 
(Table 2).
If additional risk factors are present, the patient should be monitored for symptoms 
of HN and/or for a subnormal serum sodium concentration. This is particularly 
relevant in the first two weeks of combined treatment (when the risk of developing 
HN is the highest).
Monitoring for symptoms of HN and/or for a subnormal serum sodium 
concentration may also be warranted at a later stage (e.g. after an increase in 
dose or when the existing risk is aggravated by a temporary risk factor, such as 
an intercurrent infection or heat wave). In a primary care study of serum sodium 
concentration in thiazide users, 20% of the HN cases were not detected by the first 
electrolyte check but on subsequent sampling.4
$PTUF G GFD UJWFOFTT PG NPOJUPS JOH
Dutch societal cost of a potentially preventable drug-related hospital admission was 
estimated at € 4,573 in 2006.42 Applying an inflation correction factor of 1.154,43 
the corresponding figure in 2013 is € 5,277. The cost of a sodium laboratory test 
in primary care is € 1.96 in 2013.44 This means that sodium testing of patients on 
a thiazide/related diuretic + SSRI/SNRI is already cost-effective if one HN-related 
hospitalization is prevented by less than 2,692 sodium tests.
3FTQPOTF  UP )/
The response to HN depends on the serum sodium concentration, the presence 
of symptoms and the reasons for prescribing an SSRI/SNRI and a thiazide/related 
diuretic:4,6,7,25,45
t Patients with NJMEUPNPEFSBUF)/ are likely to be asymptomatic or minimally 
symptomatic (nausea, vomiting, cognitive impairment, confusion). If possible, 
the thiazide or related diuretic should be replaced with an alternative 
antihypertensive drug and additional risk factors should also be corrected (e.g. 
by restricting water intake to less than 1 l/day). These measures are likely to be 
sufficient for the normalization of the sodium concentration within 1–5 days.
If blood pressure cannot be controlled without the aid of a thiazide, replacement 
of the SSRI/SNRI with another antidepressant seems the most viable option. 
Alternatively, one could provisionally continue the drug combination under 
careful further monitoring of the sodium concentration.
t Patients with TFWFSF )/ are likely to be symptomatic and often have to be 
submitted to specialized care in hospital, where a delicate balance has to be found 
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between the risk of cerebral edema and the risk of an osmotic demyelination 
syndrome due to overly rapid correction of the HN.6,12 See the articles by Liamis 
FU BM. 2006, Gross 2008, Hoorn FU BM. 2008, and Vaidya FU BM. 2010 for further 
details.45-48
In the primary care study by Clayton FU BM. 2005,4 all except one of the patients 
who continued thiazide treatment despite moderate or severe HN remained 
hyponatraemic, suggesting that spontaneous normalization is unlikely if the 
thiazide is continued.
Strateg y III .  C onsultat ion and instr uction of  the  patient  [Grade C]
Patients at increased risk of HN (or their carers) should be instructed orally and 
in written form to consult with their prescriber, if they start to experience HN-
like symptoms (such as fatigue, nausea, and vomiting, abdominal pain, muscular 
weakness, gait and attention deficits, headache, confusion, dizziness, and lethargy).
Patients at increased risk should be warned about the risk of excessive fluid intake 
and they should be informed about which situations increase the risk of sodium 
and water loss (e.g. intercurrent infections, vomiting, diarrhea, fever, great physical 
strain, or a heat wave [see above]). Vulnerable elderly patients may require 
additional guidance in such situations.
The following caveats should be taken into consideration, when the patient or carer 
is informed about the risk of HN:
t the first symptoms of HN are not specific and may develop slowly, both of which 
can hamper timely recognition.17
t the information should be presented very carefully (preferably in oral plus 
written form) to prevent that the patient is so frightened that he decides on his 
own not to take the prescribed risk medication.13
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6.  Summar y ¶
#BDLHSPVOE	3FBTPO GPS NBOBHJOH  UIF ESVHESVH JOUFSBDUJPO

Both thiazides/related diuretics and SSRIs/SNRIs entail a risk of hyponatraemia 
(HN), when given alone. The resulting HN is most often mild (sodium ≤ 135 
mmol/l but ≥ 130 mmol/l ), but both drug groups have been associated with severe 
HN in case reports [Grade C], which can potentially be fatal [Seriousness code F].
Severe HN has been observed in 0.9% of 951 thiazide users in primary care 
[Grade B] and in one of 75 (1.3%) elderly depressed patients started on paroxetine 
[Grade C]. It is generally assumed that the risk of severe HN can increase further 
by combining the thiazide with an SSRI/ SNRI but the extent to which this occurs 
is not known. A small-sized case control study has provided evidence to suggest 
that such combinations may have a synergistic effect rather than an additional one 
[Grade C]. A pragmatic selection of major patient susceptibility factors is presented 
in Table 2 [Grade C].
.BOBHFNFOU  TUSBUFHZ  	)PXUP NBOBHF

The different options for management of the DDI between a thiazide/related 
diuretic (T) and an SSRI/SNRI (S) in a patient who is started on T and/or S are 
summarized in the algorithm in Figure 1.
The first step is to establish the presence or absence of additional risk factors before 
the DDI is started (Table 2):
t When additional risk factors are absent, the only action to be considered is 
consultation and instruction of the patient [Grade 2-C].
t When one or more additional risk factors are present (but the patient has not 
experienced HN associated with a thiazide or SSRI/SNRIs in the past), one may 
consider the option to change the newly prescribed drug [Grade 2-C]. If this 
is not the preferred option the sodium concentration of the patient should be 
¶ See Appendix A at the end of this monograph for details.
The quality of the body of evidence for harm caused by the DDI has been graded by using the 
rating system of the American College of Chest Physicians (ACCP), which is an adaptation of 
the grading method of the GRADE (Grading of Recommendations Assessment, Development and 
Evaluation) Working Group system.2
The strength of each recommendation for intervention has also been graded by means of this 
system.
The seriousness of the potential adverse DDI outcome has been rated by means of the six-point 
scale developed for this purpose by the Dutch Working Group on Pharmacotherapy and Drug 
Information.3
The pharmacological plausibility of the DDI has been rated by means of a three-point scale 
developed for this purpose by the authors of the article to which this appendix belongs.
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measured before and within the first 2 weeks after the start of the DDI [Grade 
1-C] and the patient should be consulted/instructed [Grade 2-C].
t If the patient has already experienced HN associated with a thiazide/related 
diuretic or an SSRI/SNRI in the past, the best action is to avoid drugs from the 
incriminated drug class [Grade 1-C]. After substitution of the incriminated 
drug, the patient should be measured before and within two weeks after the 
start of the DDI [Grade 1-C] and the patient should be consulted/instructed 
[Grade 2-C].
As there are no well-designed studies to support the effectiveness of the proposed 
interventions, the evidence underlying each recommendation for intervention has 
each time been rated as weak [Grade C]. In view of the potential seriousness of the 
adverse outcome, some recommendations have nevertheless been graded as strong:
Figure 1 Algorithm for management of DDI between thiazide/related diuretic (T) and 
SSRI/SNRI (S) in patient started on T and/or S
Check presence of
additional risk factors
Has patient already experienced
HN due to T or S in the past?
Can DDI be easily avoided by substitution
of T or S with drug from another class?
Monitor sodium level before and just
after start of DDI [Grade 1-C]
Consult/instruct patient [Grade 2-C]
Yes
Yes
Consider
substitution
[Grade 2-C]
Yes
Consider to consult/instruct
patient [Grade 2-C]
No
No
No
Substitute incriminated drug with drug
from another drug class [Grade 1-C]
Monitor sodium level before and just
after start of this other drug [Grade 1-C]
Consult/instruct patient [Grade 2-C]
DDI = drug-drug interaction; SSRI = Selective Serotonin Reuptake Inhibitor; SNRI = Serotonin-Norepinephrine 
Reuptake Inhibitor 
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t do not start a thiazide/related diuretic or SSRI/SNRI, if the patient has already 
experienced HN associated with that particular drug class in the past [Grade 
1-C].
t monitor the sodium concentration of the patient before and just after the start 
of the DDI if the patient has additional risk factors for HN [Grade 1-C].
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Appendix  A Explanation of the grading and coding systems used in this monograph
The quality of the body of evidence for harm caused by the drug-drug interaction (DDI) and the 
quality of the body of evidence for the presented DDI management options have been graded by 
using the rating system of the American College of Chest Physicians (ACCP), which is an adaptation 
of the grading method of the GRADE (Grading of Recommendations Assessment, Development and 
Evaluation) Working Group system 2:
A = high quality evidence from RCTs without important limitations or exceptionally strong evidence 
from observational studies;
B = moderate quality evidence from RCTs with important limitations (inconsistent results, 
methodologic flaws, indirect or imprecise), or very strong evidence from observational studies;
C = low quality evidence from observational studies with at least one critical outcome, case series, or 
from RCTs with serious flaws or indirect evidence.
The strength of each recommendation for intervention has also been graded by means of the 
rating system of the American College of Chest Physicians (ACCP), which is an adaptation of the 
grading method of the GRADE (Grading of Recommendations Assessment, Development and 
Evaluation) Working Group system 2:
The methodological quality of underlying evidence is expressed by means of a letter.
The strength of a recommendation is expressed by means of a number:
1 = strong;
2 = weak.
The seriousness of the potential adverse DDI outcome has been rated by means of the six-point 
scale developed for this purpose by the Dutch Working Group on Pharmacotherapy and Drug 
Information 3:
A. Clinically irrelevant effect
B. Temporary discomfort (< 24–28 h) without residual symptoms
C. Longer-lasting discomfort (48–168 h) without residual symptoms
D. Long-lasting discomfort (> 168 h) or permanent residual symptoms or handicap
E. Increased risk of failure of life-saving therapy; increased risk of pregnancy (without risks 
concerning mother or fetus or both)
F. Serious, irrecoverable disability or death; increased risk of pregnancy (with risks concerning 
mother or fetus or both)
The pharmacological plausibility of the DDI has been graded by means of a three-point scale 
developed for this purpose by the authors of the article to which this monograph serves as an 
appendix:
0 = no known mechanism
1 = plausible mechanism, but no firm evidence a
2 = mechanism supported by firm evidence a
a) Defined as sufficiently strong so that further information from other sources is unlikely to alter conclusions 
drawn from the evidence.
3
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INTRODUCTION
In this chapter we provide a clarification for each element in the final checklist, 
arranging the different elements that should be addressed in drug-drug interaction 
(DDI) management guidelines (see Figure 1). In Chapter 3.1 the development of 
the final checklist has been described.
Figure 1 Final checklist for comprehensive drug-drug interaction management 
guidelines
Strength of recommendations
for intervention
A set of symbols, letters and/ or
numbers for communication
2.  Clinical impact at population level
3.  Patient susceptibility factors
4.  Quality of evidence for harm
5.  Potential management strategies
6.  Summary
Change drug(s) or
dosage form
Adjust dosage
regimen Monitor patient
Add drug(s)
Consult and
instruct patient
Withhold or
withdraw drug(s)
Pharmacological
plausibilityLevel of evidence
1.  Interacting drugs or drug groups
Domain-1 Background
Domain-2 Management
Seriousness of potential
adverse outcomes
Incidence of adverse
outcomes
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MAIN D OMAIN -1
BACKGROUND (REASON FOR MANAGING THE DDI )
The elements in domain 'Background' should explain which harm can result from 
the DDI and why healthcare providers should manage this risk.
1.  Identif y  the  dr ugs  or  dr ug groups involved in  the  DDI.
The individual drug and drug groups involved in the DDI should be identified. 
It should not be assumed that all members of a similar pharmacological class 
will interact in the same manner without evaluating the available evidence and 
pharmacological plausibility.
2.  Address  the  cl inica l  impact  of  the  DDI at  the  populat ion 
le vel  and consider  both the  seriousness  and incidence of  the 
adverse  outcomes.
The nature of the adverse outcome of the DDI should be specified. As the clinical 
impact of an interaction at the population level depends both on the seriousness of 
the harms caused by the adverse DDI and on the chance that those harms actually 
occur, both elements should be explicitly described.
Judge  the  ser iousness  of  the  potential  adverse  outcomes  of  the  DDI.
The seriousness of an adverse outcome is a measure of the extent to which the DDI 
can or does cause harm. Seriousness (importance) must be differentiated from 
intensity (commonly called 'severity'). The intensity of an adverse outcome (e.g. 
mild, moderate, or severe) is a measure of the extent to which the adverse outcome 
develops in an individual.1,2 For example, a headache can be of severe intensity 
without being serious.
All potential adverse outcomes of the DDI need to be considered, in order to 
differentiate between the most serious and less serious outcomes. The grading 
of seriousness is based on the most critical potential adverse outcome in the 
spectrum of all possible outcomes. For example, the potential adverse outcome of 
the interaction between citalopram and cimetidine is graded as serious (e.g. life-
threatening serotonin syndrome),3 while the adverse outcome may be less serious 
in an individual (e.g. obstipation or hypotension). Different kinds of scales for 
rating the seriousness of adverse outcomes exist. The scale of SAEs (Serious Adverse 
Events) as defined by the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use judges only 
serious adverse events.4 GRADE suggests a nine-point scale to judge the importance 
of all patient outcomes. The upper end of the scale, 7 to 9, identifies outcomes of 
116
3
critical importance for decision-making (9 = mortality, 8 = e.g. myocardial infarct). 
Ratings of 4 to 6 represent outcomes that are important but not critical. Ratings of 
1 to 3 are items of limited importance.5 The six-point (A-F) scale of van Roon et al. 
(see Box 1) has been developed especially to assess the clinical relevance of DDIs.6 It 
has been used in several scientific studies 7-10 and is also preferred by our panellists.
B ox 1 Scale to judge the seriousness of the adverse outcomes of a drug-drug 
interaction 6
A Clinically irrelevant effect
B Temporary discomfort (< 24–28 h) without residual symptoms
C Longer-lasting discomfort (48–168 h) without residual symptoms
D Long-lasting discomfort (> 168 h) or permanent residual symptoms or handicap
E Increased risk of failure of life-saving therapy; increased risk of pregnancy (without risks 
concerning mother or fetus or both)
F Serious, irrecoverable disability or death; increased risk of pregnancy (with risks concerning 
mother or fetus or both)
Descr ibe  the  incidence  of  the  adverse  outcomes  in  patients  using 
the  combination of  the  interacting  drugs ;  i f  information about  the 
incidence  of  a  spec if ic  outcome i s  lacking  acknowledge  thi s .
The incidence (frequency of occurrence) of the adverse outcomes in patients given 
a combination of the drugs should be reported.6,11,12 In so far as it is meaningful and 
feasible, the incidence of different adverse outcomes should be indicated separately.
3.  Re vie w patient  susceptibi l ity  factors .
The clinical impact of a DDI at the patient level may be larger or smaller than 
the clinical impact of a DDI at the population level.13 Patient-related factors may 
influence the risk and intensity of an adverse outcome.14
In some cases the risk of an adverse outcome of a DDI is the same across the whole 
population. For example, rifampicin, a potent enzyme inducer that interacts with 
substrates of CYP3A4, drastically reduces plasma concentrations and effects of 
oral midazolam, a short-acting benzodiazepine that is metabolized by CYP3A 
enzymes.15
Of course the degree of susceptibility may vary between individuals, but the overall 
susceptibility is such that most if not all users of the drug combination will be 
affected.
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In other cases the risk of an adverse DDI outcome may be present only in patients 
with specific patient-related susceptibility factors and absent or less prominent in 
others. For example, amlodipine only leads to a 2.2-fold decrease in the apparent 
oral clearance of tacrolimus in CYP3A5 expressers, while it has no such effect in 
CYP3A5 non-expressers.16 Likewise, a low daily dose of 25 μg of vitamin K1 results 
in subtherapeutic INRs in warfarin users with low vitamin K1 levels, while it does 
not significantly affect users with normal vitamin K1 levels.17 Multiple patient-
related factors may also work in conjunction and thereby increase the risk of an 
adverse outcome additively or even synergistically.18,19
The various factors that can modify the susceptibility of an individual patient to an 
adverse DDI outcome include: unexplained drug hypersusceptibility/intolerance, 
genetic factors (e.g. race, ethnic origin, pharmacokinetic and pharmacodynamic 
polymorphisms); physiological factors (e.g. age, sex, pregnancy, body weight); 
nutritional status, exogenous factors (e.g. co-medications, smoking, food, alcohol, 
and caffeine-containing and other beverages, natural products); diseases (e.g. 
degree of renal and hepatic function impairment); and administration factors (e.g. 
adherence to therapy, dosage regimen, dosage form, duration of therapy, route and 
sequence of administration).1,12,20-22
In so far it is meaningful and feasible the quality of evidence should be indicated 
separately for different patient susceptibility factors.
4.  Grade the  qual ity  of  e v idence for  harm by the  DDI and 
make sure  that  both ' le vel  of  e v idence '  and 'pharmacologica l 
plausibi l ity '  are  weighed.  Describe  the  specif ic  grading system 
used and refer  to  a  detai led explanation of  that  system.
Many systems for grading the quality of medical evidence have been developed.23 
Most of them have been designed for ranking the evidence for the effectiveness 
of interventions. However, these systems may not be suitable for rating the 
risks of harms due to DDIs, because they only assign the highest evidence level 
to randomized controlled trials (RCTs).24 However, RCTs designed to examine 
adverse clinical outcomes from DDIs are sparse, they are not always necessary to 
gain sufficient insight into the nature and untoward consequences of DDIs,25 and 
they may thus even be unethical. Many DDI studies are pharmacokinetic crossover 
studies, in which the distribution of participants over the different treatment 
periods has often not been randomised.26 Other DDI studies are observational 
studies, which will often be ranked as being of suboptimal quality. Furthermore, 
even when a controlled clinical study has provided no significant evidence of a 
DDI, the drug combination may not be safe in all users. First, a flaw in the design 
118
3
of the controlled study may have led to an inaccurate conclusion. For example, the 
conclusion of an early study of St John's wort, that this herb was unlikely to affect 
CYP3A4 activity, was incorrect because the test subjects had not been exposed to 
St John's wort for long enough to reveal its enzyme-inducing effect.24 Secondly, 
and more importantly, controlled drug interaction studies are mostly performed in 
small homogeneous populations of healthy volunteers or relatively healthy patients. 
As a result, potentially relevant risk modifiers (e.g. infrequent genotypes, frailness, 
co-morbidities, additional drugs) may have been insufficiently represented.13 
Consequently, a well-documented case report (especially one with a positive 
rechallenge) or a well-designed observational study may sometimes constitute more 
secure evidence of a harmful interaction than a negative randomized controlled 
interaction study.18,27-29
Rate  the  quality  of  the  body of  ev idence  for  harm caused by  the 
DDI.
The grading systems of the American College of Chest Physicians (ACCP) and 
the Oxford Centre for Evidence-based Medicine (OCEBM) are identified as being 
useful general instruments for grading harm.30,31 The Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) is gaining increasing 
acceptance, because it takes into account more dimensions than just the quality of 
the evidence.32 It offers a practical way of classifying the quality of evidence into 
four levels (high, moderate, low, and very low), and five factors that can reduce 
the quality of evidence for each study design and three factors that can increase 
it.5,33 As outlined above, however, the GRADE emphasis on study design will not 
always be the most appropriate approach, when rating the level of evidence of 
DDI studies. Laine and Hennekens identify two additional criteria supporting 
causality that are not identified by GRADE, i.e. biological credibility or plausibility 
and time sequence.34,35 The former is taken into consideration separately (see 
below). The second criterion of a compatible time sequence is also useful for the 
accommodation of case reports with a positive dechallenge or rechallenge.
Two grading systems have been specifically developed to distinguish levels of 
evidence for DDI-related harm: the Swedish/Finnish interaction classification 
system (SFINX)36,37 and the system developed by the Working Group of the 
Scientific Institute of the Dutch Pharmacists (WINAp)6. These grading systems also 
give priority to controlled interaction studies over case reports or case series, no 
matter how well the latter are documented. As outlined above, this may lead to a 
false sense of security. This risk should be reduced by monitoring for DDIs that 
may have a low level of evidence but that are highly predictable.20 Our panellists 
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have suggested that a new grading system for the quality of evidence for harm by 
DDIs must be developed, in which both 'level of evidence' and 'pharmacological 
plausibility' are weighed. Until then, guideline developers should use the grading 
system of their preference and refer to a detailed explanation of this grading system.
Grade the  pharmacolog ical  plausibi l ity  of  the  DDI.
Most systems assign the lowest possible evidence rank to DDIs when there are no or 
only unpublished data.34 A potential untoward consequence is that DDIs which can 
be predicted from well-known pharmacokinetic properties (for example, an enzyme 
inhibitor combined with a substrate of that enzyme), or by analogy with other 
drugs with similar pharmacodynamic effects in the same drug class, may receive 
the lowest possible ranking until there are empirical data.38 The usual evidence 
hierarchy considers case reports about DDIs that are observed and published as the 
lowest type of evidence, even if they can be explained by a plausible mechanism,29 
and requires controlled studies for a higher level of evidence.
The principle of pharmacological plausibility should be applied as a separate 
criterion for the quality of evidence of harm by a DDI. This criterion also features in 
the revised Bradford Hill guidelines which illustrate how different types of evidence 
can complement one another:39
t direct evidence to assess whether a probabilistic association between two factors 
is causal rather than spurious;
tmechanistic evidence (i.e. a biologically plausible mechanism) to add weight to a 
judgment of causality;40-42
t parallel evidence to support the causal hypothesis suggested in a study, with 
related studies that have similar results.
The best practical solution is to grade the plausibility of pharmacological evidence 
and to provide theoretical but predictable DDIs with a special code, particularly 
when the predicted adverse reaction would be potentially serious. Our panellists 
agreed with the grading presented in Box 2.
B ox 2 Grading for the pharmacological plausibility of a drug-drug interaction
0 = no known mechanism
1 = plausible mechanism, but no firm evidence a
2 = mechanism supported by firm evidence a
a) Firm evidence is defined as sufficiently strong so that further information from other sources is unlikely to 
alter conclusions drawn from the evidence.43
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MAIN D OMAIN -2
MANAGEMENT (HOW TO MANAGE THE DDI )
The elements in this domain should indicate how the DDI should be managed.
5.  Re vie w the  potentia l  management  strategies  for  pre venting the 
adverse  DDI outcome.
The available management strategies for preventing adverse DDI outcomes should 
be reviewed and the guideline should specify (e.g. in the form of an algorithm) to 
which situations a particular management strategy for preventing an adverse DDI 
outcome applies (see Box 3).
The most frequently occurring DDI management strategies are:10,21,44
Strategy I. Withhold or withdraw drug(s): absolute or relative contraindication 
(e.g. DDI azithromycin-disopyramide: withhold azithromycin)45
Strategy II. Change drug(s) or change dosage form: use a non-interacting or less 
interacting alternative (e.g. DDI cimetidine-carbamazepine: replace 
cimetidine with ranitidine)46
Strategy III. Add drug(s): to minimize adverse outcomes (e.g. DDI NSAID-
corticosteroid: add proton pump inhibitor)47
If applicable, also specify when and how this management strategy 
should be started and stopped (see Box 3).
Strategy IV. Adjust dosage regimen: adjust dose or titrate dose slowly, adjust 
dose interval or frequency (e.g. DDI boceprevir-tacrolimus: decrease 
dosage and prolong the dosage interval of tacrolimus)48
If applicable, also specify when and how this management strategy 
should be started and stopped (see Box 3).
Strategy V. Monitor patient including self-monitoring (e.g. DDI orlistat-
cyclosporine: monitor blood cyclosporine concentration)49
Specify which biomarkers should be monitored and how they should be 
monitored (see Box 4).
If applicable, also specify when and how this management strategy 
should be started and stopped (see Box 3).
Strategy VI. Consult and instruct patient (e.g. DDI nifedipine-doxazosin: instruct 
patient to lie or sit down if experiencing dizziness or light-headedness 
when standing)50
121
Annotated check l ist  DDI  management  guidel ines  |  Chapter  3 .3
B ox 4 Specify which biomarkers should be monitored, how frequently these 
biomarkers should be monitored, which outcomes of the monitored 
biomarkers need to be looked for and how to respond to the outcomes of the 
monitoring
A biomarker is defined as a factor that can be objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic 
intervention.52,53
A. Specify which type(s) of biomarkers should be monitored.7,52
– Symptoms (what the patient states or complains of; e.g. muscle pain)
– Signs (what the health professional observe; e.g. blood pressure)
– Laboratory test results (e.g. serum drug concentrations, international normalized ratio or INR, 
estimated glomerular filtration rate or eGFR)
B. Specify how frequently the biomarkers should be monitored.
The following frequencies could be appropriate in DDI management:
– Specific frequency (e.g. every two weeks for two months)
– Frequency range (e.g. every 4–8 weeks)
– The optimal frequency of monitoring is unknown
C. Specify which outcomes of the monitored biomarkers need to be looked for.
The following outcomes could be appropriate in DDI management:
– Abnormal values (out of reference range)
– Adverse outcomes
– Decreased drug efficacy
D. Specify how to respond to the outcomes of the monitored biomarkers.
B ox 3 Specify when and how the management of the drug-drug interaction should 
be started and stopped
Among the most obvious triggers for starting, stopping or executing a management strategy are:
t when the patient is started on one or both of the interacting drugs or submitted to an increased 
dose;
t when the patient develops symptoms or signs that the DDI has an adverse outcome;
t when the patient has stabilized on both of the interacting drugs;
t when one or both of the interacting drugs is reduced in dose or withdrawn altogether.
It should be specified what are the most appropriate moments to start and stop management, e.g. 
immediately before and/or x days after the start of a drug; after an explicit period of chronic use; 
immediately after and/or x days after the discontinuation of a drug; after normalization of monitored 
parameters.51
It should also be explained (preferably in the form of an algorithm) how the different management 
options are interrelated to each other.
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6.  Provide  a  str uctured summar y that  summarizes  domain-1 
Background (reason for  managing the  DDI)  and domain-2 
Management  (how to  manage the  DDI)  and that  c lari f ies 
how strong recommendations  concerning the  management 
strategies  are.  The summar y should a lso  show in an a lgorithm 
how dif ferent  recommendations  are  interrelated.  The 
qual ity  of  the  body of  e v idence and the  strengths  of  the 
recommendations  should be  communicated by means of  a  set 
of  symbols ,  letters ,  and/or  numbers .
Classif y  the  streng th of  the  recommendation for  each DDI 
management  strateg y  to  prevent  harm by the  DDI.  Descr ibe  the 
spec if ic  grading  system used and re fer  to  a  detai led  explanation of 
the  grading.
DDI management guidelines should provide users with clear and instant guidance 
on how recommendations to prevent a DDI or its adverse outcomes should be 
interpreted. The quality of evidence supporting the recommendations should be 
indicated along with a clear statement of the strengths of the proposed management 
strategy. It should also be clear when, to which situation(s) (see Box 3) and to which 
patient population(s) each strategy applies.
Several expert groups have developed their own method to classify the strength 
of recommendations.54 The approach developed by ACCP, which has been 
modified from GRADE, distinguishes two categories of strength, which reflect the 
extent to which users of that recommendation can be confident that the desirable 
consequences of an intervention will outweigh the undesirable consequences and 
thus give healthcare providers a clear direction to hold on to.30,55
Strong (Grade 1):  Desirable effects clearly outweigh undesirable effects;
   recommendation can apply to most patients in most circumstances
Weak (Grade 2):  Desirable effects closely balanced with undesirable effects;
   best action may differ depending on circumstances or patient or
   society values.30
Our panellists did not identify one best system to classify the strength of 
recommendations for interventions to prevent harm caused by a DDI. Therefore, 
developers of DDI guidelines should use the classification system of their preference 
and refer to a detailed explanation of this system. However, our panel did agree that 
four factors identified by the GRADE approach should be considered to determine 
the strength of a recommendation: 'balance between desirable and undesirable 
effects of an intervention'; 'quality of evidence'; 'patients’ values and preferences'; 
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and 'costs' (see Box 5).55-58 Consequently, developers of DDI guidelines should 
consider and present (where appropriate) these four factors when discussing 
management strategies.
B ox 5 Four factors that should be considered to determine the strength of a 
recommendation55-58
Issue 1. Consider the balance of the desirable and undesirable consequences of each DDI 
management strategy (intervention).
The balance of desirable and undesirable consequences of a management strategy (intervention) 
should be considered. Desirable effects of an intervention include reduced morbidity and mortality, 
improved quality of life, a reduced burden of treatment (e.g. a reduced need of inconvenient blood 
tests), and reduced resource expenditure. Undesirable consequences include adverse outcomes 
that have a deleterious effect in terms of morbidity, mortality, or quality of life, or increase the use 
of resources (e.g. the increased risk of an infectious complication or nutritional deficiency by the 
addition of a proton pump inhibitor to manage the risk of a DDI that increase the risk of upper GI 
complications).59
This issue should also identify which easy and risk-free alternative management strategies clearly 
outweigh the disadvantage of potential harm (e.g. the replacement of cimetidine by ranitidine in 
users of carbamazepine)46.
Issue 2. Indicate the quality of evidence supporting each management strategy (intervention) 
by a level of evidence.
This includes an assessment and rating of the quality of the body of evidence for each management 
strategy or specific combination of strategies. The higher the quality of evidence, the more likely it is 
that a strong recommendation is warranted.
Issue 3. Consider values and preferences that can be important from the patients’ perspective.
Management strategies will always have advantages and disadvantages. Developers of DDI 
guidelines should pay attention to values and preferences that can be important from the patients’ 
perspective (in terms of expected benefits, harms, and (in)conveniences) for each of the proposed 
management strategies. The largely the variation or uncertainty in such patient values and 
preferences is, the more likely it is that a weak recommendation is warranted.
Issue 4. Assess the best available estimate of resource use for each management strategy.
The management strategy should come at a reasonable cost. Although higher costs of an 
intervention – that is, higher consumption of resources – reduce the likelihood that a strong 
recommendation is warranted, it is important to consider the cost-effectiveness of each 
management strategy versus no intervention at all or a less expensive intervention.58
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Present  a  set  of  symbols ,  let ters ,  and/or  numbers  that  communicates 
the  quality  of  the  body of  ev idence  and the  streng ths  of  the 
recommendations .  Unti l  f irm guidance  can be  g iven on how best 
to  communicate  uncer tainty  about  harms and benef it s ,  guideline 
developers  should ensure  that  a  clear  explanation i s  prov ided with 
the  chosen symbols ,  let ters  and/or  numbers .
Another relevant aspect of DDI management guidelines is how to communicate the 
levels of evidence and recommendations to healthcare professionals efficiently in 
daily practice.
Most guideline panels developing DDI guidelines have used letters and numbers 
to summarize their quality of evidence and strength of recommendations, but 
they have used them differently, which is potentially confusing.60 The intended 
function of specific letters, numbers, symbols, and words in grading systems is to 
communicate a clear message, quickly and concisely. Symbolic representations are 
appealing in that they are free of this history. On the other hand, clinicians seem to 
be very comfortable with numbers and letters.60
We could not find concrete evidence of how well various presentations in DDI 
grading systems are understood by healthcare providers. However, it seems 
necessary to present them with a coding system in which the quality of evidence for 
harm and the category of potential harm for drugs is indicated.
GRADE, SFINX, WINAp, or the system suggested by Ferner and Aronson could be 
used.6,37,55,61 GRADE offers preferred symbolic representations and, for organisations 
that want to use numbers and letters, a preferred number/letter representation, for 
quality of evidence and grades of recommendation.55 ACCP presents a letter for 
the quality of evidence, followed by a number for the judgment about the direction 
and strength of recommendations.30 SFINX uses letters and colours to indicate the 
clinical relevance of the DDI and numbers for the level of documentation.37 The 
grading of evidence system developed by WINAp offers a coding system, in which 
numbers indicate the quality of evidence and letters indicate the seriousness of the 
adverse reaction resulting from the drug interaction.6 Ferner and Aronson propose 
a visual coding system, in which the signal indicates the category of potential harm 
from drugs.61
A set of symbols, letters and/or numbers that communicates the level of evidence 
and recommendations should be presented as guideline component. More studies 
are still needed before firm guidance can be given on how best to communicate 
uncertainty about harms and benefits. In the meanwhile, guideline developers 
should ensure that a clear explanation is provided with the chosen presentation.
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ABSTRACT
Clinical risk management offers a systematic approach to minimize healthcare-
related risks by paying attention to: (1) risk identification and assessment; (2) 
development and execution of risk reduction strategies; (3) evaluation of risk 
reduction strategies. This paper reviews these key areas for the risk of interactions 
between natural products and drugs (NPDIs) to explore how the impact of these 
interactions on public health can be minimized. It argues that specific components 
of clinical risk management need to be evaluated, before adoption, and then actively 
implemented if proven valuable.
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INTRODUCTION
The concept of clinical risk management aims at the reduction of healthcare-related 
risks by shifting care-providing processes from organisational vulnerability towards 
organisational integrity. It offers a systematic approach by combining a focus on the 
following basic issues: (1) risk identification and assessment; (2) development and 
execution of risk reduction strategies; (3) evaluation of risk reduction strategies.1,2 
In the realm of drug therapy, clinical risk management is often directed at the 
post-licensing phase of newly licensed medicines.3 However, its principles are also 
relevant for reducing adverse drug reactions, drug-drug interactions (DDIs) and 
drug-disease interactions of older licensed medicines and of unlicensed herbal 
products and other natural products.
To demonstrate this, we discuss key areas in the clinical risk management of 
interactions between natural products and conventional drugs‡ (NPDIs) to explore 
how their impact on public health can be minimized. Our paper updates an earlier 
review of the same topic 4 and should preferably be read in conjunction with this 
former publication, as we saw little advantage in reiterating the details of this 
preceding article.
RISK IDENTIFICATION AND ASSESSMENT
This first basic step in clinical risk management requires that hazards are identified 
and stratified in terms of evidence, probability and significance.
Spontaneous repor ting
Spontaneous reporting systems are not only a relatively inexpensive cornerstone 
of the early detection of adverse drug reactions (ADRs) but they can also provide 
insight into the contribution of DDIs to the development of ADRs. A recent 
analysis in Vigibase, a global database of spontaneously reported ADRs maintained 
by the WHO Collaborating Centre for International Drug Monitoring in Uppsala, 
identified 31 clinically important interactions between conventional drug pairs, 
including seven pairs for which only theoretical evidence had been available and 
another four drug pairs for which there had been no previously published evidence.5 
Similarly, spontaneous reporting can yield valuable clues to the risks of adverse 
‡ To distinguish herbal products from medicines that have been licensed through the normal 
registration procedure, we use the term conventional for the latter, even though we realize that 
some herbal medicines also fall into the category of conventional medicines.
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NPDIs. For instance, spontaneous reports played an essential role in discovering 
the pharmacokinetic and pharmacodynamic drug interaction potential of St John’s 
wort (Hypericum perforatum).6
An efficient approach for the active detection of NPDI cases is the prospective 
surveillance of calls about natural products to poison control centres. A recent US 
study using this methodology for one year found, among 275 calls about dietary 
supplements, six cases that involved a suspected NPDI (three cases of yohimbe plus 
methamphetamine and single cases of yohimbe plus bupropion, fish oil plus an 
NSAID, and ginkgo plus an NSAID).7
In our preceding review, we expressed concern about the variable quality of 
natural product case reports and we emphasized the importance of providing more 
education on this topic.4 The International Society for Pharmacoepidemiology 
(ISPE) and the International Society of Pharmacovigilance (ISoP) have recently 
adopted guidelines for submitting adverse event reports to biomedical journals, and 
they encourage their incorporation into the relevant medical, pharmaceutical, and 
nursing curricula that address the detection, evaluation, and reporting of suspected 
drug or other medical product adverse events.8,9 The guidelines specify which 
information should be considered when describing the patient, the drug therapy, 
the adverse event, and the evaluation. For reports involving herbal products, the 
guidelines recommend the following points of attention:
t Required: identification by Latin binomial of the herbal ingredient(s) plus 
specification of the plants part(s) and the type of preparation (e.g. crude herb or 
extract).
tHighly desirable: whether or not the herbal product(s) implicated are authorized 
or licensed, and whether or not sample(s) have been retained for analysis, and 
any results; for extracts, the type and concentration of extraction solvent used.
t If relevant: for manufactured herbal products, whether the product was 
standardized for which constituent(s) and concentration(s); for extracts, the 
drug-extract ratio.
Besides improving the quality of natural product case reports, it is important to 
increase their quantity, because there is considerable underreporting. In a recent 
questionnaire study, 62 (47%) of 132 Canadian community pharmacists reported 
that they had encountered a patient with a suspected NPDI, but only two (1.5%) 
reported this to Health Canada.10 The number of natural product case reports 
depends directly on the perceptivity and willingness to come forward of every 
professional who comes into contact with suspected adverse events of natural 
products (e.g. physicians, pharmacists, nurses, herbal medicine practitioners, herbal 
retail sellers, and herbal company representatives). In this context, conventional 
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healthcare professionals must realize that patients may keep silent about their 
natural product use. In a large U.S. survey, only one-third of the respondents using 
herbs or dietary supplements told this to a conventional healthcare provider.11
In our previous paper, we welcomed a UK initiative to bring about statutory self-
regulation of herbal medicine practitioners, as this could provide a steppingstone 
for embedding natural product case reporting in their education and professional 
code of conduct, and patient safety systems.4 However, three years after the 
responses to a consultation on such a statutory regulation were reported early in 
2005, legislation in this domain has not yet been finalized.12
Previously, we also welcomed the European Community (EC) directive for 
traditional herbal medicines (offering a simplified registration scheme for herbal 
products which could not fulfil conventional requirements for licensing), because 
this would compel companies holding simplified licenses for herbal medicines to 
conduct pharmacovigilance for these products and to report all suspected adverse 
events to the health authorities.13 In the four years since this EC legislation has been 
passed, however, herbal companies in the UK have used this option sparingly. Only 
seventeen herbal products in the UK have been approved as traditional medicines 
so far, and there are just three more years left before the transition period will 
end and it will become illegal to market unlicensed herbal medicines.14 It seems 
unclear what will happen, if the approval of traditional herbal medicines in the 
UK remains at its current low rate: will all unlicensed herbal products indeed be 
forced to disappear from the market or will herbal companies find loopholes to 
circumvent this unpropitious prospect? In this connection, an important question 
may be to what extent it will remain possible to market medicine-like herbal 
products as food supplements. At this point in time, there seems to be a lack of 
clarity as to when herbs can be sold as nutrient, food supplement, or medicinal 
product.15 The EC directive on food supplements specifically includes ‘fibre and 
various plants and herbal extracts’ in the range of ingredients that may be present in 
food supplements,16 and the EC directive for traditional herbal medicines explicitly 
allows nonmedicinal herbal products to be regulated under legislation covering 
foods.13
The volume of natural product case reporting may also be increased by encouraging 
consumers of natural products and their lay caregivers to submit cases directly. This 
particularly seems an interesting option for the many natural products that can 
be obtained without the involvement of a conventional healthcare professional. In 
recent years, favourable experiences have been gained with direct patient reporting 
of ADRs of conventional drugs. Overall, this strategy appears to have more potential 
benefits than drawbacks, and it may lead to the identification of possible new ADRs 
134
3
that have not previously been reported by healthcare professionals.16,17 For natural 
products this strategy can only be successful, however, if their users are aware that 
these preparations can entail health risks, which is not yet always the case.18
Clinica l  studies
The advantages and limitations of different types of experimental NPDI studies (in 
vitro, animal and human studies) have been reviewed by Venkataramanan et al. (see 
their Table 1).19 Only the latter type of studies provides a definitive answer but it 
is generally much more costly than the other two types. Yet the number of clinical 
studies of NPDIs is growing rapidly. Since 2005, at least 50 clinical publications 
have appeared in Pubmed (Table 1). Such studies are generally rated as more 
valuable than case reports but one should remain aware of the risk that they may 
lead to non-generalizable conclusions, when relevant risk modifiers (e.g. infrequent 
genotypes, frailness, renal or hepatic insufficiency, comorbidities, additional 
natural products or conventional drugs) have been underrepresented in the test 
Table 1 Retrieval of recent clinical studies of herb-drug interactions published in 
2005–2008 from Pubmed
Retrieval strategy n Comments
Various searches a 50b 45 studies of herbal product(s) widely 
used in Western society
5 studies of herbal product(s) primarily 
used in non-Western societies
MeSH term “Herb-Drug Interactions” 20 15 studies if search was restricted to 
Major Topic only
MeSH terms “Dietary Supplements” OR “Drugs, 
Chinese Herbal” OR “Medicine, Herbal” OR 
“Phytotherapy” OR “Plant Extracts” OR “Plant 
Preparations” OR “Phytotherapy”
30 24 studies if search was restricted to 
Major Topic only
a) Pubmed [http://www.ncbi.nlm.nih.gov/sites/entrez/] was searched on Jul 21 and Aug 10, 2008, with different 
strategies searching for clinical studies of herb-drug interactions that appeared in 2005-2008. For instance, 
free text searching combined human AND (drug interaction* OR drug synergism) AND (herb OR herbs OR 
herbal OR plant OR plants OR phytotherap* OR Echinac* OR echinac* OR "evening primrose" OR Oenothera 
OR Parthenium OR feverfew OR Allium OR garlic OR Zingiber OR ginger OR ginkgo* OR Ginkgo* OR ginseng 
OR Panax OR Eleutherococcus OR kava OR kava-kava OR kavain* OR kawain* OR methysticum OR Viscum 
OR mistletoe OR Iscador OR “saw palmetto” OR Serenoa OR Sabal OR Permixon OR Silybum OR silymarin* OR 
“milk thistle” OR Melaleuca OR “tea tree oil” OR Valerian* OR valerian* OR goldenseal OR Hydrastis OR “black 
cohosh” OR Cimicifuga OR Cranberr* OR Cannabis OR Marihuana OR marijuana OR kola OR cola).
b) Each retrieved publication was assessed to establish whether it described a prospective original study 
in humans to evaluate the drug interaction risks of one or more herb-drug combinations. Other types of 
articles (such as animal studies, human case reports, and reviews) were excluded. The herbs had to be a raw 
or processed mixture of herbal compounds (i.e. pure single herbal constituents were excluded). A detailed 
overview of the 50 selected studies is available from the corresponding author upon request.
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population. As a consequence, well-documented case reports (especially those with 
a positive rechallenge) do not always constitute a lower level of evidence than a 
negative controlled interaction study.20
A particular concern about the currently available clinical studies is that they focus 
largely on natural products found in Western markets: 45 of the 50 publications 
in Table 1 evaluated natural products that are widely used in Western countries, 
and only five reported on natural products that are primarily used in non-Western 
societies. Yet the risk of NPDIs may be just as high or even higher in non-Western 
societies, especially since herbal medicine is an officially recognized element of 
healthcare in several regions in the world. For instance, traditional medicine is 
officially incorporated into all areas of healthcare provision in China.21 As a result, 
herbal medicines are extensively used there, outside as well as inside hospitals.§ 
This is not only true for traditional medicine hospitals in China but also for the 
Western medicine hospitals there, and in both settings herbal medicines are 
regularly combined with conventional Western medicines. Herbal medicines are 
also widely employed in India, where three major traditional medical systems 
(ayurvedic, unani, and siddha) are flourishing besides allopathic, homeopathic, and 
folk medicine.22
Although there are several clinical studies which do not reveal significant 
interactions between Asian herbs and Western drugs,23-25 other studies indicate that 
such interactions are possible and can be clinically relevant (Table 2). Various in 
vitro and animal experiments raise the possibility that these positive studies may 
represent the tip of an iceberg.37-46 In vitro and animal data do not obviate the need 
of well-designed clinical investigations, but they do indicate the necessity of such 
investigations and may serve as guidance as to which natural product-drug pairs 
deserve priority when planning human studies.4
The paucity of clinical NPDI studies is not limited to traditional Asian medicines, 
but is equally poignant for Latin America and for the African continent.47 For 
instance, traditional medicine use is common among South African individuals 
with moderate or advanced HIV disease, even when they are on conventional 
§ For instance, at least 15 million daily doses of herbal injections were employed for ‘cardiocerebral 
vascular use’ in 694 Chinese hospitals in 2005. This volume referred to six types of herbal 
injection, viz. breviscapine, Panax notoginseng saponins, ligustrazine, puerarin, Xingnaojing, 
and Acanthopanax. It is noteworthy that the underlying Chinese source also classified two pure 
botanical compounds (ligustrazine and puerarin) as herbal products. Source: Li L, Yu Z, Li Y. 
Analysis on Status Quo of Chinese Materia Medica Injection Used in People's Hospital and 694 
Nationwide Other Hospitals during 2003–2005. Department of Pharmacy, People's Hospital, 
Peking University, Beijing. Poster presented at the 67th International Congress of the International 
Pharmaceutical Federation (FIP), Beijing, 31 August – 6 September 2007.
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antiretroviral therapy.48 In vitro experiments have shown that two South African 
herbs recommended for HIV/AIDS patients (Hypoxis and Sutherlandia) 
significantly inhibit CYP3A4 and activate the pregnane X receptor approximately 
twofold. As many conventional antiretroviral drugs are predominantly metabolized 
through the CYP3A4 pathway, and as some of them are also substrates for 
P-glycoprotein, these findings raise the possibility of undesired NPDIs between 
antiretroviral agents and Hypoxis or Sutherlandia.49,50 Again, human studies are 
needed here to confirm or mitigate these concerns.
Pharmacoepidemiologica l  studies
Pharmacoepidemiological studies help to overcome the limitations of spontaneous 
case reports and clinical studies. However, epidemiological evaluations of the 
nature, volume and risk modifiers of NPDIs have been scarce. In our previous 
review, we have put forward as the most prominent reason that most natural 
products in Europe and North America are available without a prescription and 
therefore are not registered systematically in healthcare records.4
We also cautioned that the expected benefits of including all prescription-free 
natural products in routine collections of patient data for pharmacoepidemiological 
purposes should be carefully weighed against the extra time and money that this 
would require. We suggested, as an alternative way forward, to collect such data 
within the context of specific pharmacoepidemiological studies in high risk 
patients (e.g. on the contribution of NPDIs to the haemorrhagic and thrombotic 
complications of patients on oral anticoagulants).4 An example of such a specific 
study has now been reported from a Canadian research hospital, where 171 adult 
warfarin users were asked to complete a 16-week diary by recording prospectively 
bleeding events and exposure to factors previously reported to increase the risk 
of bleeding and supratherapeutic INRs, including the use of complementary 
medicines. Multivariate analysis showed that two complementary medicines were 
independently associated with an increased risk of self-reported bleeding, viz. 
coenzyme Q10 (OR 3.7; 95%CI 1.9–7.2) and ginger (OR 3.2; 95%CI 2.4–4.2).51 
These findings should be interpreted with caution, as the study was not without 
limitations. For instance, there may have been uncontrollable variation in patients’ 
interpretations of what warranted recording, and the significant association 
between ginger use and bleeding was based on only seven self-reported events in 
25 users (whereas six events in 23 users of willow bark produced no significant 
association).
Notwithstanding such reservations, this study demonstrates that it is feasible to 
perform specific epidemiological evaluations of NPDIs. Such studies could be 
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performed either among users of drugs that are known for an increased risk on 
drug interactions (e.g. antithrombotics, HIV medications and psychiatric drugs) or 
among patients that are known to use many natural products (e.g. certain ethnic 
groups or patients with certain diseases, such as HIV or cancer).
Risk assessment
The first step in the clinical risk assessment of NPDIs is a systematic collection of the 
available data on their nature, incidence and consequences. Comprehensive search 
strategies are needed for this purpose. For instance, it is worthwhile to search not 
only for general terms designating herbal products but also for specific herbs and 
major plant constituents (Table 1). And since Pubmed does not adequately cover all 
the sources that provide potentially useful information about NPDIs, it is certainly 
not the only database that should be used.
After the available data of NPDIs have been collected, it is important to consider 
the following principles in their evaluation:4,52
(1) The quality of the evidence is often variable and must therefore be carefully 
assessed. For instance, how well-designed, well-performed and generalizable 
is a clinical study (e.g. how representative is the tested natural product of 
commercially available products) and to which extent does a case report comply 
with current guidelines for submitting adverse event reports to biomedical 
journals? Consistency of data from different sources may further add to the 
validity of the evidence.
(2) The clinical impact of an adverse NPDI at the population level will depend both 
on its seriousness and on the probability that it actually occurs.
(3) Are there any data on potential risk modification by factors such as certain 
genotypes, frailness, comorbidities, renal or hepatic insufficiency, additional 
natural products or conventional drugs? Such data can help to identify the 
drug users who are at the highest risk. For instance, in a recent study of the 
pharmacokinetics of rosuvastatin in healthy volunteers, the addition of 
baicalin (a flavone glucuronide in the Chinese herbal medicine Scutellariae 
Radix) depended on the haplotype of OATP1B1 (organic anion-transporting 
polypeptide 1B1, the expression of which is considered the main uptake 
mechanism for rosuvastatin into the liver) reduced the AUC0-∞ of rosuvastatin 
by 42%, 24% and 2%, respectively, in OATP1B1*1b/*1b, OATP1B1*1b/*15, and 
OATP1B1*15/*15 subjects.32
(4) The risk of an adverse NPDI may extend beyond the natural product-drug 
pair for which there is actual clinical evidence. For instance, St. John’s wort is 
such a potent and well-established inducer of CYP3A4 that it would be wise to 
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be careful with combining this herb with any CYP3A4 substrate, even in the 
absence of concrete clinical data to underpin such interactions.
(5) Evaluations of NPDIs have a shelf life of their own: any systematic assessment 
of NPDIs must comprise an adequate method for collecting and assessing new 
emerging evidence without unnecessary delay.
DEVELOPMENT AND EXECU TION OF RISK REDUCTION 
STR ATEGIES
This phase of clinical risk management aims at the definition of operational 
strategies needed to reduce health risks, at the identification of resources, and at the 
execution of selected strategies.
As most natural products are available without prescription, it is of paramount 
importance to inform consumers about the risks of combining these products with 
conventional drugs. Regulatory authorities, manufacturers, prescribers and retail 
sellers of natural products as well as manufacturers, prescribers and dispensers 
of conventional drugs should all contribute to this goal without shifting their 
responsibility to other parties involved.
Product  information
Commercially available natural products should carry appropriate warnings 
concerning NPDIs in their product information. When the risk of NPDIs is 
pronounced, one may consider to print a conspicuous warning on the natural 
product package or to stick a special cautionary sticker. If specific data are not 
available, a general cautionary note should be included that such data are absent 
and that the safety of combining the natural product with conventional drugs has 
therefore not been adequately established. Mutatis mutandis, similar warnings 
should be included in the product information of conventional drugs.
Professional  contributions
Prescribers and dispensers of conventional drugs should systematically inquire 
whether their patients are using natural products. They should also make their 
customers aware of the possibility that an adverse event may occur, which is not 
yet described in the product information. Conversely, prescribers and retailers of 
natural products should ask their customers about the use of conventional drugs, 
particularly when they recommend or sell natural products with a well-established 
risk of NPDIs. They should be adequately educated in these topics and discuss them 
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with their customers. Perhaps the same educational methods that have proved 
useful for improving the prescribing behaviour of conventional physicians, such 
as outreach visits 53 and peer reviewing in small groups,54 can also be employed to 
influence herbal prescribers.
C omputerised screening systems
Conventional physicians and pharmacists should urge their patients to have 
their natural products registered in the same records, in which their prescription 
medicines are registered. The latter opens the door to computerised screening for 
adverse NPDIs, which is a more efficient and reliable strategy than depending on 
the ready knowledge and perceptivity of an individual healthcare professional. 
To benefit optimally from such screening, the healthcare professional must 
know exactly what the computerised system can and cannot do.55 For instance, a 
computerised system can more readily produce an alert when a CYP3A4 inducer 
is being added to a CYP3A4 substrate than detect another equally important risk 
moment, viz. when the inducer is being withdrawn again.4
Ideally, computerised systems should identify clinically relevant DDIs and NPDIs 
with high specificity (i.e. low rate of false positive alerts) as well as high sensitivity 
(i.e. low rate of the false negative absence of alerts). Unfortunately, each of these 
parameters decreases when the other increases, so a kind of trade-off between the 
two is often needed. Some researchers argue that reducing current numbers of false 
positive DDI alerts should be given priority.56-58 However, other researchers point 
out that physicians’ reasons for overriding alerts are not always convincing and that 
turning off certain DDI alerts systematically (nation-wide or even hospital-wide) 
could be problematic because of differences in physicians’ drug knowledge, routine 
drug monitoring practices, and so on.59,60 To find a way out of this dilemma, the 
following strategies should be explored in more detail:
(1) better opportunities for differentiation within alerting systems on the basis of 
the type of prescription (first time vs. second time vs. repeat prescription), the 
type of end user (e.g. degree of knowledge) and the type of setting (e.g. degree 
of routine monitoring).56,60
(2) better tailoring of DDI and NPDI recommendations to the practical needs 
of the end user (e.g. more specific information on how to adjust a dosage 
regimen).57,61
(3) making better use of the available clinical data, when the seriousness of a DDI 
or NPDI depends not only on the specific drug-drug or natural product-drug 
pair but also on the characteristics of the individual patient (cf. the discussion 
on risk modifiers above).62
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Pharmac y only  status
Regulatory authorities may reclassify general sales medicines as pharmacy only 
medicines, if information emerges that it is not safe to supply these products 
without a pharmacist checking that they are suitable for the individual patient. 
In our previous review, we proposed to bring natural products with a high risk of 
serious NPDIs (e.g. St John’s wort with a pharmacological dose level of hyperforin) 
under a pharmacy only regimen, as this will facilitate their incorporation into 
pharmacy records and will thus allow the computerised screening for interactions 
with conventional drugs.4 In line with this suggestion, the Dutch authorities have 
now categorized the first licensed St John’s wort product in The Netherlands as a 
pharmacy only medicine.63 However, this move will only have an optimal effect, if at 
the same time measures are taken to put a stop to the free availability of unlicensed 
St John’s wort products.
Patient-oriented communication
The therapeutic value of most natural products has not yet been satisfactorily 
proven, which makes them nonessential (and thus avoidable) from a professional 
perspective. However, patients may have very different ideas about the 
appropriateness of natural products. Such perceptions may be built up over time, 
informed by personal experiences and social networks, and shaped by behavioural 
norms and media reporting. Fear of the development or progress of a disease, 
mistrust in conventional medicines, and the desire to take responsibility for one’s 
health may also play a contributory role.64,65
Further research in this domain is warranted to guide natural product information 
and professional counselling about natural products. A crucial first step is, of 
course, that health professionals are aware of the use of herbal products by a patient. 
A particular point of attention should be that patients may find it difficult to deal 
with uncertainties that arise from the lack of good quality information. Current 
uncertainties about the potential benefit and harm of many natural products leave 
a wide opening for the beliefs and concerns of the individual user to come into 
play. For instance, how are patients supposed to deal with a general warning that 
the safety of combining their natural product with conventional drugs has not been 
adequately established?
In daily practice, conventional healthcare providers should aim for a middle 
ground between paternalism and consumerism by making room not only for their 
professional views but also for the values of the individual patient. In this era of 
globalization, they should also be aware that patients may come from a variety 
of cultural backgrounds, which in their turn may have a strong influence on the 
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patient’s attitude towards natural products. Cultural competence is then required to 
communicate respectfully and effectively with these patients.66,67
EVALUATION OF RISK REDUCTION STR ATEGIES
The third phase in clinical risk management is the evaluation of the impact of 
risk minimization strategies, i.e. do these strategies actually work effectively and 
efficiently. This final phase is crucial in the clinical risk management of conventional 
DDIs and should not be overlooked either in the risk management of NPDIs.
Product  information
As the package inserts of natural products and conventional medicines are a main 
tool for informing consumers about NPDI risks, it should be monitored that the 
NPDI information in such inserts is accurate, complete and useful for consumers, 
irrespective of whether the natural product is a licensed conventional medicine, 
a licensed traditional medicine, or an unlicensed food supplement. We have 
previously argued that the least that should be done to make consumers more 
aware is the inclusion of a specific advice in the product information about natural 
products to contact a physician or pharmacist in case of an unexpected adverse 
event.4 Judging from the public assessment reports of the natural products approved 
as traditional medicines in the UK, such a statement is not yet always included.68
Professional  resources
The development and maintenance of NPDI information in professional reference 
books and computerised databases should be organised in such a way that the 
quality, consistency and usefulness of the information is adequately assured.69 
Among the important points of attention are: (1) how timely and consistently are 
NPDIs included; (2) is NPDI information evaluated by a well-structured method 
before inclusion; (3) what is the scientific quality of the NPDI descriptions and of 
the recommendations on how to deal with each NPDI; (4) how unambiguous and 
practicable are the recommendations in the eyes of busy end users?
Computerised systems for DDI screening are only useful for the detection of 
NPDIs, if the natural products are adequately coded for the generation of NPDI 
alerts and if they are adequately registered in the patient record. It is also important 
to know how the DDI system performs in theory (to which degree does it allow end 
users to adjust default settings, how regularly is the software updated, etc.) and how 
the system performs in practice (to which degree have end users actually adjusted 
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default settings, how correctly has the software been actually updated, etc.). Among 
the methods used to research such issues is testing systems by means of mock 
patient profiles containing potentially hazardous drug-drug pairs.70,71
Professional  performance
It should be monitored whether healthcare professionals have adequate knowledge 
about NPDIs and whether they apply this knowledge correctly.72,73 For instance, 
how often do pharmacists ask about the use of natural products, when dispensing 
conventional medicines with a well-established NPDI? How often do pharmacists, 
health food stores and e-sellers inquire into the use of conventional medicines, before 
selling a natural product with a well-established NPDI? And to which extent do 
patients asking for natural products in pharmacies, health food stores or webstores 
receive appropriate and up-to-date counselling about NPDIs? In a questionnaire 
survey among Canadian community pharmacists, 76% of the respondents self-
reported that they could counsel consumers about the NPDI between St John’s wort 
and sertraline, but only 5% claimed to have enough knowledge about garlic plus 
ritonavir, and only 2% about goldenseal plus indinavir.10
Among the methods to measure actual performance is the use of mystery shoppers 
asking specific questions to community pharmacies and other outlets of natural 
products.74 In a recent US study, investigators posing as consumers telephoned 
community pharmacies and health food stores with the question whether there is a 
problem with taking St John’s wort together with birth control pills. Only part of the 
pharmacists correctly identified the NPDI and the result was even worse for health 
food store clerks (51% and 11%, respectively). Inappropriate advice that implied the 
absence of the NPDI was given by 26% of the pharmacists and by 35% of the health 
food store clerks.75
If the performance of pharmacists turns out to be poor, potential reasons for this 
finding should be explored, such as: heavy workload and time constraints; the 
allocation of tasks to technicians; poor relationship with prescribing physicians; 
insufficient knowledge of NPDIs and/or communication skills; overreliance 
on computerised DDI screening (vs. personal perceptivity at the counter); 
overemphasis on first-time dispensing (vs. repeat dispensing), regular customers 
(vs. passer-by customers) and/or NPDIs producing severe effects in all users 
(vs. NPDIs producing less severe effects or severe effects in just a part of the 
users).56,73,76-78 Experts of quality improvement recommend that, after the barriers to 
change have been identified, educational and organizational interventions tailored 
to the most relevant barriers should be performed, even though the evidence does 
not conclusively suggest that tailored interventions are consistently effective.79
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It should also be evaluated to which extent registration of natural products in 
healthcare records makes on-line screening for hazardous NPDIs feasible. And if 
this is the case, it should be monitored how often healthcare professionals override 
NPDI alerts 59,62 or take another action than the recommended one.76
C onsumer performance
Questions in this domain that can be addressed by active monitoring include: are 
consumers aware of the existing NPDI risks; what are their sources of information 
on these issues and how intensively do they consult them; how well informed does 
this make them; and how does this affect their actual consumption behaviour?
C ONCLUSIONS
Clinical pharmacologists, health services researchers and governmental scientists 
can further the risk management of NPDIs by contributing to the above-
mentioned domains: the collection and interpretation of spontaneous reports; 
the design and interpretation of prospective clinical studies; the development 
of pharmacoepidemiological investigations; the synthesis and weighing of 
the available evidence; the expert counselling of regulatory authorities and 
manufacturers on relevant issues; and the evaluation of existing and emerging risk 
reduction strategies.
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ABSTRACT
Background
Despite the availability and daily use of computerized drug-drug interaction 
surveillance systems, exposure to potentially relevant drug-drug interactions 
(DDIs) continues. DDI management guidelines are often inadequate and clear 
management options are lacking, which attributes to overriding of DDI signals. 
Although general criteria for the development and reporting of high-quality clinical 
practice guidelines have been identified, it appears these have not yet been applied 
to DDI management guidelines.
Object ives
To assess the clarity and applicability of guidelines for the management of 
potentially harmful DDIs.
Methods
We selected 13 DDIs that are potentially harmful for patients and frequently occur 
in community pharmacy practice in the Netherlands. The clarity and applicability 
of the management guidelines of these DDIs were appraised using the appropriate 
two domains, ‘Clarity and presentation’ and ‘Applicability’, of the validated Appraisal 
of Guidelines for Research and Evaluation (AGREE) Instrument. The appraisal 
was performed by 12 community pharmacists and 12 general practitioners. The 
standardized domain scores and mean item scores for ‘Clarity and presentation’ 
and ‘Applicability’ were compared.
Results
All DDI management guidelines were generally found to score well on ‘Clarity 
and presentation’, but poorly with respect to ‘Applicability’ (standardized domain 
scores 68.0 vs. 26.1%). Within the domain ‘Clarity and presentation’, the item 
‘tools for application’ received the lowest scores. Within the domain ‘Applicability’, 
cost implications, organisational barriers and key review criteria were all poorly 
documented. All guidelines presented nondirective advice using words such as 
‘consider’ and ‘regularly’.
Conclusions
Developers of DDI management guidelines should take the appropriate domains 
of the AGREE Instrument into consideration in their development processes. The 
applicability of DDI management guidelines should be pretested before publishing. 
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To improve guideline quality, more attention should particularly be paid to the 
available tools for applications and cost implications.
INTRODUCTION
Despite the extensive use of computerized drug-drug interaction surveillance 
systems (CIS), exposure to potentially relevant drug-drug interactions (DDIs) 
continues.1-3 In current practice, many physicians and pharmacists are overwhelmed 
by alerts of DDIs with questionable or unclear clinical significance because of a 
lack of specificity of their surveillance system.4 Therefore, they frequently override 
alerts, a phenomenon often described as alert fatigue.5-7 On the other hand, they 
experience that their systems sometimes neglect relevant DDIs and/or do not adjust 
for identifiable patient-related risk factors.7-11 Moreover, professionals complain 
that information about strategies to prevent patient harm, such as non-interacting 
alternative therapies or specific advice for dose adjustment, is sometimes lacking 
in DDI guidelines (e.g. diuretics and NSAIDs, simvastatin and diltiazem).12,13 In 
agreement, Hansten 14 observed that current DDI management guidelines are 
often inadequate and should have clear management options. These shortcomings 
stimulated Van Roon et al.15 to develop a procedure for the structured assessment 
of DDIs. Clinically relevant DDIs should be presented with appropriate information 
on the relevance for individual patients and with a clear proposal for potential 
interventions.
Clear and specific recommendations are associated with better compliance with 
clinical guidelines.16 Preferably, these recommendations should contain concrete 
and precise descriptions of the appropriate management and require few new skills 
and/or organisational changes.17-19 Criteria for the development and reporting of 
high-quality clinical practice guidelines have been identified by the Appraisal of 
Guidelines for Research and Evaluation (AGREE) Collaboration. This collaboration 
developed and validated the AGREE Instrument (http://www.agreetrust.org/).20 
This has become a widely used assessment instrument that has been proven reliable 
and valid for various clinical practice guidelines,21-23 and has been applied to all 
kinds of clinical guidelines.24-29 However, to the best of our knowledge these have 
not yet been used to assess the quality of reporting in DDI management guidelines. 
Therefore, the objective of this study was to assess the clarity and applicability of 
guidelines for the management of potentially harmful drug interactions.
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METHODS
S elect ion of  interact ions
We selected 13 DDIs that are potentially harmful for patients and frequently 
occur in daily clinical practice (Table 1). The latter criterion was based on the 
most frequently encountered DDI alerts in the Netherlands that were identified 
by Buurma et al.4 To fulfil the former criterion, there had to be evidence from 
controlled, published, interaction studies in patients or healthy volunteers, and the 
potential adverse reaction had to be considered as clinically relevant.15
Table 1 Appraisal of Guidelines for Research and Evaluation (AGREE) domain scores 
of the drug-drug interaction (DDI) management guidelines 
DDI management guidelines ‘Clarity and 
presentation’ (%)a
‘Applicability’ (%)a
Renin-angiotensin system inhibitors and diuretics 83.2 33.7
NSAIDs and renin-angiotensin system inhibitors 75.0 19.5
Diuretics and NSAIDs 74.1 35.0
β-Adrenoceptor antagonists (β-blockers) and NSAIDs 68.9 14.5
Non-selective β-blockers and β-adrenoreceptor agonists 68.3 30.7
Coumarin anticoagulants and NSAIDs 68.1 26.7
Corticosteroids and NSAIDs 67.4 32.0
Simvastatin/atorvastatin and diltiazem/verapamil 66.8 22.4
NSAIDs (excluding selective COX-2 inhibitors) and SSRIs 66.3 20.3
Levothyroxine and iron 65.8 25.2
Coumarin anticoagulants and antibacterials 65.3 31.5
Methotrexate and NSAIDs/salicylates 59.3 21.7
Calcium channel antagonists and β-blockers 55.9 26.5
Overall score (%) 68.0 26.1
NSAIDs = non-steroidal anti-inflammatory drugs; COX = cyclo-oxygenase; SSRIs = selective serotonin reuptake 
inhibitors
a) ([score obtained – minimum score possible] / [maximum score possible – minimum score possible]) × 100
Dr ug-dr ug interact ion (DDI)  management  guidel ines
In the Netherlands there are two sets of DDI management guidelines that are 
integrated in different types of CIS. One set is maintained by a working group of the 
Scientific Institute of Dutch Pharmacists (WINAp) and the other set by a working 
group of the Health Base Foundation (SHB).15,30,31 Hard copies of the entire 
management guidelines of all selected DDIs (2×13) were available.
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Assessment  of  the  DDI management  guidel ines
To assess the clarity and applicability of these DDI management guidelines 
we used the appropriate domains of the validated AGREE Instrument.20 The 
entire guidelines were assessed on the domains ‘Clarity and presentation’ and 
‘Applicability’, comprising 7 of the 23 AGREE items (see Box 1). Scoring of each 
item was performed according to the AGREE Instrument, on a 4-point Likert scale: 
1 = strongly disagree, 2 = disagree, 3 = agree, and 4 = strongly agree. As the AGREE 
Collaboration recommends a minimum number of four appraisers for a reliable 
assessment,20 and as we did not know whether different types of healthcare provider 
would produce different results or not, each guideline was independently assessed 
by four community pharmacists and four general practitioners who were randomly 
selected from a pool of 12 community pharmacists and 12 general practitioners. 
All selected healthcare providers were known by the researches and used DDI 
management guidelines in daily practice. The appraisal was individually performed 
and scores and comments returned to the researchers by e-mail or posted mail.
Data analyses
Mean item scores and standardized domain scores for the two domains (‘Clarity and 
presentation’ and ‘Applicability’) were calculated according to the instructions of 
the AGREE Instrument. Standardized domain scores were calculated by summing 
the scores given by the appraisers and standardizing them as a percentage of the 
maximum possible score for that domain (equation 1):
score obtained – minimum score possible
× 100 (Eq.1)
maximum score possible – minimum score possible
A majority of item scores of 3 or 4 and standardized domain scores above 60% 
indicate good quality within the domain, equal numbers of item scores of 3 or 4 and 
1 or 2 and standardized domain scores between 30% and 60% indicate moderate 
quality, and a majority of item scores of 1 or 2 and standardized domain scores 
below 30% indicate poor quality within the domain.
The standardized domain scores and the mean item scores of the DDI management 
guidelines were compared between SHB and WINAp and between general 
practitioners and community pharmacists using mixed-model analyses. The 
intraclass correlation coefficients (ICCs) were calculated for each item and the two 
domains to assess appraiser reliability.20,21 A one-way random effects model was 
used as pairs of appraisers were randomly selected from our pool of community 
pharmacists and general practitioners. The level of significance for all analyses was 
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B ox 1 Appraisal of Guidelines for Research and Evaluation (AGREE) items that have 
been assessed.
Domain ‘Clar it y  and presentation’
Item 1. The recommendations are specific and unambiguous
A recommendation should provide a concrete and precise description of which management is 
appropriate in which situation and in what patient group, as permitted by the body of evidence. An 
example of a specific recommendation is: inform anticoagulation clinic on start of antibacterial.
Item 2. The different options for management of the condition are clearly presented
For some recommendations, different management options might be considered. These alternatives 
should be clearly presented in the guideline. An example of a specific recommendation with 
management options for the interaction between NSAIDs and renin-angiotensin system inhibitors is: 
a. in case of short use of NSAIDs for hypertension: no action;
b. in case of long use of NSAIDs for hypertension: monitor blood pressure frequently;
c. in case of heart failure: consider replacement of NSAID by paracetamol (acetaminophen);
d. when NSAID are not replaced by paracetamol in a patient with heart failure, instruct patient to 
contact physician in case heart failure symptoms increase.
Item 3. Key recommendations are easily identifiable
Users should be able to find the most relevant recommendations easily. These recommendations 
address the main clinical questions that have been covered by the guideline. They can be identified 
in different ways. For example, they can be summarised in a box, typed in bold, underlined or 
presented as flow charts or algorithms.
Item 4. The guideline is supported with tools for application
For a guideline to be effective it needs to be disseminated and implemented with additional 
materials. These may include, for example, a summary document, a quick reference guide, 
educational tools, patient leaflets and/or computer support. Such a tool should be provided with the 
guideline.
Domain ‘Appl icabi l i t y ’
Item 5. The potential organisational barriers in applying the recommendations have been discussed
Applying recommendations may require changes in the current organisation of care within a service 
or a clinic. These changes may be a barrier to using the recommendations in daily practice and 
should be discussed in the guideline. For example, a DDI management guideline may recommend 
monitoring of serum drug levels. 
Item 6. The potential cost implications of applying the recommendations have been considered
The recommendations may require additional resources in order to be applied. For example, there 
may be a need for more specialised staff, new equipment and expensive drug treatment. These may 
have cost implications for healthcare budgets. There should be a discussion of the potential impact 
on resources in the guideline. For example, resource implications of monitoring or adding a specific 
drug to the therapy.
Item 7. The guideline presents key review criteria for monitoring and/or audit purposes
Measuring adherence to a guideline can enhance its use. This requires clearly defined review criteria 
that are derived from the key recommendations in the guideline. These should be presented. 
Examples of review criteria are:
t the HbA1c should be < 8.0%;
t the level of diastolic blood pressure should be < 95 mmHg.
HbA1c = hemoglobin A1c
159
Assessment  of  DDI  management  guidel ines  |  Chapter  4 .1
set at p < 0.05. All statistical analyses were performed using SPSS 16.0 (SPSS Inc, 
Chicago, IL, USA) and SAS software version 9.0 (SAS, Cary, NC, USA).
RESULT S
There was no significant difference in the assessment of the quality of the DDI 
management guidelines between the type of appraiser, with the exception of the 
significantly higher scores provided by community pharmacists for item 4 (tools for 
application: 2.8 vs. 2.2; p = 0.007) compared with general practitioners.
Quality  of  guidel ines
Most of the guidelines (21 of 26) were rated good quality for the domain ‘Clarity and 
presentation’ (standardized domain scores of 65.3–83.2%). However, the domain 
‘Applicability’ performed poorly for more than half of the guidelines (16 of 26) 
(standardized domain scores of 14.5–26.7%) (Table 1). The analyses revealed the 
mean score across all 26 guidelines (2×13) was low for items 5 (organizational 
barriers: 2.2), 6 (cost implications: 1.2) and 7 (key review criteria: 1.9), indicating 
the guidelines performed poorly for these items (Table 2).
Table 2 Comparison of mean item scores of the drug-drug interaction (DDI) 
management guidelines for Scientific Institute of Dutch Pharmacists 
(WINAp) and Health Base Foundation (SHB)
Domain a Mean b Range c Mean b p-value
WINAp SHB
‘Clar it y  and presentation’     
1. Specific and unambiguous 3.2 2.9–3.7 3.2 3.1   0.659
2. Clearly presented options 3.2 2.4–3.6 3.1 3.3   0.084
3. Identifiable key recommendations 3.3 3.0–3.6 2.9 3.7 < 0.0001
4. Tools for applications 2.5 1.9–3.3 2.7 2.3   0.0002
‘Appl icabi l i t y ’
5. Organizational barriers 2.2 1.8–2.6 2.2 2.2   0.842
6. Cost implications 1.2 1.1–1.6 1.2 1.3   0.561
7. Key review criteria 1.9 1.3–2.4 1.9 1.9   1.000
a) For further details on domains 1–7 see Box 1
b) Item score: maximum =  4; minimum = 1
c) Range of the mean item scores of the assessed DDI management guidelines
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For the item 6 ‘cost implications’, several appraisers reported that they could not 
find any discussion on (additional) resources required for the recommendations, 
except for the reporting of an increased risk of hospitalization in case a specific 
DDI was not prevented. The guidelines produced a moderate score for item 4 (tools 
for application: 2.5), whereas items 1–3 in the domain ‘Clarity and presentation’ 
scored good quality (specific and unambiguous: 3.2; clearly presented options: 3.2; 
identifiable key recommendations: 3.3).
Several appraisers mentioned the guidelines used non-directive advice, using words 
as ‘it is to be recommended’, ‘consider’ and ‘regularly’. Moreover, they reported 
that risk factors and patient modifiers were not always presented clearly in the 
management options.
Quality  of  guidel ines  according to  type of  working group
There was no difference in scores between SHB and WINAp guidelines for the 
domain ‘Applicability’. SHB guidelines had significantly higher scores for the 
domain ‘Clarity and presentation’ (70.4 vs. 65.7%; p = 0.031) as well as significantly 
higher scores for item 3 (identifiable key recommendations: 3.7 vs. 2.9; p < 0.0001). 
According to several appraisers ‘key recommendations’ were most easily identifiable 
in SHB guidelines since they were presented in a text box. WINAp guidelines had 
significantly higher scores for item 4 (tools for application: 2.7 vs. 2.3; p = 0.0002) 
(Table 2).
Data va l idation
The ICCs indicate moderate reliability for the domain ‘Clarity and presentation’ 
(ICC = 0.49) and low reliability for the domain ‘Applicability’ (ICC = 0.28). 
For  items 1–7 (Box 1), the ICCs were 0.19, 0.36, 0.73, 0.66, 0.00, 0.09 and 0.40, 
respectively.
DISCUSSION
All DDI management guidelines had moderate to good quality within the domain 
‘Clarity and presentation’, but had poor to moderate quality with respect to the 
domain ‘Applicability’.
Other studies that have used the AGREE Instrument to assess guideline quality 
obtained similar results; the domain ‘Clarity and presentation’ received higher 
scores than ‘Applicability’.22-25
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Domain ‘Clarity  and presentat ion’
Within the domain ‘Clarity and presentation’, the item ‘tools for application’ received 
the lowest scores. Patient leaflets, computer support and summary documents 
were often not reported in the guidelines, although they were available for most 
guidelines. The quality of guidelines could be improved by systematically referring 
to the available tools for applications.
Most of the guidelines scored well on the item ‘recommendations are specific and 
unambiguous’. Most obviously, the appraisers observed that guidelines used non-
directive advice, using words such as ‘it is to be recommended’, ‘consider’ and 
‘regularly’. The GRADE (Grades of Recommendation, Assessment, Development 
and Evaluation) system 32 recommends that guideline panels systematically apply 
such terminology (e.g. ‘it is to be recommended’, ‘consider’) in order to differentiate 
between the strength of recommendations.33 However, the appraisers did not 
recognise these wordings in the guidelines as part of a systematic terminology. 
Clearly there is a need to explain how to interpret this terminology.
Guideline users might be able to find the most relevant recommendations more 
easily when key recommendations are presented as boxed text. In addition, 
management options should clearly present risk factors and patient modifiers.
Domain ‘Applicabi l ity ’
DDI management guidelines scored lowest on the item ‘cost implications’. There 
should be a discussion of the potential impact on costs in the guidelines. Cost-
effectiveness of recommendations should be addressed.
Most of the guidelines failed to discuss key review criteria that could be used to 
measure the adherence to a guideline. Although some guidelines reported which 
biomarkers should be monitored (e.g. blood pressure, International Normalized 
Ratio, serum drug level and potassium level), the consequences of changes in 
biomarker remained mostly unreported.
Most of the guidelines were poorly documented with respect to organisational 
barriers. How to monitor and who needs to monitor was mostly unclear and 
information exchange between healthcare providers was rarely advised.
The low score on the domain ‘Applicability’ suggests there are still numerous 
barriers to the implementation of DDI management guidelines.19,34 Enhanced 
compliance with guidelines and significant improvements in clinical care could 
be achieved when guideline developers pay attention to these barriers from the 
beginning of the guideline development process.35
162
4
Limitat ions
There are some limitations in this study. First, the AGREE Instrument has primarily 
been developed to appraise the quality of disease-specific clinical guidelines;20 
however, we believe that similar quality principles are relevant for DDI management 
guidelines. This assumption seems acceptable as the AGREE Instrument has also 
been used successfully in other areas.22,24,25
Another potential limitation is that the guidelines assessed in our study may not 
be representative for all DDI management guidelines. As we appraised guidelines 
for frequently occurring DDIs with the highest level of evidence and potentially 
clinically relevant adverse events resulting from the DDI, it is most likely that our 
selection has relatively good recommendations, and guidelines in general might 
have even more problems. The appraisers may have had a preference for the set of 
DDI management guidelines (WINAp or SHB), which they used in their clinical 
practice. We have analysed this potential bias and found no substantial influence on 
the results. There is always potential for lack of reliability among appraisers when 
using the AGREE Instrument. We aimed to minimize this by providing a training 
manual that included examples of DDI management guidelines, which has been 
pretested, and the appraisers could contact the researchers by e-mail or phone for 
help. Moreover, we used two panels of four appraisers (i.e. four general practitioners 
and four community pharmacists) for each guideline, which was double the number 
advised by the AGREE Collaboration (i.e. eight appraisers instead of four).20,36
The ICCs for the two domains were lower than reported in the AGREE validation 
study 20 and by Gorman et al.,22 which reflects a lower degree of reliability among 
the appraisers. As for some items, the information provided in the guidelines was 
incomplete or even completely missing; therefore, appraisers might have relied on 
their clinical expertise. Although all appraisers used the guidelines in their practice, 
we did not ascertain whether appraisers were clinical experts in the therapeutic 
areas covered by all 13 guidelines. Thus, low reliability may relate to differences in 
the level of clinical expertise of the appraisers.
Poor reliability was evident for the domain ‘Applicability’. Appraisers might have 
had difficulties interpreting these items because of the lack of consensus about the 
meaning of these items in DDI management guidelines. Apparently, the pretested 
training manual and phone and e-mail help service were not sufficient for all 
appraisers.
There is a clear need for the comprehensive assessment of the quality of DDI 
management guidelines. A structured procedure for assessing the clinical relevance 
of DDIs has been proposed 15 but this is not sufficient since the quality of the clinical 
content of guidelines does not necessarily correspond to AGREE quality scores, 
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which focus on the methods used for developing the guideline and the quality of 
reporting.37,38 Consequently, the quality of DDI management guidelines should 
also be appraised by applying the appropriate domains of the AGREE Instrument, 
in particular ‘Clarity and Presentation’ and ‘Applicability’. However, in addition to 
a pretested training manual and help service, thorough training, with instructions 
on how to interpret items, is required when the AGREE Instrument is used for this 
particular purpose.
CONCLUSION
The selected management guidelines of DDIs that are potentially harmful for 
patients and frequently occur in community pharmacy practice were found to 
have good ‘Clarity and presentation’ but poor ‘Applicability’. To improve guideline 
quality, more attention should particularly be paid to available tools for applications 
and cost implications. Developers of DDI management guidelines should take 
the appropriate domains of the AGREE Instrument into consideration in their 
development processes. The applicability of DDI management guidelines should be 
pretested before publishing. There should also be a monitoring system in place to 
check, after dissemination, whether the guidelines offer the intended high quality 
in daily practice.
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ABSTRACT
Background
Management guidelines for drug-drug interactions (DDIs) between non-steroidal 
anti-inflammatory drugs (NSAIDs) and antihypertensives recommend blood 
pressure monitoring in hypertensive patients.
Object ives
We measured the short-term effect of initiating NSAIDs on the systolic blood 
pressure (SBP) in users of antihypertensives, aiming to investigate which outpatients 
are at risk for an increase in SBP in daily clinical practice.
Methods
A cohort study with a nested case-control design in Dutch community pharmacies. 
Patients with a DDI alert for a newly initiated NSAID and antihypertensive were 
interviewed and their SBP was measured at T0, after one week (T1) and after two 
weeks (T2). We evaluated risk factors for exceeding a predefined limit of change 
(PLoC) in SBP ( ≥ 10 mmHg to ≥ 140 mmHg) at T1 and T2 versus T0.
Results
For 112 patients the SBP at T0 was measured. Two patients were excluded (T0 
SBP ≥ 180 mmHg). PLoC was exceeded in 10 patients (10.4%) at T1 and in seven 
patients (8.0%) at T2. Patients using etoricoxib (OR 21.0; 95%CI 3.7-120.6) and 
patients using > 1 defined daily dose of an NSAID (OR 3.3; 95%CI 1.1-10.0) were at 
increased risk of a rise in SBP.
Conclusions
A newly initiated NSAID has an immediate clinically relevant effect on SBP in some 
users of antihypertensives. Management guidelines for NSAID-antihypertensive 
DDIs should advise SBP monitoring before and after initiation of an NSAID or 
intensification of NSAID therapy. Monitoring is especially relevant in patients 
prescribed high dosages of NSAIDS. Etoricoxib should not be used in hypertensive 
patients.
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INTRODUCTION
It has been reported that individual patients using antihypertensive drugs may 
experience substantial elevations of blood pressure (BP) within two weeks after 
commencement of a non-steroidal anti-inflammatory drug (NSAID).1-3
Drug interaction management guidelines advise that NSAIDs should be used with 
caution in patients using antihypertensive drugs because of a BP destabilizing 
effect.4-7 Furthermore, there is abundant evidence that high BP is associated with 
increased risk of cardiovascular morbidity and mortality.8-10 The antihypertensive 
drugs concerned in this drug-drug interaction (DDI) are renin-angiotensin 
system (RAS) inhibitors (angiotensin-converting-enzyme (ACE) inhibitors or 
angiotensin-II receptor blockers), beta-blockers or diuretics (loop or thiazide). The 
interaction does not apply for calcium channel blockers, as they are less affected by 
NSAIDs.2
In daily clinical practice physicians and pharmacists encounter a high frequency of 
DDI alerts concerning the combination of NSAIDs and antihypertensives.11 Each 
alert should be followed by an assessment of whether this combination of drugs 
is needed. Ideally, BP monitoring should be part of this assessment, keeping in 
mind that current guidelines on hypertension management and cardiovascular 
disease prevention aim at a systolic BP (SBP) below 140 mmHg.6,12-14 The question 
is whether all patients for which this DDI alert occurs are at risk for a BP elevation 
and should be routinely monitored.
While several studies have demonstrated that NSAIDs may increase BP in patients 
treated for hypertension,2,15-19 only Krum et al. performed a multivariate analysis 
on potential risk factors predisposing patients to a rise in BP after the start of an 
NSAID.20 Their study population, however, was restricted to osteoarthritis and 
rheumatoid arthritis patients. Moreover, patients with uncontrolled hypertension 
were excluded, and NSAID use was limited to etoricoxib (60 and 90 mg/day) and 
diclofenac (150 mg/day). Consequently, the risk factors found may not be applicable 
to all treated hypertensive patients using an NSAID. Moreover, the changes in BP 
were only determined after four months of continuous NSAID use, whereas in daily 
clinical practice NSAIDs are often used intermittently or for a few weeks.
Therefore, the aim of our study was to measure the short-term effect of newly 
initiated NSAIDs on SBP in outpatients on antihypertensive therapy and to 
investigate which outpatients are at risk for a rise in SBP in daily clinical practice.
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METHODS
S ett ing
A total of 78 Dutch community pharmacies, belonging to the Utrecht University 
Pharmacy Practice Research Network (UPPER) (which comprises about 50% 
of all 1,976 Dutch pharmacies 21), were invited to participate in this study from 
September 2010 to September 2011. Pharmacy master’s students from Utrecht 
University or pharmacy technicians assisted in the selection and monitoring of the 
patients. They were adequately trained to measure patients’ BP and a help desk was 
available throughout the research period.
Study populat ion
In each participating pharmacy patients with a DDI alert for a newly initiated 
NSAID and a RAS inhibitor (ACE inhibitor or angiotensin-II receptor blocker), 
beta-blocker or diuretic (loop or thiazide) were contacted. Only adult patients 
enlisted in the participating pharmacy, with a newly initiated NSAID (no NSAID 
used in the preceding week) and concomitant use of one of the aforementioned 
antihypertensives prescribed for hypertension for at least three months, and with 
no change in their antihypertensive regimen during the preceding month, were 
enrolled. Patients’ BP was measured at inclusion (T0, baseline BP). Patients with a 
baseline SBP over 180 mmHg were excluded and referred to their physician.12
Blood pressure  measurements
BP was measured according to a pretested protocol 22 at inclusion (T0), one week 
after inclusion (T1) and two weeks after inclusion (T2) by means of the automated 
and validated Omron M6 Comfort monitor.23
During measurement, patients were in the sitting position. After a minimum of 
5 min rest two consecutive measurements with 2 min in between were recorded. 
Mean SBP and mean diastolic BP (DBP) over both measurements were calculated.
When patients’ SBP at T1 was ≥ 180 mmHg the pharmacist informed the patients’ 
physician, based on European guidelines of cardiovascular disease prevention.12
Addit ional  data  col lect ion
At T0, T1, and T2 the following data were recorded using a pretested, structured 
questionnaire form 22 (requiring 10 min per patient): patients’ age, sex, height 
and weight, dose and regimen of the NSAID and antihypertensive(s) in use, 
comorbidities with a potential effect on BP (diabetes, cardiovascular diseases and 
renal dysfunction), personal habits (smoking, alcohol use, low salt diet). Defined 
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daily doses of the NSAIDs and antihypertensive(s) in use were calculated using the 
World Health Organization ATC/defined daily dose methodology.24
Data analysis
Changes in SBP from T0 (inclusion) were determined at T1 (6-10 days after 
inclusion) and T2 (13-21 days after inclusion). We applied these intervals because 
guidelines recommend that BP should be regularly monitored, particularly during 
the initiation of NSAID therapy 1-5,20 and the fact that in daily clinical practice 
NSAIDs are often used intermittently or for a limited period of time.
We calculated the number of patients in whom the SBP exceeded a predefined limit 
of change (PLoC). PLoC was defined as a SBP measurement at T1 or T2 of ≥ 140 
mmHg 12 plus a change in SBP of ≥ 10 mmHg 8,25 measured as the difference between 
T0 and T1, or T0 and T2. In a nested case-control design, cases were defined as 
patients exceeding PLoC at T1 and/or T2 while using an NSAID. Controls were 
patients not exceeding PLoC at either T1 or T2 while using an NSAID. Differences 
in potential risk factors (e.g. age, BMI, gender, comorbidities) between cases and 
controls were analysed using chi-square tests and univariate logistic regression. 
Given the small number of cases we only explored the relationship between 
the several determinants by including potential risk factors with p < 0.1 in the 
univariate model as covariates in a multivariable logistic regression model.
Data were analysed using SPSS (version 19.0) and statistical software R (version 
2.6.1).
Ethical  approval  and patient  conf identia l ity
The study was submitted to the medical ethics committee of the region Arnhem-
Nijmegen, The Netherlands (reference CMO-nr 2010/317), but did not require 
medical ethical approval according to current Dutch legislations. The work was 
conducted in compliance with the requirements of the UPPER institutional review 
board. All patient data were anonymized in the patients’ community pharmacy.
RESULT S
Patient  populat ion
The BP of 112 patients was measured at T0. Two patients with a baseline SBP above 
180 mmHg were excluded and immediately referred to their physician. Finally, 110 
patients were included in the analysis. Figure 1 presents the flow chart of our study 
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population. The BP was measured at both T1 and T2 for 84 patients (76.4%). For 
three patients (2.7%) the BP was measured only at T2.
The NSAID most often used was diclofenac. The most common antihypertensive 
therapy was monotherapy with a RAS inhibitor (21.8%), followed by a combination 
of a RAS inhibitor and a diuretic (15.5%). Relatively few patients received 
Figure 1 Response flow chart
patients with BP
measurement at T0
112
patients included 110
patients with SBP
≥ 180 mmHg at T0
2
patients without BP
measurement at T1
13
patients without BP
measurement at T2
10
patients with BP
measurement at T1 
97
patients with BP
measurement at T2 
87
patients used NSAID at T1
mean SBP (SD): 137.3 (19.6) mmHg
> PLoC: 10 patients
74
patients no NSAID use at T1
mean SBP (SD): 135.6 (21.8) mmHg 
> PLoC:  6 patients
23
patients used NSAID at T2a
mean SBP (SD): 133.4 (15.5) mmHg
> PLoC: 7 patients
patients no NSAID use at T2b
mean SBP (SD): 135.7 (18.9) mmHg
> PLoC: 2 patients
46
41
BP = blood pressure; SBP =  systolic blood pressure; NSAID: non-steroidal anti-inflammatory drug; SD = standard 
deviation; PLoC = predefined limits of changes in SBP:  ≥ 10mmHg to ≥ 140 mmHg
a) Including one patient without NSAID use at T1 and one patient without BP measurement at T1
b) Including 25 patients without NSAID use at T1 and two patients without BP measurement at T1
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monotherapy with a beta-blocker (8.2%) or diuretic (6.4%). In 47 patients (42.7%) 
the SBP at T0 was ≥ 140 mmHg (Table 1).
Table 1 Baseline characteristics of the study population (n=110)
Characteristics na (%)
Male 49 (44.5)
Female 61 (55.5)
Age in years; mean ± SD 63.2 ± 11.1
Body mass index; mean ± SD 29.3 ± 5.2
Systolic blood pressure in mmHg; mean ± SD 134.9 ± 19.0
Diastolic blood pressure in mmHg; mean ± SD 83.0 ± 11.8
Diabetes mellitus 31 (28.2)
Ischaemic heart disease 17 (15.4)
Heart failure 8 ( 7.3)
Renal disease 3 ( 2.7)
Low-sodium diet 23 (20.9)
Smoking 19 (17.3)
Alcohol male > 3 glasses/day or female > 2 glasses/day 9 ( 8.1)
NSAIDs; average duration of use in days (range) 10.2 (0–21)
Diclofenac 77 (70.0)
Ibuprofen 9 ( 8.2)
Naproxen 9 ( 8.2)
Meloxicam 7 ( 6.4)
Etoricoxib 6 ( 5.5)
Celecoxib 2 ( 1.8)
Antihypertensive drugs; mean use (range) 2.1 (1–5)
Renin-angiotensin system (RAS) inhibitors 84 (76.4)
Diuretics 64 (58.2)
Beta-blockers 51 (46.4)
Calcium channel blockers 24 (21.8)
SD = standard deviation; NSAIDs = non-steroidal anti-inflammatory drugs
a) Number of patients unless otherwise specified.
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Shor t-term ef fect  of  a  ne wly  init iated NSAID on SBP in patients 
with an antihyper tensive
According to our study protocol, the pharmacists informed the patients’ physician 
about two patients (2.1%) with an SBP ≥ 180 mmHg at T1 and about 30 patients 
(34.5%) with an SBP ≥ 140 mmHg at T2.
Analysi s  of  cases .  In Figure 2 the change from baseline SBP (T0) is provided 
for NSAID users at T1 (n=74 patients) and T2 (n=46 patients). At T1 PLoC 
was exceeded in ten NSAID users (13.5%), seven of whom used diclofenac, two 
etoricoxib and one naproxen. At T2 PLoC was exceeded in seven NSAID users 
(15.2%), three of whom used diclofenac, three etoricoxib and one naproxen. In 
three patients PLoC was exceeded at both T1 and T2, one of whom used diclofenac, 
one etoricoxib and one naproxen.
Analysi s  for  associat ions .  In 17 of the 120 measurements (14.2%) the PLoC 
was exceeded (Table 2). The risk of exceeding the PLoC was significantly associated 
with male patients, with the use of etoricoxib and with > 1 defined daily dose (DDD) 
of an NSAID used. The NSAIDs with a DDD > 1 were diclofenac (> 100mg/day 
in six of ten cases), naproxen (> 500mg/day in two of two cases) and etoricoxib 
(> 60mg/day in two of five cases). We did not find an association between type of 
antihypertensive used, comorbidity, patient’s age, BMI or other personal habits, and 
the risk of rise in SBP after initiating an NSAID. After correcting for the three risk 
factors found, male sex appeared not to be an independent risk factor.
DISCUSSION
Our study shows that the mean changes in SBP after initiation of an NSAID in 
patients using a RAS inhibitor, beta-blocker or diuretic are negligible. However, 
more than 10% of patients had SBP increases within two weeks of treatment of ≥ 10 
mmHg resulting in an SBP of ≥ 140 mmHg. Three patients developed an SBP above 
180 mmHg after initiation of an NSAID. We found patients using etoricoxib and 
high NSAID doses (DDD > 1) to be at increased risk for a relevant rise in SBP.
It is difficult to compare our findings directly with other studies because reported 
SBP changes could be related to variation in the NSAID used, doses used, duration 
of treatment, antihypertensive used, and BP measurement method (e.g. sitting or 
standing, mean arterial pressure or SBP).2,26-28 Moreover, we conducted our study 
in daily clinical practice instead of conducting a randomized controlled trial. The 
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high percentage of patients who used an NSAID for less than two weeks in our 
study is quite different from the long-term NSAID use in trials and represents the 
frequent short-term or intermittent use of NSAIDs in daily practice.29,30
Our finding that in more than 10% of the patients in our study population the PLoC 
was exceeded within two weeks after initiating an NSAID suggests the BP should be 
regularly monitored, particularly during the initiation or intensification of NSAID 
therapy, as is advised in the current drug interaction management guidelines.4,5,20 
But because of the risk of overriding the many alerts concerning the combination 
of NSAIDs and antihypertensives 11 there is a need to identify risk factors associated 
with increased SBP. This seems especially warranted, because patients with a strong 
increase in BP may be at increased risk for stroke and ischaemic heart disease 
events.8,10,31 In this regard it should also be noted that antihypertensive treatment 
should be aimed not only at reducing the average BP value, but also at reducing 
short-term and longer-term variability in BP.32,33
Despite the relatively small number of patients in our study we found that two 
risk factors were significantly associated with an SBP increase: etoricoxib and high 
NSAID dose. The finding in the univariate model that male sex was a risk factor 
has been reported by other researchers, but remains to be investigated.2,20 More 
daily practice research, preferably with a control group (as pain itself may also 
influence the SBP), is needed to corroborate the risk factors found in our study and 
to define those patients who are at risk for a rise in SBP when using an NSAID and 
antihypertensive agent together. A recent observational study showed predictors 
for attaining BP control and predictors for failing to maintain BP goals, and found 
a higher number of NSAID prescriptions in patients who lost BP control compared 
with those who maintained BP control.34
The effect of etoricoxib on BP has been described earlier both in healthy elderly 
subjects 35 and in hypertensive patients.20 The European summary of product 
characteristics (SPC) of etoricoxib and a ‘Dear Doctor letter’ alert physicians not 
to prescribe etoricoxib to patients with uncontrolled hypertension. Hypertension 
should be monitored before treatment with etoricoxib, within two weeks after 
initiation of treatment and periodically thereafter.36,37 Nonetheless, three out of 
six patients who were prescribed etoricoxib already had an SBP above 140 mmHg 
at baseline (T0). Until the reasons for this finding have been investigated in more 
depth, one could best err on the safe side of caution by giving preference to another 
NSAID in hypertensive patients.
A significant association between the NSAID dose and the SBP has not been 
reported before,18,20,38 but dose-related increases in cardiac events have been 
found.39 Whereas most studies calculated the assumed NSAID dose used, the 
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4
patients in our study reported the daily dose actually taken, which was lower than 
the prescribed daily dose in more than half of the patients. This makes it worthwhile 
to explore this dose-relationship in daily practice in future studies.
Of note, it is of concern that more than 40% of the patients with an SBP above 
140 mmHg at T0 were prescribed an NSAID while using an antihypertensive. In 
two cases, patients with a DDI alert had to be excluded from our study because 
of an initial SBP above 180 mmHg at T0. For both patients we could not find risk 
factors explaining the high SBP.
Limitat ions
There are several limitations to our study. First, it was an observational study 
without a control group. The indication for the NSAID may have increased stress 
and may therefore have been partly responsible for changes in SBP. This could have 
overestimated the effects found in this study. Secondly, the monitoring of BP in 
the pharmacy may have had the unintended effect of increased compliance with 
antihypertensives and restrained use of NSAIDs, especially in patients with high 
baseline SBP. This might have caused an underestimation of the number of patients 
with an SBP increase of ≥ 10 mmHg to an SBP ≥ 140 mmHg. Thus, without 
appropriate monitoring the risk for increased levels of SBP might be higher in daily 
practice.
Thirdly, the relatively small sample size limits the power to prove possible 
differences between the different NSAIDs and different antihypertensives used and 
the risk factors associated with an increased SBP. The large number of diclofenac 
users, which resembles real practice, complicates the finding of associations with 
the other NSAIDs. However, the SBP differences were large enough to have an 
adequate power for detection of a significant association for etoricoxib and NSAID 
dose > 1 DDD.
Fourthly, changes in SBP were measured within 2-3 weeks after initiation of an 
NSAID. It is uncertain whether the SBP had reached steady state in all patients by 
then. More patients with an SBP increase of ≥ 10 mmHg to an SBP ≥ 140 mmHg 
could have been found when measuring for a longer period. Nonetheless, only in 
three patients the PLoC was exceeded at both T1 and T2, partly caused by the fact 
that patients with an exceeded PLoC at T1 stopped using the NSAID between T1 
and T2.
Lastly, although the resistance to measure BP in the participating community 
pharmacies was low among patients, students and technicians encountered 
difficulties with identifying patients. Some patients were missed because of the 
high workload in the pharmacy resulting in the unnoticed overriding of the DDI 
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alert. More importantly, many patients had (intermittently) used NSAIDs in the 
preceding week, often without prescription and not documented in the pharmacy 
information system. This emphasizes the need to know which patients are at risk 
for a rise in SBP in order to provide patients with appropriate monitoring and 
treatment. Finally some patients could not be monitored as NSAIDs were not 
supplied in the pharmacy, but delivered to the patients’ homes.
CONCLUSION
Concomitant use of a newly initiated NSAID plus a RAS inhibitor, beta-blocker or 
diuretic had a small effect on the mean changes in SBP (measured at one and two 
weeks after initiation of the NSAID). Patients using etoricoxib and high NSAID 
doses (> 1 DDD) were at risk for an SPB increase within two weeks of use. As long 
as risk factors for a SBP rise by NSAID-antihypertensive interactions are not fully 
explored, NSAIDs should be used with caution in patients with antihypertensives, 
in the lowest dose possible, and with appropriate monitoring before treatment and 
during the initiation or intensification of NSAID therapy. Although the prescribing 
physician should be the first to monitor the BP, the pharmacist should accept his 
responsibility when a DDI alert for a newly initiated NSAID and antihypertensive 
occurs.
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INTRODUCTION
We started this thesis with the principal precept of medical ethics that healthcare 
providers are taught: ‘First, do no harm’.1 How realistic is this oath, as the only way 
to guarantee that no patient is harmed by a drug is to never use a drug. The reality 
is that all drugs bring a certain level of risk for drug-induced harm.2 Marketing 
authorisation holders (MAHs), regulators, healthcare professionals, and patients 
continuously have to weigh the expected benefits and risks of drugs. Drug approval 
processes and clinical practice guidelines are meant to assist healthcare providers 
in this decision-making process.3 Guidelines inevitably deal with populations of 
patients, but they should assist healthcare providers how to establish the potential 
risks of drug treatment for their individual patients and how to realise adequate 
management of these risks (e.g. by adequate communication with their patients).4 
Each individual patient should receive the right medicine, in an adequate dose for 
an adequate duration, with appropriate information and planning of treatment 
follow up.5 Drug treatment, however, is a complex process and failures can occur 
at every step of the drug therapy process, including regulation plus registration, 
prescription, dispensing, use and monitoring of the drug.6 A failure in the (drug) 
treatment process, that (potentially) leads to harm to the patient is called a 
medication error.7,8 Such errors need to be identified, whether their actual outcome 
is clinically important or not, because the occurrence of any error indicates a 
weakness in the system, which might on a future occasion lead to a clinically 
relevant error.9 Different actors such as MAHs, regulatory authorities (i.e. medical 
licensing authorities and healthcare inspectorates), professional associations and 
their working groups, software vendors, healthcare professionals, and patients 
are responsible for different steps in the drug therapy process. Therefore all actors 
should be involved in the evaluation and redesign of systems and processes that 
lead to errors, and implement effective strategies to reduce the risk of future errors. 
The systematic approach to clinical risk management (CRM) is one of the core 
tasks of the practising pharmacist. Pharmacists have always applied risk reduction 
strategies to quality control within the manufacturing of medicines, either small 
scale protocolled compounding in the pharmacy or using Good Manufacturing 
Practice standards in the large scale drug production of medicines within the 
pharmaceutical industry. Nowadays, practicing pharmacists dedicate their time 
to optimize the benefit-risk balance of drug treatment in individual patients. This 
shift in the pharmacy profession occurred gradually and was accompanied with 
emerging descriptions of the tasks of pharmacists in which communication with 
the patient, increased cooperation between physicians and pharmacists and the 
introduction of pharmacy information systems were important for the envisioned 
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transition.10,11 For over four decades pharmacists have used their information 
systems to safeguard drug therapy for dosing problems, drug-drug interactions 
(DDIs), drug-disease interactions, drug intolerability interactions and duplicate 
medications.12-15 Professional evidence-based guidelines and protocols were 
developed to provide pharmacists with risk reduction strategies, such as drug-
drug interaction management guidelines and condition-specific guidelines (e.g. 
diabetes mellitus).12,14 The systematic evaluation of these guidelines on the safety 
and effectiveness of drug treatment receives growing attention.11 Several pharmacy 
practice research studies, that described or evaluated risk reduction strategies 
suggest opportunities to improve the professional contribution of pharmacists to 
CRM.16-23
This thesis comprises a variety of studies that further elaborate on the professional 
contribution to risk management in several kinds of drug interactions (DDIs, drug-
disease interactions, drug-intolerability interactions). The prevention, detection 
and resolution of these drug interactions have high priority in safeguarding drug 
therapy in individual patients. In these studies we also focused on the support 
of pharmacists by professional associations, who are responsible to improve 
professional guidelines, and by their software vendors, who need to integrate the 
content of the guidelines in computerised information systems.
In this general discussion we will connect the evidence of the separate studies 
with the previous literature and present opportunities to improve CRM of drug 
interactions. In addition, we will identify and discuss the gaps in CRM that still 
exist. Finally, the most important implications for society and science are described.
EVIDENCE EMERGING FROM OUR STUDIES
Good quality electronic patient records (EPRs) are a prerequisite for computerised 
systems to efficiently generate drug therapy alerts. Therefore, we assessed the 
quality of EPRs in community pharmacies in two separate studies (Chapter 2.1 and 
2.2). Both studies showed that relevant patient information (e.g. (non)prescription 
drugs, diseases) was frequently missing in the EPRs. In the second study we 
additionally showed that missing information actually leads to missed alerts. 
For DDI management guidelines to achieve their full potential as risk reduction 
strategy they should meet criteria for good quality guidelines.3,24 The core criteria 
are the rigour of development, the clarity and presentation, and the applicability 
of the guidelines.24 We therefore defined the relevant items of a checklist for DDI 
management guidelines (Chapter 3.1). We added an exemplary DDI monograph 
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and extensive guidance on how to interpret and apply the checklist (Chapter 3.2 
and 3.3). In a separate study we assessed the clarity and applicability of the current 
guidelines for the management of potentially harmful DDIs (Chapter 4.1). We 
ascertained possibilities to improve current guidelines: additional materials, such 
as patient leaflets, computer support and summary documents should be reported 
in the guidelines; guidelines should discuss the potential financial impact of the 
recommendations (e.g. monitoring or adding a specific drug to the therapy); 
and finally the key review criteria to measure the adherence to a guideline 
should be presented. Next, we evaluated the risk reduction strategies of a specific 
management guideline, i.e. the DDI between non-steroidal anti-inflammatory 
drugs (NSAIDs) and antihypertensives (Chapter 4.2). We found that current risk 
reduction strategies that recommend blood pressure monitoring after two weeks 
were insufficient for patients using etoricoxib and patients with high NSAID doses 
(> 1 defined daily dose), because they were at risk for an increase in systolic blood 
pressure (SBP) within two weeks of use. The latter study also illustrated that CRM 
of drug interactions needs to be integrated into each step of the drug therapy 
process. We emphasized this systematic approach in our review (Chapter 3.4) in 
which we explored key areas in CRM of interactions between natural products and 
conventional drugs.
KEY AREAS IN THE CLINICAL RISK MANAGEMENT OF DRUG 
INTER ACTIONS
We would like to illustrate the key areas in the CRM of drug interactions by using 
the example of etoricoxib, described in Chapter 4.2 (see Figure 1). We found that 
etoricoxib was prescribed and dispensed to patients with an SBP above 140 mmHg 
despite the use of one or more antihypertensive drugs, whereas the summary 
of product characteristics (SmPC)25 and the direct healthcare professional 
communication (DHPC)26 advice not to prescribe etoricoxib to patients with 
hypertension whose blood pressure is elevated above 140/90 mmHg.25,26 (key 
area: professional resource) How could this drug interaction still reach the patient? 
A root cause analysis is required to uncover the different failures that led to 
this drug interaction.27-29 Several patients concomitantly used etoricoxib and 
antihypertensives for at least two weeks whereas their baseline SBP was already 
above 140 mmHg at initiation of etoricoxib. Did these patients read and understand 
the information leaflet that specifically mentions the cardiovascular risk of 
etoricoxib and did this affect their behaviour? (key area: patient performance) The 
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pharmacist dispensed etoricoxib to the patient. Was the pharmacist informed about 
the elevated SBP? Was the pharmacist aware of the contraindication of etoricoxib in 
patients with elevated SBP? Did the pharmacist know that the pharmacy information 
system would only provide a general drug therapy alert for the interaction between 
NSAIDs and antihypertensives but no specific advice for management of the DDI 
with etoricoxib? Did the pharmacist contact the physician to discuss the drug 
interaction or did the pharmacist refer the patient to the prescriber to discuss 
the use of etoricoxib with elevated SBP? (key area: professional performance) The 
physician prescribed etoricoxib for the patient despite the presence of elevated 
SBP. Did the physician measure the patient’s SBP before prescribing etoricoxib? 
Did the physician schedule a follow-up SBP measurement within two weeks? Was 
the physician aware of the specific precautions that apply to etoricoxib? Was the 
physician aware that his information system would not provide him with an alert 
Figure 1 Key elements and key areas in the clinical risk management of drug 
interactions
1A. Risk identification
Spontaneous reporting
Clinical studies
Pharmacoepidemiology studies
1B. Risk assessment
Seriousness and incidence of the harms
Patient susceptibility factors
Pharmacological plausibility of the
interaction
Quality of the body of evidence for harm
3. Evaluation of risk reduction strategies
Product information
Professional resources
Professional performance
Patient performance
2A. Development of  risk reduction 
strategies
Product information
Professional resources
Computerised screening systems
Legal status for supply of medicines
2B. Execution of risk reduction strategies
Professional contribution
Patient-centred communication
190
5
to check the SBP before initiating etoricoxib? (key area: professional performance) 
Why did both the pharmacy and physician information system not give the 
alert to monitor the SBP before and two weeks after initiating etoricoxib? (key 
area: computerised screening systems) Why was this warning not included in the 
drug interaction management guideline? (key element: risk assessment; key area: 
professional resources) Why did neither the regulatory authorities nor the MAH 
monitor whether their warnings ensured compliant prescribing and dispensing of 
etoricoxib?30 (key area: product information)
Although we did not perform an in depth root cause analysis, the ‘root cause’ seems 
to be that specific precautions concerning etoricoxib were not included in the drug 
interaction management guidelines. This example demonstrates that one error by 
one of the actors may directly lead to potential harm to a patient. It makes obvious 
that risk can only be managed effectively when all actors systematically apply the 
principles of CRM in the key area(s) they are involved in and above all do not 
overlook to evaluate the effectiveness of their risk reduction strategies.
RISK IDENTIFICATION
The first step in the clinical risk management of drug interactions requires both 
identification of risks relating to medicinal products and stratification of these risks 
in terms of evidence, probability, clinical significance, and risk factors. Adverse 
drug reactions (ADRs) from drug interactions may be identified from spontaneous 
reports and by analysis of experimental or observational studies (Chapter 3.4).31-33 
Regulatory authorities oblige MAHs to proactively monitor the safety of medicines. 
The risk management plans of MAHs should describe the strategies applied to 
identify ADRs from drug interactions.
Spontaneous repor ting
Healthcare professionals and patients ‘spontaneously’ report suspected adverse 
reactions to either the medicines regulatory authorities or the MAH. In the 
European Union these spontaneous reports are transmitted to EudraVigilance, 
the medicines safety database (http://eudravigilance.ema.europa.eu/human/index.
asp), and are available in the European database of suspected ADR reports (http://
www.adrreports.eu).34 Though both websites undoubtedly support sharing of 
information, the responsibility for reporting and the quality of the reported data 
still lies with the individual healthcare professional and patient.
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A systematic review revealed that underreporting of ADRs is strongly associated 
with the knowledge and attitudes of healthcare professionals.35 For example, in 
some countries pharmacists regarded the reporting a task of the physician rather 
than their responsibility. Lack of confidence about diagnosing ADRs might 
attribute to this attitude. On the other hand, there is ample evidence that shows that 
pharmacists are both willing and capable to adequately report ADRs.36 Educational 
interventions that increase knowledge about ADRs and focus on underreporting 
related attitudes might serve to increase reporting.
A review on patient reporting of ADRs in 11 countries proposed that the volume 
of spontaneous reports might be further enhanced by educating patients about 
their medications and increasing their awareness that they can report suspected 
ADRs.37 Media attention can play a major role in increasing awareness as was 
shown by the increased reporting by patients about the safety of statins.38,39 This 
increased reporting is called ‘notoriety-bias’.40 Although, it seems difficult to obtain 
a complete picture from these kinds of reports and although recall-bias cannot be 
excluded, patient reports are a useful source of information in addition to healthcare 
professionals’ reports.39 Moreover, patient reports may be beneficial as known 
and unknown ADRs may be detected earlier by patients compared to healthcare 
professionals.41 Recently, the black triangle T was introduced in the patient 
information leaflet (PIL) of medicines, which are subject to additional monitoring. 
The black triangle is supposed to encourage patients and healthcare professionals to 
spontaneously report suspected ADRs of the particular product.42,43
Spontaneous reporting system databases are increasingly used to analyse 
spontaneous reports and detect potential ADRs.44-46 Researchers found, for 
example, that pravastatin and paroxetine, when administered together, increased 
blood glucose levels.47 A systematic screening of the World Health Organization 
(WHO) ADR database, VigiBase, uncovered known, clinical relevant DDIs and 
suggested an unknown drug interaction between statins and azithromycin with 
rhabdomyolysis.48,49 Such results should, however, always be evaluated in the 
context of other relevant data and cannot replace careful medical and scientific 
evaluation of identified ADRs.50
In addition to spontaneous reports, some countries apply additional methods to 
identify potential ADRs such as (modified) prescription event monitoring (PEM) 
or intensive monitoring (IM). Generally PEM and IM ask prescribers, pharmacists 
or patients to report any possible ADR or change in their health occurring during 
the use of a drug.51-54
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Clinica l  studies
Human studies are still needed to identify and assess drug interactions. We have 
described the limitations of different types of human studies in Chapter 3.3 and 
3.4. It is important to realise that controlled drug interaction studies are mostly 
performed in small homogeneous populations of healthy volunteers or relatively 
healthy patients. As a result, potentially relevant risk modifiers (e.g. infrequent 
genotypes, frailty, co-morbidities, additional drugs) may be insufficiently 
represented.55 The MAH is formally responsible for performing and reporting 
interaction studies as needed during the life-cycle of the medicinal product. It 
might be difficult to point out a single accountable MAH because drug-drug 
interactions always involve two suspected drugs and often concern a class effect of 
drugs. Regulatory authorities are responsible to safeguard whether all MAHs take 
their responsibility.31,33
Pharmacoepidemiologica l  studies
Pharmacoepidemiological studies help to overcome the limitations of spontaneous 
case reports and controlled clinical trials (Chapter 3.4).33 A good example is a study 
by Juurlink et al who observed an increase in hyperkalemia-associated morbidity 
and mortality in older patients using angiotensin-converting–enzyme (ACE) 
inhibitors in combination with spironolactone after the Randomized Aldactone 
Evaluation Study (RALES) had demonstrated that addition of spironolactone 
to ACE-inhibitors significantly improved outcomes in patients with severe heart 
failure. Apparently the rate of serious ADRs from combining ACE-inhibitors 
with spironolactone in daily clinical practice was much higher than in the 
relatively healthy study population of RALES. A combination of poor monitoring 
of potassium levels, symptoms and conditions during therapy, neglecting of risk 
modifiers, increased dietary potassium intake, and inappropriate prescribing may 
have accounted for this increase in hyperkalemia.56
In order to be able to conduct retrospective cohort and case–control studies reliable 
and routinely collected data need to be available (e.g. administrative claims and 
electronic health records and linkage between databases).51,57-59
RISK ASSESSMENT
Risk assessment of drug interactions aims to determine which harm can result from 
the identified drug interaction and why this risk should be managed. Developers of 
drug interaction management guidelines should apply a systematic and transparent 
193
General  d iscuss ion |  Chapter  5
methodology to retrieve and select potential drug interactions that require active 
risk assessment in order to be able to timely and consistently update their drug 
interaction management guidelines. Software vendors should implement new 
information on drug interactions appropriately in their computerised screening 
systems.
In Chapter 3.2 we assessed the risk of the DDI between thiazides/related diuretics 
and selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine 
reuptake inhibitors (SNRIs). The first step in the assessment is a systematic 
collection of data as to the nature, incidence and consequences of the drug 
interaction. The second step is to consider the following elements in its assessment 
(Chapter 3.1–3.4):
 - The seriousness and incidence of the harm(s)
The clinical impact of an interaction at the population level depends both on the 
seriousness of the harm caused by the adverse drug interaction and on the chance 
that harm will actually occur (incidence). The seriousness should be based on the 
most critical potential adverse outcome. In Chapter 3.1 and 3.3 we concluded 
that the preferred scale to judge the seriousness of the adverse outcomes of a DDI 
is the scale by van Roon et al.60 which was adapted from the common toxicity 
criteria of the US National Cancer Institute.61
 - The patient susceptibility factors
The various factors that can modify the susceptibility of an individual patient to 
an adverse drug interaction should be assessed. In Chapter 3.3 we described the 
factors that should be considered in the assessment. Information on susceptibility 
factors seems not yet sufficiently assessed systematically, which is confirmed in 
the exemplary DDI monograph (Chapter 3.2).
 - The pharmacological plausibility and scope of the drug interaction
We presented a grading for the pharmacological plausibility of a DDI in Chapter 
3.3. The risk of an adverse drug interaction may extend beyond the interaction for 
which there is actual clinical evidence. Therefore, DDIs which can be predicted 
from well-known pharmacokinetic properties, or by analogy with other drugs 
with similar pharmacodynamic effects in the same drug class, need to be assessed.
 - The quality of the body of evidence for harm caused by a drug interaction
There is not yet consensus about how evidence related to harm caused by DDIs 
should be graded. One of the reasons might be that current grading systems are 
considered either less appropriate or unnecessarily complex. We concluded in 
Chapter 3.1 and 3.3 that a new grading system for the quality of evidence for 
harm by DDIs has to be developed. Until then, guideline developers may apply 
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the grading system of their preference, so long as they specify which system they 
have used (see Chapter 3.2).
MAHs, regulatory authorities and guideline developers should assure a consistent 
retrieval and high-quality assessment of the retrieved potential drug interactions 
without unnecessary delay. In the process of interpreting the evidence of a drug 
interaction there is a risk that different assessors need different amounts of 
confirmatory evidence.62 One should find a balance between waiting too long for 
more evidence and accepting data too quickly, because both extremes might cause 
harm to patients. The first by missing important drug interaction alerts, the latter 
by furthering alert fatigue.
DEVELOPMENT OF RISK REDUCTION STR ATEGIES
This element of CRM aims to develop the most appropriate management strategies 
to avoid or reduce health risk from drug interactions. The feasibility of potential 
strategies needs to be assessed taking into account the intended and unintended 
effects of the strategy, the beliefs and perspectives of the actors involved, and the 
necessary resources. The actors involved are the MAHs, regulatory authorities, 
professional associations and their working groups or committees, software 
vendors, individual healthcare providers and patients.
The most appropriate risk reduction strategy or combination of strategies should 
be selected. This strategy should include an evaluation of its effectiveness to reduce 
risk from drug interactions. To ensure that all actors are aware of their individual 
responsibilities and accountabilities within the risk reduction strategy, the 
developer of the strategy should append a communication plan.63 Key areas in the 
development of risk reduction strategies are described below.
Product  information
MAHs and regulatory authorities inform healthcare professionals and patients 
about the safety and safe use of medicines through several routes including the 
summary of product characteristics (SmPC), patient information leaflet (PIL), 
package labelling and in certain cases through direct healthcare professional 
communication (DHPC). The EU guideline on summary of product characteristics 
regulates the content of the SmPC.64 Unlike for the PIL, there is no requirement 
to test the SmPC among potential users (e.g. prescribers and pharmacists). The 
importance of the SmPC to communicate risk to healthcare providers stresses the 
need for such a requirement.
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The PIL must be included in each package of a medicinal product. This PIL 
is primarily intended for patients and must be scientifically correct as well as 
comprehensible and relevant for the patient. The PILs of drugs under additional 
monitoring have to contain an inverted black triangle.42,43 The pharmaceutical 
packaging also plays an important role in communicating risk. For certain 
medicines (e.g. over-the-counter drugs) regulatory authorities impose specific 
warning statements for the outer packaging.65,66 PILs and packaging are drafted by 
the MAH and need to be approved by the regulatory authorities.
The DHPC is the last risk communication tool, that MAHs use to inform healthcare 
professionals on urgent drug safety issues. The regulatory authority has to agree 
with the MAH on the contents, intended recipients and time schedule of the 
DHPC before distribution.67,68 The EU guideline on pharmacovigilance of 2008 
requires that after dissemination of a DHPC the MAH should monitor the uptake 
of recommendations and key messages and should evaluate the effectiveness of 
the DHPC. MAHs and regulatory authorities also need to inform each other of 
difficulties they have identified in this follow-up phase and when needed should 
take action to prevent harm to patients.69 The etoricoxib example (see above, 
Chapter 4.2) suggests that MAHs and regulatory authorities may need to improve 
their performance in this follow-up phase.
Professional  resources
In daily clinical practice consultation of SmPCs or PILs to assess drug interaction 
risks is impractical. Therefore, several organisations, such as professional 
organisations, have developed drug interaction guidelines. Such drug interaction 
guideline developers are responsible for providing healthcare professionals with 
good quality drug interaction management guidelines. They should apply a 
systematic and transparent methodology to identify and select potential drug 
interactions, to assess the quality of evidence for harm by a drug interaction, 
to prioritize the drug interaction on clinical relevancy and to formulate 
recommendations for managing the drug interaction. We defined a checklist for 
DDI management guidelines with an extensive guidance and an exemplary DDI 
monograph to help developers produce high-quality guidelines (Chapters 3.1, 
3.2 and 3.3). The quality of these guidelines can especially be improved by paying 
attention to the strength of recommendations of the management strategies, the 
presentation of risk modifiers, details of the monitoring of biomarkers, and the 
cost-effectiveness of recommendations. We believe our checklist will contribute to a 
systematic, transparent and comprehensive approach to assess and report both the 
potential clinical impact of a DDI and the recommendations to manage the DDI.
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Such an approach will also support the integration of these guidelines in 
computerised screening systems and clinical decisions support systems.70 Further 
research is needed to investigate if the checklist can also be used by developers 
of other drug-related guidelines, such as drug-disease, drug-herb, and drug-food 
interaction guidelines.
C omputerised screening systems
Computerised screening systems have the potential to detect potentially hazardous 
situations due to drug interactions.71-74 These systems offer screening tools for the 
detection of drug-related problems (DRPs) such as over- and undertreatment, 
incorrect dosing, drug-drug interactions, drug-disease interactions, drug allergies, 
intolerance, and duplicate medications (see Chapter 2.1). Drug interaction 
management guidelines should be translated into a knowledge database that can 
be used to produce concise and practicable alert messages. Therefore, software 
vendors should integrate drug interaction management guidelines meticulously in 
their systems, guided by the realization that different implementations may produce 
evidently different results.72,75 To be useful, a computerised screening system must 
be both sensitive (to alert the user to potential clinically significant interactions) 
and specific (to avoid inundation with irrelevant alerts). Knowledge bases tend 
to be overly inclusive and will therefore generate many alerts with low clinical 
relevance.72 This leads to ‘alert fatigue’ and the overriding of alerts by physicians 
and pharmacists. Unfortunately, the selection of which alerts can be safely turned 
off is very difficult.76 On the other hand, systems may sometimes neglect relevant 
drug interactions and/or do not sufficiently adjust for identifiable patient-related 
risk factors (Chapter 4.1). In Chapter 3.4 we provided potential strategies to obtain 
a better balance of alerting to adequate detection of drug interactions.
It is important that physicians and pharmacists are aware of the possibilities and 
limitations of their systems, including the quality and sources of the underlying 
evidence. They have to realise that the system generates drug therapy alerts at the 
population level and that their professional assessment may thus be essential to 
assess the importance of an alert for the individual patient.
The software vendors should inform their customers on how their systems 
perform in theory. For example, to which degree the system allows end users to 
adjust default settings and to customise it to local requirements, and how regularly 
the software is updated. And what happens to local settings if there is a general 
update. Ideally, physicians and pharmacists should know which kind of drug 
therapy alerts the system may generate and which kind of alerts might not occur. 
As we have shown in Chapter 2.2, the appearance of drug therapy alerts largely 
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depends on the completeness and quality of individual patient’s data. We found 
that missing medical and/or pharmaceutical information may lead to missed 
drug therapy alerts and potentially hazardous situations in more than one-third of 
patients. To overcome some of the above presented limitations of the conventional 
computerised screening systems, nowadays systems are developed that apply 
so-called ‘clinical rules’. Clinical rules use algorithms that combine all available 
medical (e.g. diagnosis and laboratory test results) and pharmaceutical information 
(e.g. drugs, dose and duration of use). Clinical rules may even draw attention to the 
absence of relevant data. Although the advantages of these clinical rules systems in 
daily clinical practice require further evaluation, preliminary data suggest that they 
generate more specific drug therapy alerts.77,78
L egal  status  for  supply  of  medicines
Regulatory authorities may switch the legal status of a medicinal product from 
general sales to pharmacy-only if new risks, e.g. the occurrence of a drug 
interaction, are identified which alter the benefit-risk ratio (Chapter 3.4).18,79 
The pharmacy-only status obliges the pharmacist to counsel the patient on the 
correct choice and safe use of the medicine. In order to check effectively for drug 
interactions pharmacists should ensure complete and up to date EPRs. If applicable, 
pharmacists should counsel the patient on preventing the drug interaction or on the 
recognition of potential ADRs that might result from these interaction. Our finding 
that a relatively high number of NSAID- interaction alerts was missed because 
over-the-counter (OTC) NSAID was not documented in the EPR (Chapter 2.2), 
and a recent study by Olesen et al.80 confirms the importance of documenting OTC 
medicinal products in the EPR and screening for OTC interactions. The pharmacy-
only status will be more effective, if concurrently the free availability of the same 
OTC product (i.e. low dose NSAIDs in reduced package size) is revoked. This is 
also the case for St John’s wort, for which both unlicensed products are marketed 
as food supplement and licensed products are authorised as medicinal product or 
traditional herbal medicinal product. St John’s wort as food supplement is freely 
available and drug interactions can thus escape monitoring.81
EXECU TION OF RISK REDUCTION STR ATEGIES
This element of CRM aims at the execution of the risk reduction strategies. The 
responsibility for the execution of the developed strategy should lie with the 
competent actor.
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Professional  contributions
Physicians and pharmacists should systematically document medical and 
pharmaceutical information of their patients (Chapter 2.1 and 2.2). They should 
inquire whether their patients use OTC medicinal products and complementary 
drugs, because these are frequently missing in the EPRs. All relevant information 
should be recorded in the EPR in such a way that it enables drug therapy alerts to 
appear through computerised screening. For the safety of their patients, healthcare 
professionals should strive to link their computerised information system to enable 
data exchange.
Healthcare professionals should educate patients and customers about the 
benefits and risks of their medications and increase their awareness that they can 
spontaneously report suspected ADRs.
Patient-centred communication
Providing good quality PILs and packaging labels cannot replace communication 
between patients and healthcare professionals.82 The traditional paternalistic model 
of decision-making, in which physicians or pharmacists make decisions on behalf 
of their patients is being replaced by a model in which patients are engaged in 
shared decision making.83,84 In order to make informed decisions, patients need 
to understand the nature and preventability of harm caused by drug interactions. 
Physicians and pharmacists also need to inform them on the advantages and 
disadvantages of the available management options to prevent a drug interaction. 
They should pay attention to values and preferences that can be important from 
the patients’ perspective in terms of expected benefits, harms, and (in)conveniences 
for each of the available drug interaction management options (Chapter 3.3). They 
should be aware of the cultural backgrounds of their patients and should adjust 
their communication also in case of low health literacy levels (Chapter 3.4).
EVALUATION OF RISK REDUCTION STR ATEGIES
The effectiveness and efficiency of any risk reduction strategies should be evaluated. 
This evaluation is a subdomain of pharmacy practice research that has to be further 
developed.
Product  information
Since legislation requires active monitoring of risk minimisation strategies 85 
risk communication tools, such as SmPC, PIL and DHPC, should be assessed on 
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usefulness for healthcare professionals and patients. So far, studies have revealed 
that SmPCs provide less comprehensive management recommendations on drug 
interactions than other information sources.86,87 These findings stress the need for 
a carefully structured SmPC with sufficient emphasis on selected key messages (e.g. 
by presenting them in a boxed text, see Chapter 4.1). SmPCs should preferably be 
available in an electronic format (e-SPC) that can be integrated in clinical decision 
support systems (CDSS).88,89
Information in the PIL concerning DDIs and drug-disease interactions is often 
difficult for patients to comprehend, in contrast with other information in the 
PIL.90,91 Perhaps, the etoricoxib users in our study did not understand this part of 
the PIL (see our example above, Chapter 4.2). As a result of the shortcomings in 
the PILs, the European regulatory authorities have recently revised their general 
template and guidelines.43
A systematic review of the effects of safety warnings (i.e. DHPC) on clinical 
practice showed that safety-related regulatory action has some impact on clinical 
practice.92 The majority of healthcare professionals appreciated risk communication 
and almost one-third reported taking action following a DHPC.93 The DHPC 
template 68 does improve the uptake of DHPC recommendations.94 The case of 
etoricoxib, however, illustrates that the regulatory authorities and MAHs do not 
always monitor the effectiveness of their safety warning (Chapter 4.2).
In addition to the lack of an intended effect, safety warnings can sometimes have 
unintended effects. This is, for example, indicated by the unintended increase in 
suicides after the issuance of warnings restricting the use of selective serotonin 
reuptake inhibitors in children and adolescents, and the unintended increases in 
conceptions and abortion rates after the safety warning for third-generation oral 
contraceptives.92
Professional  resources
Professional resources on drug interactions (i.e. management guidelines, and 
computerised screening systems) should be evaluated with respect to their quality, 
consistency and usefulness, and preferably also with respect to their effectiveness 
to reduce risk from drug interactions (Chapter 3.4). The responsibility for the 
evaluation lies with the developer of the risk reduction strategy. In practice, scientific 
researchers are often involved in the evaluation of risk reduction strategies. Much 
research on the assessment of professional drug interaction sources has already been 
published (see Chapter 4.1). We assessed the clarity and presentation of guidelines 
for the management of DDIs (Chapter 4.1). In general we suggest that guidelines 
could be improved by systematically referring to the available tools for application, 
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the explanation of the terminology used, the presentation of recommendations as 
boxed text, and clear presentation of risk factors and patient susceptibility factors. 
To enhance the applicability of DDI guidelines they should address how to monitor 
the necessary biomarkers, the organizational barriers and cost-effectiveness of the 
recommendations, and review key criteria to measure adherence to the guidelines. 
We also evaluated the management guideline for a specific DDI between non-
steroidal anti-inflammatory drugs (NSAIDs) and antihypertensives (Chapter 4.2). 
We suggested that the management guideline should recommend systolic blood 
pressure (SBP) monitoring before and after initiation of an NSAID or intensification 
of NSAID therapy, and that the guideline should clearly state that etoricoxib should 
not be used in patients with uncontrolled hypertension.
Software vendors and professionals should evaluate the performance of their 
computerised screening systems in daily practice. For example, to which degree 
can users adjust default settings, how correctly has the software been updated, and 
does the system provide all expected drug therapy alerts. To enable professionals 
to monitor the effectiveness of computerised screening systems, vendors should 
provide test materials and the system should have a functionality to report how 
often alerts are provided and how often the professionals are responding to the 
alerts.72
Professional  performance
In addition to the evaluation of guidelines and computerised screening systems, 
the performance of individual physicians and pharmacists should also be assessed. 
This may identify both 'competent' healtcare providers who perform well, and 
'incompetent' healthcare providers, as well as 'competent' healthcare providers who 
not perform well.95 Incompetency and/or poor performance may lead to harm in 
patients, because drug interactions are not (timely) detected and not appropriately 
managed. A competent healthcare provider combines knowledge, skills and attitude 
to optimally perform CRM. In the CanMEDS Framework the key competencies 
are described in seven roles: Medical/Pharmaceutical Expert, Communicator, 
Collaborator, Manager, Health Advocate, Scholar, and Professional. This framework 
has been adapted around the world in medicine profession and other professions, 
including pharmacy.96,97 Pharmacists and physicians should be competent in each of 
the seven roles to be able to fulfil their responsibilities in CRM of drug interactions 
(see Box 1 for further details about the competencies of the pharmacist).
Several methods for assessing competence and individual performance are 
available. For example, the mini-clinical evaluation exercise (mini-CEX), multi-
source feedback and the evidence-based portfolios.95,98 The feedback resulting from 
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the assessment is aimed to drive learning and professional development, and to 
enhance the performance and competency of the healthcare provider.98,99
One should realise that in several countries pharmacy technicians play a major role 
in dispensing. Even more than pharmacists, technicians will rely on computerised 
screening systems and the help of the pharmacist to identify and manage drug 
therapy alerts. Assessment of the individual performance of the pharmacist should 
therefore be accompanied with performance assessment of pharmacy staff. Among 
the methods to measure the professional performance in counselling the simulated 
patient method seems the most reliable research design.100 In the simulated patient 
method, a trained individual, also known as mystery shopper, visits the pharmacy. 
A review shows that pharmacists fulfil the minimum requirement in counselling 
by providing information on name of medicine, indications, dose, and directions 
for use, whereas the safety aspects, such as side effects, precautions, interactions, 
contraindications, and storage, were less likely to be given.100 Immediate 
Box 1 Examples of competencies in the seven roles of the pharmacy specialist 97
As pharmaceutical expert the pharmacist should systematically detect and manage drug therapy 
alerts.
In the role of communicator the pharmacist counsels patients on the appropriate use of drugs and 
on the recognition of potential ADRs. The pharmacist explains the consequences of drug therapy 
alerts in a clear and comprehensible manner to patients.
As collaborator the pharmacist discusses about alternative drug treatments with the prescriber in 
response to individual drug therapy alerts. Moreover the pharmacist collaborates with physicians 
and other healthcare professionals to accomplish exchange of (electronic) patient data. When 
unintended effects occur despite precautions, the pharmacist provides feedback to the regulatory 
authorities and national medication incident system by spontaneous reporting.
In the role of manager the pharmacist has to ensure that pharmacy staff detects and manages 
drug therapy alerts and adequately counsels patients. The pharmacist is responsible for the 
implementation of computerised screening systems.
In the role of health advocate the pharmacist informs individual patients and the general public on 
the potential harm caused by inappropriate use of drugs and of DDIs and drug-disease interactions 
specifically.
As a scholar the pharmacist is expected to be familiar with and to apply available scientific and 
professional resources, such as the drug interaction management guidelines. The pharmacist should 
continuously keep up with the professional literature and participate in postgraduate education. 
The pharmacist needs to know exactly how his computerised screening system performs and has 
adequate insight into the documentation of data in the EPR.
In the role of professional the pharmacist provides a high standard of patient care with integrity 
and in a sincere and engaged manner. The pharmacist knows the limitations in his or her own 
competencies and acts accordingly. The pharmacist practises pharmacy conform the ethical 
standards of the profession.
ADRs = advers drug reactions; DDIs = drug-drug interactions; EPR = electronic patient record
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performance feedback in the simulated patient methods is limited, while this might 
reinforce appropriate counselling.101
Quality indicators are increasingly used to measure professional performance. In 
the Netherlands the first set of quality indicators for community pharmacy care was 
developed in 2008. A substantial proportion of these indicators evaluate CRM in 
drug interactions.102 Individual pharmacists do receive a benchmark report. It is 
recommendable to evaluate the effect of this type of feedback on quality indicators 
in CRM.
Several studies have evaluated the adherence to professional guidelines.16,17,19,21,23 
We studied the documentation of relevant medical and pharmaceutical information 
in the EPR and found that pharmacists should have more complete and accurate 
medical and/or pharmaceutical information to ensure optimal monitoring of drug 
therapy and patient counselling (Chapter 2.1 and 2.2).
Patient  performance
Although the focus of this thesis is not on the patients' performance, patients 
undoubtedly are key actors in the drug therapy process and have certain 
responsibilities in preventing harm from drug interactions. First, patients are 
expected to help healthcare professionals to keep the EPR up-to-date (Chapter 
2.1 and 2.2). Second, patients are expected to be unrestrained in asking questions 
about their conditions and medications. Third, patients are expected to either 
adhere to their medication or inform healthcare professionals when they doubt the 
need for adherence. Finally, patients are expected to report suspected ADRs either 
directly to the regulatory authorities or to healthcare professionals. Several studies 
have shown that the performance of patients can be reinforced. Actually, reading 
and understanding the PIL and packaging labels still needs attention.82,90 Patients 
participation in shared decision making needs education of both the healthcare 
professionals and patients.83 Furthermore, patients’ understanding of the risk for 
harm by drug interactions and its’ affect on their actual behaviour (i.e. medication 
adherence) need further research to develop interventions that will improve patient 
behaviour.103,104
As patients are not always in the position to take their own responsibility, 
healthcare professionals should consider the competencies of the individual 
patient when providing care. An assessment framework for patient competencies 
could assist healthcare professionals in patient-centred communication. Although 
the development of such a framework is beyond the scope of this thesis, it should 
minimally include competencies related to health literacy, self-efficacy, and 
behaviour.
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IMPLICATIONS FOR SO CIET Y
In this final chapter, we illustrated that CRM of drug interactions involves several 
key actors in different key areas. We showed there is ample opportunity to 
improve CRM of drug interactions. Pharmacists should strive for complete and 
relevant medical and pharmaceutical information in the EPR (Chapter 2.1 and 
2.2). The developers of DDI management guidelines should test the checklist for 
standardized reporting of these guidelines (Chapter 3.1 and 3.3) and should take 
the appropriate domains of the AGREE instrument (incl. cost-effectiveness) into 
consideration in their development processes (Chapter 4.1). Guideline developers 
should systematically collect and analyse evidence of potentially preventable 
unsafe practices and include the resulting safety warnings into their management 
guidelines, while software vendors should integrate the revised DDI management 
guidelines in their systems (Chapter 4.2).
Integral CRM of drug interactions in the drug therapy process requires a 
coordinating 'Kapellmeister' both at the national level of the population and at the 
local level of the individual patient. At the local level when a patient uses different 
chronic medications prescribed by different physicians, these prescribers should 
reach agreement on which physician is the overall director of drug therapy or 
should delegate this to the pharmacist of the patient (which is not necessarily the 
same as assuming all responsibility in the legal sense).18
At the national level this could either be the licensing authorities or the healthcare 
inspectorates depending on their specific tasks at the national level. The coordinator 
should assure all actors, and especially the healthcare providers and patients, are 
involved in the development, execution and evaluation of risk reduction strategies. 
Thus overregulation and superfluous duplication can be avoided which could, for 
example, lead to alert fatigue, but remaining unacceptable gaps should also be 
identified.
Despite the societal obligation of healthcare professionals to avoid preventable harm 
to patients as much as possible, additional resources for the further development, 
execution and evaluation of CRM of drug interactions are necessary. Remarkably, 
cost-effectiveness of risk reduction strategies is mostly not yet considered and the 
strengths and limitations of risk reducing strategies are often not made explicit.
Such an evaluation may show that some of the current risk reduction strategies are 
weak and might even have unintended effects. If necessary, regulatory authorities 
and professionals will have to act accordingly by adjusting current CRM regulations. 
For instance, the retrospective double check of a generated list of drug therapy 
alerts by Dutch community pharmacists, within 24 hours after the medication has 
been dispensed, might add relatively little to the real-time management of these 
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alerts when they appear.105 It might be more effective to devote the time spent on 
this double check on other risk reducing strategies.
CRM of drug interactions requires that all actors optimally execute the tasks within 
their competency. Educational interventions to improve professional performance 
and increase patient participation should be further developed and evaluated.
The seemingly insatiable demand for healthcare and shortage of healthcare 
workers emphasizes the need for delegation of tasks and more inter-professional 
collaboration to efficiently perform CRM of drug interactions. Pharmacists have the 
competencies to fulfil an important role in the CRM of drug interactions. In several 
countries they are increasingly becoming integrated into primary healthcare teams. 
The improvements in medication use and health outcomes and the reduction in 
health-service use and costs by such teams should urge individual professionals 
to quickly overcome the barriers, and regulators and professional associations to 
facilitate integration of healthcare professionals.106-111
IMPLICATIONS FOR SCIENCE
Future research elaborating on the studies in this thesis may focus on the effectiveness 
of the developed checklist for standardized reporting of DDI management 
guidelines and on the usefulness of such a checklist for the development of 
drug-disease, drug-herb, and drug-food interaction guidelines. It is necessary to 
investigate the effectiveness of advanced clinical rules in CDSS to generate specific 
drug therapy alerts as substitute for the conventional computerised screening 
systems. It would also be interesting to further monitor the use of etoricoxib in 
patients with an elevated SBP. Next to this example the risk reduction strategies of 
other drug interactions, especially the drug interactions for which safety warnings 
and advices in SmPCs and DHPCs are published, should be evaluated. In addition, 
an assessment whether the impact of safety warnings and advices in SmPCs and 
DHPCs on prescribing and dispensing depends on integration of the warning in 
management guidelines and computerised screening systems could be valuable for 
improving CRM.
From a broader perspective, more research into the evaluation of CRM of drug 
interactions is needed to explore which (combination of) risk reduction strategies 
ensure the largest reduction in risks for harm to patients in order to prioritise 
risk reducing strategies. For example, when is ‘laboratory monitoring’, ‘enhancing 
appropriate prescribing’ or ‘improving medication adherence’ the most appropriate 
strategy for a certain drug interaction?18 The strength of a risk reduction strategy can 
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be determined using four factors, which we can derive from the factors described 
in Chapter 3: ‘balance between intended and unintended effects of the strategy’; 
‘quality of the body of evidence for the strategy’; ‘patients’ values and preferences 
for a strategy’; and ‘the applicability and costs of a strategy’. New information 
can change (one of the) factors whereupon the strength of the strategy should be 
reassessed. An additional factor to consider is the ‘level of care of the strategy’ (i.e. 
primary, secondary, tertiary), because each care level may have a different weighing 
of the benefit-risk balance and thereof may need different risk reduction strategies.
A joint effort of all actors involved is needed to increase the body of evidence 
for risk reduction strategies. Practice research will help to achieve this. Despite 
the challenge of diminished research funding, and an increasingly competitive 
pharmacy market,112 several national professional associations (i.e. the Royal Dutch 
Association for the Advancement of Pharmacy [KNMP], Pharmacy Research UK, 
the Pharmaceutical Society of Western Australia [PSWA], and the Canadian Society 
of Hospital Pharmacists [SCHP]) have stimulated practice research by issuing a call 
for research proposals. The trend towards more inter-professional collaboration 
already leads to more multi-disciplinary research in, for example, medication 
reviews.108,110
To assess and adapt risk reduction strategies, to guide (inter-)professional 
development and to develop new educational programmes, data on professional 
performance should be routinely collected and analysed. A very promising 
development is the application of data mining and other quantitative research 
methods to comprehensive databases that either bring together patient data from a 
variety of sources into one comprehensive database or consist of a virtual collection 
that links different large database sources to each other. Examples of the latter are 
the linkage of the Clinical Research Datalink (CPRD) with the Hospital Episodes 
Statistics repository from the UK,113 and the PHARMO Record Linkage System 
in The Netherlands.114 Such databases offer countless new possibilities to identify 
risks and to increase the body of evidence for the prioritisation of risk reduction 
strategies. They can be analysed to detect known and unknown ADRs from drug 
interactions, to determine the impact and costs of ADRs, to find risk modifiers and 
to systematically and continuously analyse the effectiveness and cost-effectiveness 
of risk reduction strategies.57,113,114
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CONCLUSIONS
The research presented in this thesis demonstrates that CRM of drug interactions 
needs further improvement to fulfil the societal obligation of healthcare 
professionals to safeguard drug therapy in individual patients as much as possible. 
The responsibility for this improvement lies with the healthcare providers 
themselves, with the patients and with all other national actors (MAHs, regulatory 
authorities, professional associations) involved in the drug therapy process.
Cooperation, communication and integration between all actors need to be 
intensified and coordinated, and risk reduction strategies need to be prioritised to 
effectively detect and manage potential drug interactions in order to prevent harm 
to patients. The latter will be greatly facilitated by the further development and 
analysis of large databases and their conglomerates.
The key areas we identified in the CRM of drug interactions provide a useful 
structure to identify gaps in CRM and explore opportunities to strengthen the 
system and processes. There is a need for well-coordinated evaluation of both the 
effectiveness and the strength of a specific risk reduction strategy in daily practice. 
Regulatory authorities should oversee the accountability of each actor for the 
effectiveness of its risk reduction strategies and should identify poor performance 
and gaps in the CRM of drug interactions. Regulators and professional associations 
should support healthcare professionals to improve performance and to resolve 
the remaining gaps. Pharmacists should take their responsibility in the national 
CRM of drug interactions by participating in guideline development and pharmacy 
practice research. At the local level they should strengthen the collaboration with 
the patient and with other healthcare professionals towards primary healthcare 
teams to provide optimal individualized care.
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Drug therapy is a complex process in which failures can occur at every step: from 
the regulatory phase, through prescribing and dispensing to the use of drugs 
and monitoring of drug use. These failures in the process can give rise to adverse 
drug events (ADEs) which are important causes of morbidity and mortality. As 
a substantial part of these ADEs are caused by medication errors, and thus are 
potentially preventable, the different actors involved in the drug therapy process 
should apply a systematic approach to avoid patient harm. Such an approach, 
commonly called clinical risk management (CRM), consists of three key elements: 
(1) risk identification and assessment; (2) development and execution of risk 
reduction strategies; (3) evaluation of risk reduction strategies.
This thesis aims to illuminate the importance of a systematic approach towards the 
clinical risk management of drug interactions. It comprises a range of studies that 
elaborate on the professional contribution to clinical risk management in several 
types of drug interactions (drug-drug interactions, drug-disease interactions, drug-
intolerability interactions).
This thesis consists of three parts:
Chapter 2 describes the level of completeness of documentation in the electronic 
patient record (EPR) in community pharmacies.
Chapter 3 focuses on the development of drug-drug interaction (DDI) management 
guidelines and the key areas in the clinical risk management of drug interactions.
Chapter 4 addresses the evaluation of the clarity, applicability and effectiveness of 
current guidelines for the management of potentially harmful DDIs.
Complete and up-to-date medical and pharmaceutical information in the electronic 
patient record (EPR) is a prerequisite for comprehensive risk management in 
community pharmacy. In Chapter 2.1 we investigated the level of completeness 
of documentation in the EPR after a patient’s first visit to a Dutch community 
pharmacy. For each of the 154 included patients relevant patient data (i.e. personal 
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identifiers, current drugs used, diseases, intolerabilities, specific conditions, 
diagnostic and monitoring data, personal experiences and habits, and drug use 
problems) were gathered from both the patient’s EPR and through a structured 
telephone interview with the patient.
Data from both sources were compared. We found that the EPR after a patient’s first 
visit to the community pharmacy is often incomplete: only 68% of the prescription 
drugs, 20% of the diseases, 4% of the intolerabilities, and none of the over-the-
counter (OTC) drugs, specific conditions, personal experiences and habits, and 
drug use problems, that were reported by patients had been documented in the 
EPR. Furthermore, poor documentation of telephone numbers was a major reason 
for nonresponse. Chapter 2.2 shows that such a medical and pharmaceutical 
information gap partly persists for patients who have been enlisted for at least 
three months in a community pharmacy. Although 97% of the prescription drugs 
were recorded, only 6% of the OTC drugs, 25% of the diseases, and 33% of the 
intolerabilities were recorded. As a result of this missed information in the EPR, 
drug therapy alerts failed to appear in 38% of all 442 patients: drug-disease 
interactions in 34% of all 442 patients, duplicate medications in 4%, DDIs in 4%, 
and drug intolerabilities in 2%. Among the missing (non-)prescription drugs, 
NSAIDs were most frequently responsible for missed alerts. Diseases most 
frequently associated with missed alerts were gastroesophageal reflux disease, renal 
insufficiency, asthma/chronic obstructive pulmonary disease, and heart failure.
Both studies suggest that pharmacists should more proactively and systematically 
gather and document patient information to reduce the risk of patient harm.
Inconsistencies and lack of adequate information in DDI management guidelines 
may lead to harm and suboptimal therapy. Therefore, the systematic approach of 
clinical risk management should be applied to all phases of DDI management, 
including the development and presentation of DDI management guidelines. In 
Chapter 3.1 we carried out a two-round Delphi process with an international panel 
of healthcare providers, most of whom were pharmacists involved in providing 
DDI information, in order to select those items that should be addressed in DDI 
management guidelines (including grading systems that could be used). A total of 
19 items were consolidated in a checklist of 15 elements for standardized reporting 
of DDI management guidelines. This checklist can contribute to a transparent 
and comprehensive approach to assess the potential clinical impact of a DDI and 
to report the DDI management strategies (i.e. interventions by the physician or 
pharmacist to avoid or reduce harm by a DDI). We confirmed earlier studies which 
found that the clarity of guidelines for the management of potentially harmful 
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drug interactions can be further improved by a clear differentiation between the 
strength of recommendations of the management strategies and the presentation 
of risk factors and patient modifiers. We also suggested that the monitoring of 
biomarkers should be reported in more detail and that the cost-effectiveness of 
recommendations should preferably be addressed. In Chapter 3.2 we tested this 
checklist for feasibility by applying it to a concrete example: the DDI between 
thiazides (and related diuretics) and selective-serotonin reuptake inhibitors 
(SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). This exemplary 
guideline differs from various current guidelines for the management of this DDI 
by providing extensive information on, for example, patient susceptibility factors 
for hyponatraemia; the different management options including details about 
monitoring and patient consultation and instruction; and an algorithm of the 
different steps that can be taken when thiazides and SSRIs are combined for the 
first time. The exemplary guideline showed us that the checklist could be further 
improved. Chapter 3.3 presents the final checklist together with extensive guidance 
on how to interpret and apply the elements of the checklist when developing 
specific DDI management guidelines.
In Chapter 3.4 we discussed key areas in the CRM of interactions between natural 
products and conventional drugs (NPDIs) by exploring how their impact on 
public health can be minimized. We argued that specific components of the CRM 
of NPDIs need to be evaluated, before adoption, and then actively implemented 
if proven valuable (e.g. risk reduction strategies as the package inserts of natural 
products and the management guidelines of NPDIs) .
Because the effectiveness and efficiency of any risk reduction strategy should be 
evaluated, we present in Chapter 4.1 the appraisal of the clarity and applicability 
of guidelines for the management of potentially harmful DDIs by community 
pharmacists and general practitioners. For this we used the validated Appraisal 
of Guidelines for Research and Evaluation (AGREE) Instrument. The DDI 
management guidelines were generally found to score well on clarity, but poorly 
with respect to applicability. Current guidelines could be improved by adding 
patient leaflets, a summary document, and decision support systems. Guidelines 
should also discuss the potential financial impact of the recommendations (e.g. 
monitoring or adding a specific drug to the therapy) and should present the key 
review criteria to measure adherence to the guideline.
Finally, we evaluated management guidelines for a specific DDI between 
non-steroidal anti-inflammatory drugs (NSAIDs) and antihypertensives that 
recommend blood pressure monitoring in hypertensive patients in daily clinical 
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practice. In Chapter 4.2 we evaluated the effect on systolic blood pressure (SBP) 
of initiating NSAIDs in users of antihypertensives in 112 patients. Two of these 
patients already presented a SBP ≥180 mmHg before actually starting with an 
NSAID. Among the remaining patients the predefined limit of change (PLoC) in 
SBP (rise ≥10mmHg and SBP≥140 mmHg) was exceeded in 10 patients (10.4%) 
after one week and in seven patients (8.0%) after two weeks of NSAID use. Patients 
using etoricoxib (odds ratio (OR), 21.0; 95% confidence interval (CI), 3.7–120.6) 
and patients using more than one defined daily dose of an NSAID (OR, 3.3; 95% CI, 
1.1–10.0) were at increased risk of a rise in SBP. We concluded that a newly initiated 
NSAID has an immediate relevant effect on SBP in some users of antihypertensives. 
Management guidelines for NSAID-antihypertensive DDIs should advise SBP 
monitoring before treatment and during initiation or intensification of NSAID 
therapy. Monitoring is especially relevant in patients prescribed high dosages of 
NSAIDs. Etoricoxib should not be used in patients with uncontrolled hypertension.
In Chapter 5 (General discussion) the evidence of the separate studies is connected 
with the previous literature and opportunities to improve CRM of drug interactions 
are presented. In addition, the gaps in CRM that still exist are identified and 
discussed and the most important implications for society and science are 
described.
Our studies showed there is ample opportunity to improve CRM of drug 
interactions. Pharmacists should strive for complete and relevant medical and 
pharmaceutical information in the EPR. The developers of DDI management 
guidelines should apply the checklist for standardized reporting of DDI 
management guidelines and should take the appropriate domains of the AGREE 
instrument (incl. cost-effectiveness) into consideration in their development 
processes. Guideline developers should systematically collect and analyse evidence 
of potentially preventable unsafe practices and include the resulting safety warnings 
into their management guidelines, while software vendors should integrate the 
revised management guidelines in their decision support systems.
We argued that CRM of drug interactions involves several key actors (marketing 
authorisation holders, regulatory authorities, professional associations, guideline 
working groups or committees, software vendors, individual healthcare providers 
and patients) in different key areas. Integral CRM of drug interactions in the drug 
therapy process requires a coordinating 'Kapellmeister' both at the national level 
of the population (i.e. licensing authority, healthcare inspectorate or professional 
organizations) and at the local level of the individual patient (i.e. a physician or 
pharmacist as overall director of drug therapy). Additional resources for the 
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further development, execution and evaluation of CRM of drug interactions are 
necessary. Evaluation of the cost-effectiveness of risk reduction strategies and the 
strengths and limitations of different risk reducing strategies is needed. Regulatory 
authorities and professionals will have to act in case current CRM regulations need 
to be adjusted. Educational interventions to improve professional performance 
and increase patient participation should be further developed and evaluated. 
Pharmacists should become an integrated part of primary healthcare teams.
More research into the evaluation of CRM of drug interactions is needed to explore 
which (combinations of) risk reduction strategies ensure the largest reduction in 
risks for harm to patients in order to prioritise risk reducing strategies. A joint 
effort of all actors involved is needed to increase the body of evidence for risk 
reduction strategies. To assess and adapt risk reduction strategies, to guide (inter-)
professional development and to develop new educational programmes, data on 
professional performance should be routinely collected and analysed.
In conclusion, the research presented in this thesis demonstrates that CRM of drug 
interactions needs further improvement to safeguard drug therapy in individual 
patients as much as possible. The responsibility for this improvement lies with 
the healthcare providers themselves, with the patients and with national actors 
(marketing authorisation holders, licensing authorities, healthcare inspectorate, 
professional associations, software vendors) involved in the drug therapy process. 
Regulatory authorities should oversee the accountability of each actor for the 
effectiveness of its risk reduction strategies and should identify poor performance 
and gaps in the CRM of drug interactions. Regulators and professional associations 
should support healthcare professionals to improve performance and to resolve 
the remaining gaps. Pharmacists should take their responsibility in the national 
CRM of drug interactions by participating in guideline development and pharmacy 
practice research. At the local level they should strengthen the collaboration with 
the patient and with other healthcare professionals towards primary healthcare 
teams to provide optimal individualized care.
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De therapie met geneesmiddelen, de farmacotherapie, is een complex proces waarbij 
fouten kunnen optreden in elke fase: van regulering, voorschrijven en distribueren 
tot het gebruik van geneesmiddelen en monitoren van het geneesmiddelgebruik. 
Fouten in het proces kunnen leiden tot geneesmiddelgerelateerde schade, wat in 
de Engelse literatuur adverse drug events (ADE’s) wordt genoemd. ADE’s zijn een 
belangrijke oorzaak van morbiditeit en mortaliteit. Een substantieel deel van deze 
ADE’s wordt veroorzaakt door medicatiefouten, waardoor zij potentieel vermijdbaar 
zijn. Het is van belang dat alle actoren (zorgverleners en hun organisaties), die in 
het farmacotherapieproces betrokken zijn, de risico’s op medicatiefouten op een 
systematische manier aanpakken om schade bij patiënten te voorkomen. Een 
dergelijke systematische aanpak wordt klinisch risicomanagement of clinical risk 
management (CRM) genoemd. Deze aanpak bestaat uit drie hoofdelementen: 
1) identificatie en beoordeling van risico’s; 2) ontwikkeling en uitvoering van 
risicoreducerende strategieën; 3) evaluatie van risicoreducerende strategieën.
Het doel van dit proefschrift is om het belang van CRM bij verschillende soorten 
geneesmiddelinteracties, wisselwerkingen met geneesmiddelen, te belichten:
geneesmiddel–geneesmiddel interacties (IA’s), geneesmiddel–aandoening inter-
acties ofwel contra-indicaties (CI’s), en geneesmiddel–overgevoeligheid/allergie 
interacties.
Het proefschrift bestaat uit drie delen:
Hoofdstuk 2 beschrijft hoe volledig de documentatie van patiëntgegevens in het 
elektronisch patiëntendossier (EPD) in openbare apotheken is.
Hoofdstuk 3 richt zich vooral op de ontwikkeling van richtlijnen voor de 
afhandeling van geneesmiddelinteracties. Bovendien gaan we in op de kernterreinen 
van het CRM van geneesmiddelinteracties.
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Hoofdstuk 4 evalueert bestaande richtlijnen voor de afhandeling van geneesmiddel-
interacties, waarbij het gaat om aspecten als helderheid, toepasbaarheid en 
effectiviteit.
Volledige en actuele medische en farmaceutische informatie in het EPD is een 
voorwaarde voor risicomanagement in de openbare apotheek. In Hoofdstuk 2.1 
laten we het onderzoek zien naar de mate van volledigheid van deze gegevens in 
het EPD bij het eerste bezoek van een patiënt aan de apotheek. Voor elke patiënt 
werden deze gegevens zowel verzameld uit het EPD als door middel van een 
gestructureerd telefonisch interview. Het betrof: naam/adres/woonplaats (NAW) 
gegevens, geboortedatum en geslacht, huidig geneesmiddelgebruik (zowel met 
en zonder recept), aandoeningen en specifieke condities (zoals zwangerschap), 
overgevoeligheden en allergieën, laboratoriumwaarden, persoonlijke ervaringen 
en gewoonten (bijvoorbeeld roken) en problemen met geneesmiddelgebruik. De 
gegevens uit beide bronnen werden met elkaar vergeleken. We vonden dat het EPD 
na een eerste bezoek van een patiënt aan de openbare apotheek vaak onvolledig 
is. Slechts 68% van de receptgeneesmiddelen, 20% van de aandoeningen, 4% van 
de overgevoeligheden en allergieën, en geen van de zelfzorgmiddelen, specifieke 
condities, persoonlijke ervaringen en gewoonten en geneesmiddelgebruik 
problemen, die door de patiënt werden gemeld waren gedocumenteerd in het EPD. 
Bovendien was slechte documentatie van telefoonnummers een belangrijke reden 
dat geselecteerde patiënten niet konden worden bereikt voor het interview.
In Hoofdstuk 2.2 tonen we aan dat het ontbreken van medische en farmaceutische 
gegevens gedeeltelijk blijft bestaan voor patiënten die ten minste drie 
maanden in een openbare apotheek zijn ingeschreven. Hoewel nu al 97% 
van de receptgeneesmiddelen was gedocumenteerd, waren slechts 6% van de 
zelfzorgmiddelen, 25% van de aandoeningen en 33% van de overgevoeligheden 
en allergieën geregistreerd in het EPD. Als gevolg van deze gemiste informatie 
in het EPD ontbraken medicatiebewakingssignalen bij 38% van de patiënten. 
Dit betrof CI’s in 34% van alle patiënten, dubbelmedicaties in 4%, IA’s in 4%, en 
geneesmiddel-overgevoeligheid/allergie interacties in 2%. Van alle ontbrekende 
receptgeneesmiddelen en zelfzorgmiddelen zorgden de niet-steroïdale anti-
inflammatoire geneesmiddelen (NSAID’s) voor het grootste aantal gemiste signalen. 
De aandoeningen die het meest frequent gemiste signalen veroorzaakten waren 
slokdarmontstekingen (reflux oesofagitis), nierinsufficiëntie, astma/chronische 
obstructieve longziekten (astma/COPD) en hartfalen. Beide studies suggereren dat 
apothekers meer proactief en systematisch patiëntgegevens moeten verzamelen en 
documenteren om het risico op schade bij patiënten verder te verminderen.
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Inconsistenties en gebrek aan voldoende informatie in IA afhandelingsrichtlijnen 
kunnen leiden tot schade en suboptimale therapie. Daarom moet ook de 
ontwikkeling van dergelijke richtlijnen systematisch plaatsvinden. In Hoofdstuk 3.1 
beschrijven we een onderzoek met de Delphi-methode met een internationaal 
panel van deskundigen op het gebied van interacties. Het doel was om vast te stellen 
welke items in een IA afhandelingsrichtlijn beschreven moeten worden. Er werd een 
checklist opgesteld met 15 onderwerpen die aan bod moeten komen, waaronder 
de ernst van de mogelijke bijwerkingen door de IA en de kwaliteit van het bewijs 
dat de IA schade veroorzaakt. Deze checklist kan bijdragen aan een transparante 
en volledige beoordeling van de potentiële klinische gevolgen van een interactie en 
een beter onderbouwde afhandeling van deze interacties. We bevestigden eerder 
onderzoek dat de helderheid en presentatie van de richtlijnen voor het afhandelen 
van potentieel schadelijke IA’s verder kunnen worden verbeterd. Het is van belang 
de sterkte van de aanbevelingen voor de afhandelingsopties te onderbouwen en 
helder te presenteren welke factoren (zoals de dosering of bepaalde kenmerken 
van een patiënt) het risico op schade door een interactie vergroten. Het monitoren 
van biomarkers (bijvoorbeeld de bloeddruk, natrium- of kalium of nierfunctie) zou 
in meer detail moeten worden beschreven. Bijvoorbeeld, hoe vaak moet worden 
gemeten en bij welke afkapwaarden moet actie worden ondernomen. Tenslotte is 
het van belang ook de kosteneffectiviteit van de afhandelingsopties te beschrijven.
In Hoofdstuk 3.2 laten we zien dat we de haalbaarheid van deze checklist met een 
concreet voorbeeld hebben getest: de IA tussen plastabletten (thiaziden en verwante 
diuretica) en antidepressiva (selectieve serotonine heropnameremmers [SSRI’s] of 
serotonine-noradrenaline heropnameremmers [SNRI’s]). Deze voorbeeldrichtlijn 
verschilde van diverse bestaande richtlijnen voor deze IA doordat uitgebreide 
informatie wordt verstrekt over bijvoorbeeld patiëntgebonden risicofactoren 
voor hyponatriëmie, de verschillende afhandelingsopties met inbegrip van details 
over monitoring en patiënten begeleiding en instructie, en een algoritme van de 
verschillende maatregelen die genomen kunnen worden wanneer deze middelen 
voor de eerste keer worden gecombineerd. Deze voorbeeldrichtlijn toonde 
ons dat de checklist verder kon worden verbeterd. Hoofdstuk 3.3 presenteert 
de verbeterde checklist en een uitgebreide toelichting over de interpretatie en 
toepassing van de onderwerpen uit de checklist bij de ontwikkeling van specifieke 
IA afhandelingsrichtlijnen.
Natuurproducten worden steeds vaker tegelijk met reguliere geneesmiddelen 
gebruikt, waardoor klinische relevante interacties kunnen optreden. Om de kans 
op nadelige gevolgen van deze interacties te minimaliseren is een systematische 
aanpak nodig. In Hoofdstuk 3.4 besteden we daarom specifiek aandacht aan CRM 
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bij interacties tussen natuurproducten en reguliere geneesmiddelen. Voor elk 
van de drie hoofdelementen van het CRM is beschreven op welke terreinen deze 
verder ontwikkeld, geïmplementeerd of geëvalueerd moeten worden bij deze 
interacties. Hierbij valt te denken aan het stimuleren van spontane meldingen van 
bijwerkingen door patiënten en zorgverleners of het opnemen van waarschuwingen 
voor interacties met natuurproducten in bijsluiters.
Aangezien de effectiviteit en efficiëntie van risicoreducerende strategieën moeten 
worden geëvalueerd, presenteren we hiervan 2 onderzoeken, zoals in Hoofdstuk 4.1 
de beoordeling van de ‘helderheid en presentatie’ en ‘toepasbaarheid’ van 
afhandelingsrichtlijnen van een aantal potentieel schadelijke IA’s. Hiervoor hebben 
we gebruik gemaakt van het gevalideerde AGREE- (Appraisal of Guidelines for 
Research and Evaluation) Instrument. Een panel van apothekers en huisartsen 
beoordeelde een aantal richtlijnen met dit instrument. De IA afhandelingsrichtlijnen 
bleken in het algemeen goed te scoren op het domein ‘helderheid en presentatie’, 
maar slecht op het domein ‘toepasbaarheid’. Huidige richtlijnen kunnen worden 
verbeterd door toevoeging van patiëntenfolders, een samenvattend document en 
beslissingsondersteunende computersystemen. Het is van belang dat richtlijnen ook 
de mogelijke financiële consequenties van de afhandelingsopties bediscussiëren, 
zoals bijvoorbeeld de kosten van monitoring van een bepaalde biomarker of de 
toevoeging van een geneesmiddel aan de therapie. Een richtlijn dient tevens de 
belangrijkste criteria weer te geven om na te gaan of de richtlijn wordt nageleefd in 
de dagelijkse praktijk.
Tot slot evalueerden we afhandelingsrichtlijnen voor de specifieke IA tussen 
NSAID's en bloeddrukverlagende geneesmiddelen. Deze richtlijn doet de 
aanbeveling de bloeddruk bij hypertensieve patiënten die een NSAID krijgen 
te meten. Hoofdstuk 4.2 laat het effect zien op de systolische bloeddruk (SBP) in 
112 patiënten die bloeddrukverlagers gebruiken en starten met een NSAID. Twee 
van deze patiënten hadden reeds een SBP ≥ 180 mmHg voorafgaand aan het 
gebruik van het NSAID en hadden eigenlijk niet mogen starten met het NSAID. 
Onder de resterende 110 patiënten werd de vooraf gedefinieerde limiet van 
verandering in SBP (een stijging ≥ 10mmHg en SBP ≥ 140 mmHg) overschreden 
in 10 patiënten (10,4%) na één week en in zeven patiënten (8,0%) na twee weken 
NSAID gebruik. Patiënten die etoricoxib gebruikten (odds ratio (OR) 21.0; 
95%-betrouwbaarheidsinterval (95%CI) 3.7–120.6) en patiënten met een relatief 
hoge dosering (meer dan één DDD [defined daily dose]) van een NSAID (OR 3.3; 
95%CI 1.1–10.0) hadden een verhoogd risico op een stijging van de SBP.
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Wij concludeerden dat de start van een NSAID een direct bloeddruk verhogend 
effect kan hebben bij een klein deel van de gebruikers van bloeddrukverlagers. 
Afhandelingsrichtlijnen voor interacties tussen NSAID’s en bloeddrukverlagers 
moeten adviseren de SBP voorafgaand aan de behandeling en tijdens de start of 
intensivering van NSAID therapie te monitoren. Monitoring is vooral relevant bij 
patiënten met een hoge dosering NSAID. Etoricoxib mag niet worden gebruikt 
in patiënten met ongecontroleerde hypertensie. Het gebruik van etoricoxib werd 
overigens al afgeraden bij personen met een slecht gereguleerde bloeddruk. Dit 
laatste was blijkbaar niet bij alle voorschrijvers en apothekers bekend.
In Hoofdstuk 5 (algemene beschouwing) worden de uitkomsten van de 
afzonderlijke onderzoeken in een breder verband besproken en worden 
mogelijkheden om het CRM van geneesmiddelinteracties verder te verbeteren 
gepresenteerd. Bovendien worden de huidige lacunes in CRM geïdentificeerd 
en bediscussieerd en worden de belangrijkste gevolgen voor samenleving en 
wetenschap beschreven. Onze onderzoeken toonden dat er volop mogelijkheden 
zijn om CRM van geneesmiddelinteracties verder te verbeteren. Apothekers 
moeten streven naar volledige en relevante medische en farmaceutische informatie 
in het EPD. De ontwikkelaars van IA afhandelingsrichtlijnen dienen systematischer 
te werk te gaan en moeten meer aandacht besteden aan onderbelichtte 
onderwerpen zoals de kosteneffectiviteit. Ze kunnen hiervoor de juiste domeinen 
van het AGREE-Instrument en de checklist voor gestandaardiseerde vastlegging 
in IA afhandelingsrichtlijnenen in hun ontwikkelingsproces meenemen. 
Richtlijnontwikkelaars moeten aanwijzingen voor potentieel vermijdbare 
onveilige farmacotherapie systematisch identificeren en analyseren. De daaruit 
voortvloeiende veiligheidswaarschuwingen, zoals een brief van de fabrikant 
van een geneesmiddel naar artsen en apothekers met informatie over de risico’s 
van een geneesmiddel, moeten ze in hun afhandelingsrichtlijnen opnemen. 
Het is de verantwoordelijkheid van de softwareleveranciers om de (herziene) IA 
afhandelingsrichtlijnen in hun beslissingsondersteunende computersystemen te 
integreren.
We voerden aan dat meerdere actoren (registratiehouders, regelgevende autoriteiten, 
beroepsorganisaties, richtlijnwerkgroepen en commissies, softwareleveranciers, 
individuele zorgaanbieders en patiënten) de verantwoordelijkheid hebben om 
CRM te verbeteren. Integraal CRM van geneesmiddelinteracties vereist een 
coördinerende 'Kapellmeister', zowel op populatieniveau (vergunningverlenende 
autoriteiten, inspectie van de gezondheidszorg of beroepsorganisaties) als op 
lokaal niveau voor de individuele patiënt (dat wil zeggen een huisarts of apotheker 
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die hier de verantwoordelijkheid voor neemt). Integratie van de apotheker in de 
eerstelijnsgezondheidszorg biedt hier kansen toe.
Er zijn financiële middelen nodig voor de verdere ontwikkeling, uitvoering en 
evaluatie van CRM van geneesmiddelinteracties. Evaluatie van de kosteneffectiviteit 
en de sterkten en zwakten van de verschillende risicoreducerende strategieën is 
nodig. Zowel regelgevende autoriteiten als professionals zullen proactief moeten 
inspelen op nieuwe ontwikkelingen. Educatieve interventies om professionele 
prestaties en patiëntparticipatie te verbeteren moeten verder worden ontwikkeld 
en geëvalueerd. CRM behoeft een continue evaluatie om te komen tot de meest 
optimale risicoreducerende strategie. Een gezamenlijke inspanning van alle 
betrokken actoren is hiervoor gewenst. Om risicoreducerende strategieën te 
beoordelen en aan te passen, om (inter-)professionele ontwikkeling te sturen en 
nieuwe educatieve programma’s te ontwikkelen moeten gegevens over professionele 
prestaties routinematig worden verzameld en geanalyseerd.
Concluderend, de onderzoeken die in dit proefschrift gepresenteerd zijn 
tonen aan dat CRM van geneesmiddelinteracties verder verbeterd moet 
worden om de farmacotherapie bij individuele patiënten te optimaliseren. De 
verantwoordelijkheid voor deze verbetering ligt bij de zorgaanbieders zelf, bij de 
patiënten en bij de nationale actoren (registratiehouders, vergunningverlenende 
autoriteiten, inspectie voor de gezondheidszorg, beroepsorganisaties) die 
betrokken zijn in het farmacotherapie proces. Regelgevende autoriteiten moeten 
toezicht houden of elke actor zijn verantwoordelijkheid voor de doeltreffendheid 
van de risicoreducerende strategieën neemt. Ook moeten zij slechte prestaties 
en lacunes in het CRM van geneesmiddelinteractie identificeren. Regelgevende 
autoriteiten en beroepsorganisaties moeten zorgaanbieders ondersteunen om hun 
prestaties te verbeteren en de resterende CRM lacunes op te lossen. Apothekers 
moeten op nationaal niveau hun verantwoordelijkheid nemen in het CRM 
van geneesmiddelinteracties door deel te nemen aan richtlijnontwikkeling en 
farmaceutisch praktijkonderzoek op dit gebied. Op lokaal niveau moeten ze de 
samenwerking met de patiënt en andere zorgaanbieders versterken, waarbij wordt 
toegewerkt naar primaire gezondheidszorg teams om optimale geïndividualiseerde 
zorg te verlenen.
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Vier dagen na afronding van dit manuscript voor de leescommissie kwam klinisch 
risicomanagement voor mij in een ander daglicht te staan. Door een ervaring 
in de familie werd mij duidelijk dat het functioneren van de patiënt als actor in 
risicomanagement veel belangrijker is dan ik eerder dacht. Aangezien deze focus op 
de patiënt in dit proefschrift beperkt aan bod komt, krijgt de ‘patiënt’ als ‘mens’ de 
hoofdrol op de omslag. De onderliggende boodschap van de omslag is mijn wens 
dat zorgprofessionals de zorg gerelateerde behoeften van de zieke of kwetsbare 
medemens altijd centraal stellen. De idee om met dit promotietraject te starten 
kwam in eerste instantie niet voort uit een wens van mijn kant. Als werknemer bij 
SIR Institute for Pharmacy Practice and Policy word je regelmatig gestimuleerd om 
met een promotieonderzoek te starten. Nadat onze directeur, Henk Buurma, was 
gepromoveerd begon de behoefte aan een nieuwe uitdaging bij mij te kriebelen. Al 
snel werd ik door hem gemotiveerd om als promovendus aan de slag te gaan. In 
het achterom zien voelt het goed en het geeft vertrouwen in de toekomst dat ik in 
deze uitdaging nooit alleen stond. Als eerste stelling heb ik daarom een uitspraak 
van Steve Jobs gekozen: ‘Great things are never done by one person, they are done 
by a team of people.’ Alhoewel ik hoop dat dit proefschrift een bijdrage levert aan 
het voorkomen van schade en leed door geneesmiddelinteracties bij patiënten, 
wil ik met deze uitspraak allerminst pochen dat dit proefschrift iets groots is. De 
kern van deze uitspraak ligt voor mij in ‘een team van mensen’. Gedurende de jaren 
dat ik aan de onderzoeken in dit proefschrift heb gewerkt mocht ik deelnemen in 
verschillende ‘teams’. Met deze teams heb ik diverse wegen mogen afleggen om 
verschillende gemeenschappelijke doelen te bereiken. Daarom is een dankwoord 
hier absoluut op zijn plaats.
In de eerste plaats wil ik het geweldige herenteam bedanken dat mij als promovendus 
begeleidde en waarmee ik samen het gemeenschappelijke doel van een proefschrift 
mocht bereiken: Peter de Smet, Marcel Bouvy en Henk Buurma.
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Beste Peter, in 1998 solliciteerde ik bij jou op een functie bij de KNMP. Als net 
afgestudeerde apotheker trok de uitdaging bij de ESCP mij meer aan. Wat ben ik 
blij dat je me een aantal jaar later in de functie van hoogleraar in de kwaliteit van de 
farmaceutische patiëntenzorg aan de Radboud Universiteit van Nijmegen als eerste 
promotor wilde begeleiden. Ik heb genoten van de vele gesprekken en discussies 
die wij over de farmacie in het algemeen en de specifieke onderzoeken hebben 
gevoerd. Jouw jarenlange ervaring en kennis bleken een onuitputtelijke hoeveelheid 
ideeën voor onderzoek voort te brengen. Ze gaven bovenal waardevolle input 
voor alle discussiestukken. Telkens wist je me terug te brengen naar de kern van 
het onderzoek en het belang van de uitkomsten voor de patiënt en de dagelijkse 
klinische praktijk. Ik ben je zeer erkentelijk voor de begeleiding die je me gaf en 
voor de positieve woorden die je sprak.
Beste Marcel, tijdens de opstartfase van mijn promotietraject ben je benoemd tot 
hoogleraar farmaceutische patiëntenzorg aan de Universiteit Utrecht en heb je het 
promotorschap van Toine Egberts overgenomen. Met respect luister ik naar je als 
je jouw kennis over geneesmiddelen, jouw ervaringen als apotheker en jouw visie 
op de farmaceutische patiëntenzorg met mij en anderen deelt. Het delen van onze 
werkkamer maakte dat jij voor mij heel toegankelijk was en altijd bereid om advies 
te geven over onderzoek gerelateerde vragen, uitleg te geven over Access of SPSS of 
om mij een hart onder de riem te steken. Op die manieren heb je heel wat uren aan 
mijn promotieonderzoek besteed. Hartelijk dank daarvoor.
Beste Henk, als directeur van SIR Institute for Pharmacy Practice and Policy en 
apotheek Stevenshof te Leiden, vroeg jij me in 2001 om bij SIR te komen werken. 
Jouw passie voor en visie op de farmacie leidt telkens tot vernieuwende ideeën 
en inspireert de mensen om je heen om de farmaceutische zorg en het vak van 
apotheker naar een hoger niveau te tillen. Als mijn copromotor hielp jij met jouw 
pragmatische kijk op de onderzoeken om vooruitgang te boeken als we vastliepen. 
Bij tegenslagen in de onderzoeken en publicaties was jij vaak een luisterend oor en 
wist je me te bemoedigen om door te gaan. Bij voorspoed deelde je mee in mijn 
vreugde. Ik ben je dankbaar voor alle kansen en begeleiding die ik van je kreeg.
Tijdens de opstartfase van mijn promotietraject was een vierde heer, Toine Egberts, 
hoogleraar klinische farmacie aan de Universiteit Utrecht, in het team betrokken. 
Beste Toine, jouw kritische vragen over de onderzoeken zorgden voor de nodige 
diepgang en prikkelden mijn hersencellen. Dank voor jouw bijdrage aan dit 
proefschrift.
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Ik mocht ook samenwerken in inspirerende en wisselende teams van onderzoekers 
en co-auteurs. Ons gemeenschappelijke doel om een interessant onderzoek uit te 
voeren en een artikel te publiceren is behaald. Mette Heringa, collega-onderzoeker 
bij SIR, ik wil je graag hartelijk danken voor jouw bijdrage aan het tweede 
onderzoek naar het patiëntendossier en onze prettige onderonsjes. Arjen Geerts, 
projectapotheker UMC Utrecht, wij mochten als promovendi samen aan de slag 
om een instrument te ontwikkelen voor de beoordeling van geneesmiddelinteractie 
afhandelingsrichtlijnen. Het was fijn om met zo’n gedreven collega op zo’n plezierige 
wijze samen te werken. Jeffrey Aronson, reader in clinical pharmacology at the 
University of Oxford, many thanks for your willingness to take part in the Delphi-
study to develop a checklist for drug-drug interaction management guidelines. 
Especially, because you are not generally in favour of Delphi processes. It was a 
great opportunity for me to cooperate with you and learn from you. Robin Ferner, 
professor of clinical pharmacology at the University of Birmingham, I would 
like to thank you very much for your valuable contribution to the Delphi-study. 
Your comments and suggestions during the whole research were of considerable 
importance. Your e-mails often made me smile, because of the encouraging words 
and greetings in the Dutch language. Kris Movig, ziekenhuisapotheker in het 
Medisch Spectrum Twente, dank dat je op korte termijn bereid was om als co-
auteur een bijdrage te leveren aan de monografie. Michel Wensing, hoogleraar 
implementation science aan de Radboud Universiteit Nijmegen, graag wil ik je 
bedanken voor je co-auteurschap van het artikel over klinisch risicomanagement 
bij interacties tussen natuurproducten en reguliere geneesmiddelen. Sonia 
Amini, projectondersteuner bij SIR, onze samenwerking bleek succesvol, jij kon 
afstuderen als farmakundige en van het onderzoek is het artikel gepubliceerd. Ik 
wil je graag hartelijk danken voor jouw nauwgezette ondersteuning en gezelligheid 
tijdens de vele uren dat we mochten samenwerken. Chris Tromp, apotheker bij 
Stichting Health Base, dank voor je bijdrage aan het onderzoek “het monitoren 
van de bloeddruk in geneesmiddelinteractie afhandelingsrichtlijnen”, waaraan jij 
veel van jouw kennis, kunde en tijd hebt gegeven tot aan de publicatie toe. Kees 
Kramers, internist en klinisch farmacoloog in het Radboud Universitair Medisch 
Centrum, hartelijk dank dat je bereid was om als co-auteur mee te werken om 
het artikel “NSAIDs-antihypertensive drugs: patients at risk for a rise in systolic 
blood pressure” gepubliceerd te krijgen. Jouw commentaren en suggesties bleken 
succesvol! Svetlana Belitser, onderzoeker/statisticus aan de Universiteit Utrecht, 
en Jan Mulder, statisticus aan de Radboud Universiteit Nijmegen, ik ben jullie zeer 
erkentelijk voor jullie analyses, advies en geduld bij het interpreteren en beschrijven 
van de statistiek. Martine Kruijtbosch, collega-onderzoeker SIR, jij hielp me bij de 
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dataverzameling van het eerste onderzoek naar het patiëntendossier. Graag bedank 
ik je hiervoor. Bovenal wil ik je bedanken voor jouw niet aflatende inzet en de fijne 
samenwerking als SIR collega’s.
Het UPPER-team van de Universiteit Utrecht, Helma van der Horst, Daphne 
Philbert, Willem Rump, Majanne Wolters en Peter Chen wil ik graag hartelijk 
danken dat ik mij altijd welkom voelde in jullie team en jullie bereid waren mij te 
ondersteunen. Lyda Blom, naar jou gaat mijn bijzondere dank uit. Jij hielp bij het 
ontwerp en de uitvoering van diverse studies en wist de farmacie masterstudenten 
en hun stagebegeleiders te motiveren een bijdrage aan deze onderzoeken te leveren.
Mijn speciale dank wil ik ook schrijven aan het ‘SIR Masterclass team’, Wilma 
Göttgens, Leonie Hulst, Javotte Manni, en Aris Prins. Zij hielpen bij het ontwerpen 
en uitvoeren van het tweede onderzoek naar de kwaliteit van het patiëntendossier. 
Ik wil Marleen Buurma, Jorien Buurma en Lies Wouters bedanken voor het 
verwerken van de grote hoeveelheid aan data die verzameld is voor de onderzoeken 
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